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S1EditorialIssues related to the prevention of type 2 diabetes
(T2D) have become a major cause in health care
during the last decade. Although the prevention
of T2D sounds almost self-evident today, the sit-
uation was very different only 25 years ago, that
is, no serious attempts for T2D prevention had ex-
isted [1]. Yet, diabetes has been one of the best-
known chronic diseases during the past 4000
years.
Nowadays, while epidemiological transition has
resulted in a dramatically improved life expectan-
cy, in particular in developed countries, the prev-
alence of chronic noncommunicable diseases in-
cluding T2D has exploded. Previously, daily life ac-
tivities and nomotored transportation made peo-
ple to have a right energy balance and physical fit-
ness that also assured goodmetabolic health. This
was the situation still about 50 year ago. In addi-
tion, due to limited food supply in general, exces-
sive energy intake was uncommon for most of the
people. Therefore, obesity was not a major public
health problem until recently. The modern “era of
obesity and physical inactivity” really emerged
with full might around the 1970s.
Every epidemic has its roots. Accordingly, every
mass epidemic must be tackled with mass inter-
ventions. Type 2 diabetes has its origins in a com-
plex interplay between societal, behavioural ge-
netic, and metabolic factors. These are not easy
to control. Nevertheless, the history of public
health has plethora of examples to demonstrate
how preventive measures can lead to the reduc-
tion of common diseases and their consequences.
While today the news headlinesmanifestly report
that some individuals had died from avian or
swine flu, deaths due to diabetes that occur every
10 seconds worldwide do not reach the threshold
of news coverage.
It may not be possible to eradicate chronic non-
communicable diseases, but their burden can be
reduced dramatically. Good examples are coro-
nary heart disease, stroke, lung cancer, etc. FromTuomilehto J, Schwarz PE. Primary Prevention of Tythese actions to reduce the burden of noncommu-
nicable diseases we have learned that a successful
preventionmust be based simultaneously on both
population-based actions targeted to the entire
community and the high-risk approach targeted
to individuals at the highest risk of a particular
disease [2].
There is something old and something new that
we need to consider. The old facts described by
our ancient predecessor medical doctors empha-
size the importance of healthy diet, physical ac-
tivity, and social support. It would be naive to
even think that these facts would not be applica-
ble in the human population today, since our
genes have not changed much during the past
few thousand years. On the other hand, the envi-
ronment where we live has changed drastically,
but only during the last one or two centuries,
most notably during the last 50 years.
Luckily, scientists have been alerted about this
emerging epidemic of diabetes and considered ac-
tions that might work to prevent this epidemic
growing further. In the beginning this was just a
small effort from a few people [3], and even
though the World Health Organisation (WHO) or-
ganised a Study Group meeting on the prevention
of diabetes and its complications in 1994 [4],
WHO and its member states did virtually nothing
to implement the recommendations of this ex-
pert group. It seems that the development of the
understanding as to how to establish the preven-
tion was left to the hands of individuals who vol-
unteered to devote time and effort to find out
how and to what extent T2D may be prevented
[5].
Today, the situation looks much brighter for the
prevention of T2D. First, research to establish the
necessary data base for the evidence-based pre-
vention has accumulated large amount of data
from observational studies around the world. Sec-
ond, simple and efficient risk scores for screening
for T2D risk have been developed and used inpe 2 Diabetes… Horm Metab Res 2010; 42 (Suppl. 1): S1–S2
S2 Editorialpublic health setting [6]. Third, randomised controlled trials have
demonstrated that lifestyle intervention targeting to main modi-
fiable risk factors for T2D in high risk individuals is highly effec-
tive reducing the incidence of T2D by about 50% [7–9]. Fourth,
nationwide or regional T2D prevention programmes have been
set up in order to translate the research findings to the real-life
settings – Finland was the first country to establish such a pro-
gramme 10 years ago [10] followed by others [11].
These experiences have increased our understanding about the
potential for the prevention of T2D, and also about obstacles in
setting up T2D prevention in the community. Thus, it has been
possible to collate this information in a systematic manner,
which now appears in this journal. These include evidence-based
guideline on T2D prevention [12], a toolkit for the prevention
[13], and a report on quality indicators in T2D prevention [14].
These have been developed within the IMAGE [15] project
funded by the European Community and participating institu-
tions. The information in these papers will represent a major fur-
ther step in the work to make T2D prevention a reality in Europe.
It will now be the task of various stakeholders to take action as
outlined in these documents. As estimated by the International
Diabetes Federation, the number of T2D patients is likely to in-
crease during the forthcoming years, and maybe decades in Eu-
rope, but with the implementation of these recommendations
now outlined it is anticipated that the increase of the T2D epi-
demic will be eventually controlled and the burden of diabetes
gradually diminished. These recommendations should be now
adopted into various national and international recommenda-
tions. Although these recommendations effectively target the
European populations, it is obvious that much of them are also
valid for many other parts of theworld, at least with certain mod-
ifications.
There will be a lot of work in implementing these recommenda-
tions in the future. Also, there is a need to continue systematic
research into the aetiology, prevention, and management of
T2D. In particular, translational research regarding the imple-
mentation of existing knowledge into public health and clinical
practice must be carried out. This is not possible without the
proper research funding that should become available through
various national and international funding sources. In any case,
the future of T2D prevention has never been as bright as it is to-
day. Early advocates for diabetes prevention including Dr. Elliot
Joslin [16] would be surprised about this very remarkable devel-
opment we are witnessing at the present time.Tuomilehto J, Schwarz PE. Primary Prevention of Type 2 Diabetes… Horm Metab ReReferences
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Abstract
!
Background: The prevalence and socioeconomic
burden of type 2 diabetes (T2DM) and associated
co-morbidities are rising worldwide. Aims: This
guideline provides evidence-based recommenda-
tions for preventing T2DM. Methods: A European
multidisciplinary consortium systematically re-
viewed the evidence on the effectiveness of
screening and interventions for T2DM prevention
using SIGN criteria. Results: Obesity and seden-
tary lifestyle are the main modifiable risk factors.
Age and ethnicity are non-modifiable risk factors.
Case-finding should follow a step-wise procedure
using risk questionnaires and oral glucose toler-
ance testing. Persons with impaired glucose toler-
ance and/or fasting glucose are at high-risk and
should be prioritized for intensive intervention.
Interventions supporting lifestyle changes delay
the onset of T2DM in high-risk adults (number-
needed-to-treat: 6.4 over 1.8–4.6 years). These
should be supported by inter-sectoral strategies
that create health promoting environments. Sus-
tained body weight reduction by ≥ 5% lowers risk.
Currently metformin, acarbose and orlistat can be
considered as second-line prevention options.
The population approach should use organized
measures to raise awareness and change lifestyle
with specific approaches for adolescents, minor-
ities and disadvantaged people. Interventions
promoting lifestyle changes are more effective if
they target both diet and physical activity, mobi-
lize social support, involve the planned use of es-
tablished behaviour change techniques, and pro-
vide frequent contacts. Cost-effectiveness analysis
should take a societal perspective. Conclusions:
Prevention using lifestyle modifications in high-
risk individuals is cost-effective and should be
embedded in evaluated models of care. Effective
prevention plans are predicated upon sustained
government initiatives comprising advocacy,
community support, fiscal and legislative
changes, private sector engagement and continu-
ous media communication.
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It is estimated that the number of people with diabetes will reach
285 million people worldwide in 2010, with almost half of those
affected in the 20–60 age group. In Europe about 55 million peo-
ple aged 20–79 will have diabetes in 2010 and this number is ex-
pected to rise to 66 million by 2030 unless effective preventive
strategies are implemented. Type 2 diabetes (T2DM) accounts
for about 90% of diabetes cases. People with T2DM have a 2- toPaulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 2014-fold increased risk of cardiovascular disease (CVD) and at least
two thirds die from CVD. Increased CVD risk is already present in
prediabetic states, particularly in individuals with impaired glu-
cose tolerance (IGT) [1,2] and/or the metabolic syndrome
(MetSy) [3]. Diabetes and its complications represent an enor-
mous burden not only for patients but also for society. Direct
healthcare costs, which represent about 30% of total costs to so-
ciety, will be about 70 billion € per year in 2010. It has been esti-
mated that if an individual is diagnosed as having diabetes at the
age of 40 years, men will lose on average 11.6 life-years and 18.6
quality adjusted life years (QALY) and women will lose 14.3 life-
years and 22.0 QALYs [4]. Thus, primary prevention of T2DM and
its complications is a major public health issue.
Despite the fact that inherited factors predispose to T2DM, envi-
ronmental and lifestyle factors are held mainly responsible for
the increasing prevalence of the disease over the past decades.
There is now strong evidence from controlled trials that T2DM
can be prevented by interventions that deliver relatively modest
lifestyle changes. Thus, the potential to prevent T2DM represents
a major opportunity for European governments and healthcare
systems.
In order to address the challenge of reversing the epidemic of
T2DM, a European multidisciplinary consortium (the IMAGE
project: www.image-project.eu) developed this guideline for the
prevention of T2DM which provides evidence based recommen-
dations for health care practitioners, organizations, and funders
on the prevention of type 2 diabetes in European healthcare set-
tings.Definition of Risk and Target populations
!
Definition of risk
The risk for T2DM is predominantly determined by number and
severity of non-modifiable and modifiable risk factors (l" Table
1).
Non-modifiable risk factors
Age. Age is one of the strongest risk factors for T2DM (A). Epide-
miological data for diabetes and impaired glucose regulation
from 13 European countries have been published by the DECODE
study group [5]. The prevalence of diabetes rises with age up to
the 8th decade in both men and women. It is less than 10% in
subjects below 60 years and exceeds 20% above 80 years. The
mean plasma glucose concentration at 2 hours (2-h PG) of the
oral glucose tolerance test (OGTT) rises with age in European
populations, particularly after 50 years. Women have higher
mean 2-h PG levels than men, particularly above 70 years. Mean
fasting plasma glucose (FPG) levels increase only slightly with
age. They are higher in men than in women aged 30–69 years
and become higher in women after 70 years. Among middle aged
subjects, the prevalence of impaired glucose regulation (impaired
glucose tolerance [IGT] and impaired fasting glucose [IFG], or
both) is about 15%, whereas in the elderly, 35–40% of Europeans
have impaired glucose regulation. Over the last years, the age of
onset of diabetes has decreased considerably in countries in
which the prevalence of obesity has increased significantly [6–
10]. T2DM now accounts for as many as 50% of cases of newly di-
agnosed cases of diabetes in pediatric populations [11]. Earlier
onset of T2DM leads to earlier onset of the complications.
Markers of increased CVD risk may appear even before the diag-
nosis of the MetSy among obese children and adolescents [12]0; 42 (Suppl. 1): S3–S36
Table 1 Risk factors for T2DMNon-modifiable risk factors Modifiable risk factors
" Age " Overweight and obesity
" Family history/Genetic predisposition " Physical inactivity
" Ethnicity " Disturbances in intrauterine development/prematurity
" History of gestational diabetes (GDM) " Impaired fasting glucose (IFG)/Impaired glucose tolerance (IGT)
" Polycystic ovary syndrome (PCOS) " Metabolic syndrome (MetSy)
" Dietary factors
" Diabetogenic drugs
" Depression
" Obesigenic/diabetogenic environment
" Low socio-economic status
S5Guidelinesand metabolic abnormalities diagnosed in the adolescence tend
to persist into adulthood [13].
Family history/genetic predisposition. Occurrence of the dis-
ease is highly concordant (60–90%) in monozygotic twin pairs,
but less so (17–37%) in dizygotic twins [14–17] (A). The child of
a parent with T2DM has a 40% chance of developing the disease,
whereas the risk in the general population is about 7% [18]. In the
Botnia study, a positive family history with at least one affected
first degree relative was associated with a hazard ratio (HR) of
2.2 for development of the disease [19]. In recent years a large
number of genetic variants have been identified, which increase
the risk for T2DM [20]. Genome-wide association studies pro-
vided by far the biggest increment to our knowledge of the genet-
ics of T2DM [21–26]. At least 25 gene loci have been identified so
far affecting susceptibility for T2DM [27] (A). The effect on T2DM
risk per susceptibility allele ranges from about 10% to 40%. The
majority of these genes appear to play a role in beta-cell function
rather than in insulin sensitivity. Collectively, however, these var-
iants explain less than 10% of the genetic component of diabetes
risk. Therefore despite the encouraging progress in our under-
standing of the genetic basis of T2DM, it is too early to use genetic
information as a tool for targeting preventive efforts [19].
Ethnicity. Studies in multiethnic populations suggest that some
ethnic groups have a particular predisposition, most likely on a
genetic basis, to develop insulin resistance and T2DM, when ex-
posed to adverse conditions [20]. There are wide differences in
the prevalence of diabetes between ethnic groups (A) [28]. The
prevalence of diagnosed diabetes among Hispanics is 1.9 times
higher than that among Caucasians. Diabetes is diagnosed at an
earlier age and Hispanics suffer from higher rates of diabetes-re-
lated complications and mortality [29]. Afro-Caribbeans and
Asian Indians also exhibit higher prevalence of T2DM than Cau-
casians [30]. One important factor contributing to increased
T2DM risk in Asian Indians is the greater insulin resistance com-
pared to Caucasians [31].
Gestational diabetes (GDM). GDM is defined in terms of having
glucose intolerance in the diabetic range as assessed from OGTT
and/or FPG that begins or is first diagnosed during pregnancy
[32,33]. It is estimated to affect between 3 and 5% of all pregnan-
cies [32] There is a strong correlation between a history of GDM
and later development of T2DM and its co-morbidities [34]. A re-
cent meta-analysis of 20 studies reported that womenwith a his-
tory of GDM had about a 7.5-fold increased risk for T2DM com-
pared with womenwith normoglycemic pregnancy [35] (A). Eth-
nicity has been proven to be an independent risk factor for GDM
[36]. In the DPP women with a history of GDM randomized toPaulweber B et al. IMAGE-Gplacebo had an incidence rate of T2DM about 70% higher than
that of women without such a history, despite equivalent levels
of glucose intolerance at baseline [37]. Metabolic assessments
recommended after GDM are [33,38] (D): post delivery (1–3
days): FPG or random PG to detect persistent or overt diabetes,
6–12 weeks postpartum: OGTT, 1 year postpartum: OGTT, annu-
ally: fasting plasma glucose, tri-annually and pre-pregnancy:
OGTT to classify glucose metabolism.
Polycystic ovary syndrome (PCOS). PCOS affects about one in 15
womenworldwide with up to 10% of women of reproductive age
[39] and shows familial aggregation and ethnic variation in its
prevalence. At present, there are three main definitions for PCOS.
The National Institutes of Health (NIH) criteria require the pres-
ence of hyperandrogenism and/or hyperandrogenemia, chronic
anovulation, and exclusion of related disorders such as hyperpro-
lactinemia, thyroid disorders, and congenital adrenal hyperplasia
[40]. The 2003 Rotterdam criteria include two or more of the fol-
lowing in addition to exclusion of related disorders: oligo-anovu-
lation or anovulation, clinical and/or biochemical signs of hyper-
androgenism, polycystic ovaries [41]. The most recent criteria
was defined by a task force of the Androgen Excess Society (AES)
in 2006, which recommended the following criteria: hirsutism
and/or hyperandrogenemia, oligo-ovulation and/or polycystic
ovaries, exclusion of other androgen excess or related disorders
[42]. Using the NIH criteria in unselected populations of women
of the reproductive age the prevalence of PCOS is 6.5–8.0% [43].
The 2003 Rotterdam criteria result in a 1.5 fold higher prevalence
of PCOS [44].
The etiology of PCOS is incompletely understood, but studies sug-
gest a strong genetic component influenced by gestational envi-
ronment and lifestyle factors. Most women with PCOS have in-
creased insulin resistance and impaired β-cell function compared
with age- and BMI-matched controls [45]. Approximately 30% of
women with PCOS have IGT and up to 10% are diabetic [46]. In
the United States up to 40% of all women with PCOS have devel-
oped T2DM or IGT by the age of 40 years [47]. More pronounced
endocrine disturbances conferring a particularly high risk for
T2DM are observed in women with PCOS and obesity as com-
pared with normal weight women with this condition [48].
Women with PCOS have a higher incidence of GDM, pregnancy-
induced hypertension, and preeclampsia [49]. A recent meta-
analysis revealed an approximately 3-fold increased risk as as-
sessed from the odds ratio of 2.94 [95% confidence interval, CI
1.70, 5.08] for GDM among women with PCOS [50].
Modifiable risk factors
Overweight and obesity. Obesity (BMI ≥ 30 kg/m2) and over-
weight (BMI 25–30 kg/m2) increase the risk for developing bothuideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
Table 2 Classification of glucose homeostasis based on fasting blood glucose and 2-hour blood glucose after a 75-g oral glucose tolerance test (OGTT)
Fasting glucose Venous plasma (mmol/l/mg/dl) Capillary whole blood (mmol/l/mg/dl)
Normal fasting glucose < 6.1/<110 < 5.6/<100
Impaired fasting glucose 6.1 and < 7.0/110 and < 126** 5.6 and < 6.1/100 and < 110
Diabetes 7.0/126 6.1/110
2 h glucose*
Normal glucose tolerance < 7.8/140 < 7.8/140
Impaired glucose tolerance 7.8 and < 11.1/140 and < 200 7.8 and < 11.1/140 and < 200
11.1/200 11.1/200
*Glucose level 2 h after ingestion of 75 g oral glucose load; if 2 h glucose is not measured, status remains uncertain as diabetes or IGT cannot be excluded; ** according to the
classification recommended by the ADA impaired fasting glucose is defined as fasting plasma glucose levels between 5.6 and 7.0mmol/l (100–126mg/dl)
S6 GuidelinesIGT and T2DM at all ages [51]. They act, at least in part, by induc-
ing insulin resistance [52]. More than 80% of cases of T2DM can
be attributed to obesity. Reversal of obesity also decreases the
risk for T2DM (A) [53] and improves glycemic control in patients
with established diabetes (A) [54]. A strong curvilinear relation-
ship between BMI and the risk for T2DM was found in women in
the Nursesʼ Health Study (B) [55]. The age-adjusted relative risk
for diabetes was 6.1 times higher for people with BMI >35 kg/m2
than for people with BMI < 22 kg/m2. The degree of insulin resis-
tance and the incidence of T2DM are highest in those subjects
with upper body or abdominal adiposity, as assessed from waist
circumference [56,57]. Adiposity of the “gynoid" type, which pri-
marily affects the gluteal and femoral region is not associated
with glucose intolerance or increased CVD risk. However, studies
trying to discern the relative importance of waist circumference
(or waist-to-hip ratio) compared to BMI regarding risk for T2DM
development have not shown a major advantage of one over the
other (A) [58].
Physical inactivity. Recent data from the Nurses Health Study in-
dicate that both obesity and physical inactivity independently
contribute to the development of T2DM: the magnitude of risk
contributed by obesity, seems to be greater than that imparted
by lack of physical activity [59,60]. The benefit of physical activ-
ity in preventing diabetes has been demonstrated in several stud-
ies (A) [61–69].
Disturbances in intrauterine development/prematurity. There
is an inverse association between birth weight and risk for
T2DM. Specifically, subjects who had a low birth weight for ges-
tational age have, as adults, reduced β-cell function [70], insulin
resistance [71] and an increased incidence of T2DM (B) [72].
Small-for-gestational-age babies are those whose birth weights
lie below the 10th percentile for their gestational age. Low birth
weight (< 2500 g) is sometimes used synonymously. Thinness at
birth and in adult life have opposing effects on insulin resistance,
such that subjects who were underweight at birth, but who be-
come overweight in middle age, have the most severe insulin re-
sistance and the greatest risk for T2DM [73]. Higher birth weight
(> 4000 g) may also be associatedwith an increased risk for T2DM
(B) [74]. Large-for-gestational-age babies are those whose birth
weights lie above the 90th percentile for their gestational age. A
meta-analysis of 14 studies demonstrated a U-shaped relation-
ship between birth weight and diabetes risk [75]. Both high and
low birth weight were similarly associatedwith increased risk for
diabetes later in life (OR: 1.36 and 1.47). Children born prema-
turely, whatever their weight, may also be at increased risk for
T2DM (B) [76,77].Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201Impaired fasting glucose (IFG) and impaired glucose tolerance
(IGT). IFG and IGT are early abnormalities of glucose metabolism
that precede diabetes. These are often called prediabetes. IFG is
defined as an elevated FPG concentration between 6.1–
6.9mmol/l. In 2003 the lower cut-off value was reduced to
5.6mmol/l by the American Diabetes Association (ADA) [78],
which was not accepted by the WHO in 2006 [79] (l" Table 2).
IGT is defined as an elevated PG between 7.8 and 11.1mmol/l at
2 hours after a 75-g OGTT, in the presence of an FPG < 7mmol/l
[78,80]. It is clear that with the definitions above, there is overlap
between the two groups. Thus, additional groups have been cre-
ated, namely isolated IFG (i-IFG), isolated IGT (i-IGT) and IFG plus
IGT (IFG + IGT).
The prevalence of IFG and IGT varies considerably among differ-
ent ethnic groups and increases with age (B). IGT is more com-
mon in women. IFG and IGT are believed to represent different
metabolic abnormalities. The reported estimates of diabetes de-
velopment in IFG and IGT individuals vary widely, depending on
the ethnicity of the population studied, with a higher incidence
of T2DM noted in non-Caucasian populations (B).
Two recent meta-analyses found no evidence of a difference in
T2DM risk among people with either IGT, IFG, i-IGT or i-IFG
[81,82], but both concluded that individuals with IFG + IGT have
a substantially increased risk of T2DM compared to all other
groups (B). The first meta-analysis included 44 studies and calcu-
lated the unadjusted annualized relative risk (RR) for progression
to diabetes at 6.02 for IGT, 5.55 for IFG and 12.21 for IFG + IGT. The
second meta-analysis included 40 studies and the RR was found
to be 6.35 for IGT, 4.66 for IFG and 12.13 for IFG + IGT. Of note,
most of the literature on IFG is based upon the older cut-off point
(6.1–6.9mmol/l) while the risk associated with IFG as more re-
cently defined by the ADA (5.6–6.9mmol/l) in 2003 remains to
be evaluated.
According to the available data, it has been estimated that the
majority of individuals (probably up to 70%) with these predia-
betic conditions will eventually develop diabetes [83]. However,
studies of shorter duration have shown that during a period of
3–5 years about 25% of individuals progress to diabetes, 25% re-
turn to a normal glucose tolerance status and 50% remain in the
prediabetic state (B) [84,85].
Metabolic syndrome (MetSy). MetSy is defined as a cluster of
metabolic risk factors for cardiovascular diseasewhich are associ-
ated with insulin resistance [86,87]. It is associated with an up to
2-fold elevated risk for CVD [3]. Although several diagnostic crite-
ria have been proposed by different organizations, there is an on-
going debate regarding the existence of unique underlying path-
ophysiology [88–90]. The most widely used criteria were defined0; 42 (Suppl. 1): S3–S36
S7Guidelinesby the National Cholesterol Education Program (NCEP‑ATP III)
and include central obesity, high fasting plasma glucose, high tri-
glycerides, low HDL-cholesterol and high blood pressure [86]. A
harmonized definition of the MetSy has recently been suggested
in a joint statement issued by several international organizations
[91]. Despite the fact that the MetSy strongly predicts progres-
sion to T2DM [92], several reports [93–95] show that a single
measure of blood glucose is a better predictor of incident diabe-
tes than the complex definition of the MetSy. In a recent analysis
from the San Antonio heart study, however, the metabolic syn-
drome as defined by the NCEP criteria predicted T2DM indepen-
dently of the presence of elevated FPG [96]. The MetSy was as
good a predictor for the occurrence of T2DM as iIFG (OR: 5.03
versus 7.07). If both conditions occurred simultaneously, the risk
for T2DM was much higher (OR: 21.0).
Dietary factors. Diet is thought to play an important role, and
some data suggest that certain dietary factors may predict
T2DM but confounding factors limit many nutritional clinical
studies. Even randomized nutritional clinical trials often suffer
from several short-comings as they may start too late in the dis-
ease process, not be continued for sufficient duration or be inad-
equately powered. In addition, the protective (or deleterious) ef-
fect of a certain nutrient may only operate in conjunction with
other nutrients or at a particular intake level. Finally, poor dietary
compliance is another common problem of dietary trials. It is
clear however that diet can influence the development of T2DM
by affecting bodyweight. It has been shown that a dietary pattern
promoting weight loss reduces the risk of T2DM (A) [61,65,68].
More recently, higher T2DM risk was also found to be associated
with diet composition, particularly with low fibre intake.
Low fibre intake [97–100]. Individuals with low intake of dietary
fibre, particularly of insoluble cereal fibre, have been found to be
at increased risk for T2DM in several epidemiologic studies (B)
[101,102]. In studies aimed at diabetes prevention by lifestyle
modification, an increase in fibre consumption was often part of
the intervention [61,65]. Fibre has a low glycemic index, which
may contribute to T2DM risk reduction. However, the evidence
for an increased risk associated with high glycemic index and
high glycemic load diets is mixed [98–100,103]. Nevertheless, a
recent meta-analysis of 37 prospective cohort studies (B)
showed, in fully adjusted models, that both high glycemic load
(RR 1.27 [95% CI 1.12, 1.45]) and high glycemic index (RR 1.40,
[95% CI 1.23, 1.59]) diets are associated with increased risk for
T2DM [104]. It must be emphasized that fibre rich foods gener-
ally have a low GI, although not all foods with a low GI necessarily
have high fibre content.
Low unsaturated/saturated fat ratio [105–107]. Shifting from a
diet based on animal fat to a diet rich in vegetable fat might re-
duce the risk for T2DM (B) [61,65]. An increased intake of
monounsaturated fat appears to be of particular benefit (C)
[108]. Recent studies revealed a weak positive correlation be-
tween intake of long chain omega-3 fatty acids (LCFA) and diabe-
tes risk [109,110].The beneficial effects of LCFA on other health
outcomes, however, are well established [108,111]. The con-
sumption of trans fatty acids has consistently been found to be
associated with increased risk for T2DM [112] and CVD [113] (A).
Other nutrients. A less consistent but still significant body of evi-
dence suggests that the risk for T2DM is lowered by regular con-Paulweber B et al. IMAGE-Gsumption of moderate amounts of alcohol (B) [114,115], fruits
and vegetables (B) [116], nuts (B) [117] and coffee (B) [118]. It
must be emphasized that people do not consume nutrients in
isolation but rather ingest a variety of nutrients at the same time
as they eat their food [119]. The study of different dietary pat-
terns such as the “Mediterranean diet” is an alternative approach
to examining the possible relationships between diet and T2DM
[120].
Diabetogenic drugs. A large number of drugs mayworsen in gly-
cemic control in diabetic patients, or even cause diabetes in pre-
disposed people. These drugs include various classes of agents
[121], such as glucocorticoids, antihypertensive drugs (beta
blockers, thiazide diuretics) [122], niacin, immunosuppressive
drugs, gonadotropin releasing hormone agonists, pentamidine,
diazoxide, atypical antipsychotic agents [123], the antineoplastic
agent asparaginase, danazole, and anti-retroviral drugs used for
the treatment of HIV infection [124].
Obesogenic/diabetogenic environment. The recent increase in
T2DM seems to be strongly linked to unfavorable changes in the
environment (B) [125]. The abundant availability of energy dense
and highly palatable food and changes in transport, work and lei-
sure infrastructure and opportunities decreasing physical activ-
ity are the main obesogenic and diabetogenic environmental fac-
tors [126]. To change this environment in a beneficial way is a
major challenge for T2DM prevention [127,128].
Smoking increases the risk for T2DM by adversely affecting insu-
lin sensitivity and beta-cell function [129,130]. The potential of
xenobiotics to disturb glucose and lipid metabolism in mammals
is well established [131].
A strong correlation between insulin resistance and serum con-
centrations of persistent organic pollutants (POPs), especially or-
ganochlorine compounds has been reported [131–136]. It has al-
so been proposed that modern food processing can generate dia-
betogenic compounds, such as glycation end products or oxidized
ascorbic acid and lipoic acid [125].
Depression. Psychosocial factors may play a causal role in the
chain of events leading to development of the MetSy [137]. De-
pression has been considered as a risk factor for T2DM and its
complications [138,139] and an increased risk for developing
T2DM in adults with depression has been demonstrated in a
meta-analysis of 9 longitudinal studies [140] (B). A recent analy-
sis of the DPP found that baseline antidepressant use was associ-
atedwith diabetes risk in the placebo and intensive lifestyle arms,
but not in the metformin arm [141]. Potential mediators of the
effects of depression on diabetes risk have been summarized
elsewhere [139].
Low socio-economic status. Several studies have recognized the
adverse influence of low socioeconomic status (SES) on general
health, prevalence of obesity, smoking, CVD, and early mortality
[142–148]. There is also an inverse association between SES and
T2DM, with a higher prevalence among less-advantaged groups.
This appears to be consistent across several developed countries
and across different ethnic groups (B) [149–157]. An inverse
graded association between diabetes prevalence, metabolic dis-
orders and different measures of SES such as education, occupa-
tion, income, poverty income ratio, and measures of material
deprivation and poverty has been found (B) [158–162]. Although
T2DM prevalence is increasing in the population at large, the in-uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
S8 Guidelinescrease is more pronounced among people with lower SES [163].
In some, but not all studies an independent association between
lower SES in childhood and increased risk for T2DM and cardio-
vascular disease in adulthood has been observed [163–168]. The
underlying processes are not yet fully understood, but associa-
tions between lower SES and diabetes risk factors like obesity,
waist circumference, smoking, inappropriate diet, and leisure
time inactivity appear to be important [169–171].
Definition of target populations
For successful prevention of T2DM both a whole population ap-
proach and an individual (targeted high-risk) approach are rec-
ommended.
Whole population approach
The IDF consensus [172] recommends a population as well as an
individually targeted approach for diabetes prevention. Simply
distributing information about T2DM risk and available strat-
egies for risk reduction, however, is not sufficient to reverse the
T2DM epidemic. For successful prevention it is important to cre-
ate environmental conditions that are conducive to achieving and
maintaining a healthy lifestyle. The health sector on its own can-
not accomplish such population-wide changes. National diabetes
prevention plans are required, which should include the compo-
nents proposed in the IDF consensus, namely advocacy, com-
munity support, fiscal and legislative measures, engagement of
the private sector, media communication, and improving level of
knowledge and motivation of the population [172].
Unlike interventions that focus on high-risk individuals, the pop-
ulation approach is not supported by a large database of clinical
studies. A UK cohort study found that diabetes incidence was in-
versely related to the achievement of five “healthy behaviour
goals for diabetes prevention” (BMI < 25 kg/m2, fat intake < 30%
of energy intake, saturated fat intake < 10% of energy intake, fibre
intake ≥ 15 g/4, 184 kJ, physical activity > 4 h/week) [173]. The in-
cidence of T2DMwas inversely and linearly related to the number
of goals achieved. None of the participants who met all five goals
developed diabetes, whereas the highest incidence was observed
in subjects who did not meet any of the goals. (2++, B).
High-risk approach
It is current practice in several countries (e.g. UK, USA, Finland
and France) to recommend targeted or opportunistic screening
to identify high risk individuals. The IDF consensus document
[172] recommends the use of opportunistic screening by health
care personnel, particularly those working in primary care. Risk
for T2DM and CVDmay be assessed quantitatively by appropriate
methods such as blood testing (fasting plasma glucose, OGTT, lip-
id profile, and HbA1c) and searching for the presence of other risk
factors like family history of premature CVD, hypertension, vis-
ceral obesity, physical inactivity, unhealthy diet and smoking.
Appropriate interventions (e.g. antihypertensive and lipid ther-
apy, aspirin, smoking cessation, dietary changes, exercise, weight
loss) targeting all identified risk factors should subsequently be
initiated.
The IDF recommends the following criteria for opportunistic
screening (or targeted screening) [172]: obesity (including vis-
ceral), family history of diabetes, age, history of raised blood pres-
sure and/or heart disease, history of GDM, and drug history. Re-
cently best practice guidelines for vascular risk assessment and
management have been issued by the UK National Health Service
(www.dh.gov.uk/publications). According to these guidelines tar-Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201geted screening for T2DM risk by measuring either FPG or HbA1c
is recommended in asymptomatic subjects aged 40–74 years
with obesity and/or elevated blood pressure (≥ 140/90mmHg).
In subjects with FPG (6–7mmol/l) or HbA1c (6–6.5%) in the pre-
diabetic range, an OGTT is recommended.
Target populations for interventions
It is thought that most patients pass through a prediabetic phase
before developing T2DM [174]. Subjects with IGT are at highest
risk for T2DM, but individuals with isolated IFG and the MetSy
[95,96,175] are also at increased risk [96,176]. Particularly high
conversion rates (> 10% per year) have been observed in subjects
with a combination of 2 or 3 prediabetic conditions (IGT ± IFG,
±MetSy) [83,96]. Therefore a hierarchical approach is proposed
starting with subjects with IGT ± IFG, ±MetSy (A), IFG and/or
MetSy (C), (overweight, obesity, hypertension, or physical inac-
tivity) (C) and finally the general population (C) [177,178] (l" Ta-
ble 6). It has to be emphasized that the major prevention trials
[120] have all focused on patients with IGT (± IFG). Given the fact
that resources are limited, the intensity of the intervention
should be adjusted to the level of risk, implying that subjects at
highest risk should receive the most intensive intervention (B).
Recommendations
A hierarchical approach for prevention of T2DM is proposed:
A starting with subjects at highest risk for T2DM (IGT ± IFG,
±MetSy) with highest priority,
C followed by subjects at high risk (IFG and/or MetSy) with high
priority,
C subjects with overweight, obesity, hypertension, or physical
inactivity with medium priority and
C finally the general population with low priority.
B Given the fact that resources are limited, the intensity of the
intervention should be adjusted to the level of risk, implying that
subjects at highest risk should receive the most intensive inter-
vention.Screening Tools, Diagnosis and Detection
!
Categorization of abnormal glucose metabolism
In practice, the glucometabolic category depends on whether
FPG is measured alone or combined with a 2-h PG. For example
an individual falling into the IFG category may also have IGT or
diabetes, which would only be discovered by a post-load BGmea-
surement. In the text, IFG and/or IGTwill be defined as prediabe-
tes. As to HbA1c, a high HbA1c level may only identify a fraction
of asymptomatic people with diabetes. HbA1c is insensitive in
the low range and a normal HbA1c level cannot exclude the pres-
ence of diabetes or prediabetes.
Epidemiological arguments
Several epidemiological studies have challenged the practice of
not using the 2-h PG and have showed that a substantial number
of people who do not meet the FPG criteria for glucose disorders
will satisfy the criteria when exposed to an OGTT [180–182].
Thus, the OGTT is more sensitive than FPG for detecting diabetes
and the only way to detect IGT. The probability of false negative
results is substantial, when measuring FPG only. But there are
some important arguments against OGTT. OGTT needs to be per-
formed in appropriate conditions and should be standardized
(Appendix 1). In particular, OGTT should be carried out after at0; 42 (Suppl. 1): S3–S36
S9Guidelinesleast 3 days of unrestricted (> 150 g) carbohydrate intake daily.
This test has been considered to be less appropriate at a popula-
tion level, mainly because it takes more than 2 h to perform, is
costly and has a low reproducibility. However, the true primary
prevention of diabetes requires the identification of high-risk
subjects and treatment to prevent their transition to overt diabe-
tes. This needs a definite categorization of glycemic states.
Arguments based on the natural history of glucose
abnormalities
The rate of conversion to diabetes is very high in people with IGT
or IFG, and even higher in those with IGT + IFG, as discussed ear-
lier. Approximately 30% of people with IGTwill convert to T2DM
within 5 years [183] implying that at-risk individuals should be
screened for both IFG and IGT.
Arguments based on prevention trials
To date, prevention trials mainly included patients with IGT,
whereas only one trial included also patients with IFG only [61,
65,68,184–187]. This trial showed that prevention of the transi-
tion from IFG to diabetes is possible so that IFG may also be con-
sidered a target for intervention [188].
Arguments based on CVD risk
Patients with IGT are at high risk for developing CVD. The most
convincing evidence of increased CVD risk was provided by the
DECODE (Diabetes Epidemiology: Collaborative analysis Of Diag-
nostic criteria in Europe) study, which showed that IGT is more
predictive of CVDmortality than FPG levels [5]. Many individuals
with prediabetes have a cluster of other cardiovascular risk fac-
tors, i.e. abdominal adiposity, elevated triglycerides, low HDL-
cholesterol, elevated blood pressure, known as components of
the MetSy, as well as raised LDL-cholesterol levels [189].
Taking all of the above arguments into account, it is strongly sug-
gested that clinicians categorize the type of glycemic abnormal-
ities as precisely as possible to identify people with IFG and IGT
and, in those with IGT, to screen for associated CVD risk factors,
in order to achieve the goals of both diabetes and CVD preven-
tion. However this step should be preceded by a screening phase
in order to select subjects with a high chance of having prediabe-
tes or developing T2DM.
Detection of people at high risk for diabetes
Detection programmes may be targeted widely or restricted to
higher risk populations. They may use risk scores and/or blood
glucose measurement. Scoring systems based on the presence
and extent of a number of aetiological factors may be helpful to
identify people at high risk for T2DM. They need to be reliable,
simple and practical. A number of tools have been developed to
screen for undiagnosed diabetes and/or diabetes and for the risk
of incident diabetes (l" Tables 3, 4).
Several risk scores based on large cohort studies are available
[85,190–196]. However, fewof these rely on factors that aremea-
surable with non-invasive methods and are not therefore appli-
cable outside of clinical practice. Most were developed to rate
the risk for developing T2DM (l" Table 4) and some seem to be
valuable for detecting current undiagnosed diabetes (l" Table 3),
and for identification of patients with MetSy, insulin resistance
and at risk for CVD. Therefore such questionnaires are able to se-
lect populations in whom blood glucose could be measured and/
or lifestyle advice provided in order to prevent diabetes. Some
scores directly require a diagnostic test, such as random capillaryPaulweber B et al. IMAGE-Gglucose measurement (interpreted according to time since last
meal) [197].
European population
The Finnish risk test (FINDRISC) takes only a couple of minutes,
can be taken online (www.diabetes.fi or http://care.diabetesjour-
nals.org for an English version) and provides a measure of the
probability of developing T2DM over the following 10 years. The
FINDRISC test is based on a representative random sample of the
Finnish population, aged 35–64 years and their 10-year incidence
of drug-treated T2DM. It includes 8 items: age, BMI, waist cir-
cumference, antihypertensive medication, history of elevated
blood glucose (including GDM), meeting the criterion for daily
physical activity and daily intake of fruit or vegetables. The last 2
variables were introduced to increase awareness about the im-
portance of lifestyle modifications, although they were not asso-
ciated with increased diabetes risk. The performance of this scor-
ing test as a screening tool was assessed in a cross-sectional, pop-
ulation-based survey of subjects aged 45–74 years. The risk score
was associatedwith the presence of previously undiagnosed T2D,
IGT, MetSy and CVD risk factors. Using a cut-off score of 11 (max-
imum: 20), the sensitivity to identify undiagnosed diabetes was
66% in men and 70% in women, with false-negative rates of 31%
and 39% [198]. The performance was also satisfactory in an Ital-
ian cohort [122].
A simplified version of the FINDRISC consisting of 6 questions
was validated in a German population aged 41–79 years with a
family history of T2D, obesity, or dyslipoproteinemia and found
to be a simple tool with high performance to predict diabetes risk
but less efficient to identify asymptomatic T2DM [199]. In the
IGLOO (Impaired Glucose tolerance and Long-termOutcomes Ob-
servational) study in an Italian cohort aged 55–75 years with one
or more CVD risk factors, the FINDRISC score had a sensitivity of
77% and a specificity of 45% to detect people with T2DM [122].
A Danish diabetes risk score including six questions (age, sex,
BMI, family history of diabetes, known hypertension, physical ac-
tivity at leisure time) has been developed in a population-based
sample of individuals aged 30–60 years who underwent an
OGTT. This simple score which can be completed at home identi-
fied 76% of individuals with previously undiagnosed T2DM, with
a specificity of 72%, reducing the proportion of individuals in the
population that need subsequent testing to 29% [200].
The Cambridge risk score comprises data routinely available in
UK general practice (age, sex, BMI, family history of diabetes,
smoking habits, and prescribed anti-hypertensive drugs or ste-
roids) [201] and allows to identify individuals with undiagnosed
diabetes in different ethnic groups [202–204]. It has also been
validated in a Danish population where a risk score above the
threshold of 0.246 provided a sensitivity of 71%, a specificity of
81%, and a positive predictive value of 8% to detect diabetes
[205]. The QDS score has been developed from data of 2540753
patients aged 25–79 years collected by 355 GPs in UK and Wales,
of whom 78081 had an incident diagnosis of type 2 diabetes. This
score includes ethnicity, age, sex, BMI, smoking status, family his-
tory of diabetes, Townsend deprivation score, treated hyperten-
sion, cardiovascular disease, and current use of corticosteroids.
It can be applied systematically to computerised patient data-
bases [196].
A questionnaire including readily available information (age, sex,
presence of obesity, use of anti-hypertensive medication) has
been developed from a sample of participants aged 55–75 years
who were recruited in the Rotterdam Study, to screen for preva-uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
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S12 Guidelineslent T2DM. This simple questionnaire has been tested in the
Dutch Hoorn Study and provides good performance at the cut-
off point of > 6 with a sensitivity 78%, specificity 55%, negative
predictive value 98%, positive predictive value 8% [206].
The German Diabetes Risk Score which includes information on
age, waist circumference, height, history of hypertension, physi-
cal activity, smoking, and consumption of red meat, whole-grain
bread, coffee, and alcohol is also publicly available (http://www.
dife.de). This score has been developed in the prospective Pots-
dam cohort of the EPIC (European Prospective Investigation into
Cancer and Nutrition) study of individuals aged 35–65 years. It
was further shown to be an accurate tool to identify individuals
at high risk for undiagnosed T2DM and to correlate well with
measures of insulin resistance and impaired insulin secretion in
three other German cohorts [207].
The Data from Epidemiological Study on the Insulin Resistance
syndrome (DESIR) study produced a risk score from a French co-
hort followed up over 9 years, and validated in two other French
cohorts [208]. It includes waist circumference and hypertension
in both sexes, and smoking in men and family history of diabetes
in women. A risk score of 5 confers a > 30% chance of diabetes in
the following 9 years.
In conclusion, the FINDRISC score meets the requirements of
being a simple, non-invasive and inexpensive tool. It has been
used in several European cohorts, and shown to be a reliable tool
both for detecting undiagnosed diabetes and for predicting fu-
ture diabetes risk. The DESIR score also meets the same criteria
but has not been tested for detecting undiagnosed diabetes. It is
simpler than the FINDRISC score, but that latter provides more
opportunities for lifestyle discussion and has been validated in
several European populations.
US population
The ADA risk test is a simple, user-friendly risk test based on age,
weight, family history of diabetes, and for women, having a baby
weighing more than 9 pounds at birth (www.diabetes.org).
The score, derived from the San Antonio Heart Study, includes
age, sex, ethnicity, BMI, family history of diabetes and systolic
blood pressure, and two biological parameters (FPG and HDL-
cholesterol) but does not perform better than FPG alone [85].
The ARIC risk score demonstrated low validity in the testing sam-
ple [100]. Furthermore its applicability to European Caucasian
populations may be limited because it was derived from a US
population.
The Diabetes Risk Calculator has been developed as a screening
tool for undiagnosed diabetes and prediabetes, based on the
Third National Health and Nutrition Examination Survey
(NHANES III) dataset (7092 participants ≥ 20 years with FPG
being measured in all at fasting, and an OGTT being performed
in approximately half of those aged 40–75 years). This tool in-
cludes simple questions and performed well [209].
Asian population
An Indian Diabetes Risk Score has been developed from the Chen-
nai Urban Rural Epidemiological Study (CURES) in India for
screening for undiagnosed diabetes. This simple test uses four
risk factors (age, waist circumference, family history of diabetes
and physical activity), and has a sensitivity of 72% and a specific-
ity of 60% with a positive predictive value of 17% and a negative
predictive value of 95% [210].Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201A simple risk equation (including age, BMI, and hypertension) has
been described in a high-risk Thai population and allowed to de-
tect 87% of undiagnosed diabetes [211].
Applicability of screening tools
Screening tests using questionnaires also need to be performed
in appropriate conditions. The FINDRISC score may be used as a
self-administered test (as it was in the first validation study).
However it is recommended that the answers should be checked
by a nurse or a physician.
More importantly, four published screening tests (Rotterdam
Diabetes Study, Cambridge Risk score, San Antonio Heart Study
and FINDRISC score) have been applied to detect undiagnosed
diabetes in a German population (KORA Survey 2000). These
tests yielded low validity when applied to that new population,
most likely due to differences in population characteristics
[212]. Low performances were also demonstrated in German
subjects with a family history of T2DM [199] and in the popula-
tion of Oman [213]. This suggests that performance of diabetes
risk questionnaires or scores must be assessed in the target pop-
ulation where they will be ultimately applied. However, all these
screening tools had a high negative predictive value (94–98%),
and thus may be helpful when the findings are negative rather
than positive.
The DETECT-2 project, an international data pooling collabora-
tion, on screening for T2D specifically addressed ethnicity and
population differences [214]. Nine datasets were selected, which
were representative of people from a diverse range of ethnic
backgrounds. The use of the Rotterdam Predictive Model [206],
yielded awide variation of the performancewith sensitivity, spe-
cificity, and percentage needing further testing ranging between
12 and 57%, 72 and 93%, and 2 and 25%, with a worse perfor-
mance in non-Caucasian populations. Thus, a risk score devel-
oped in Caucasian populations cannot be applied to other popu-
lations of more diverse ethnic origins.
After scoring for diabetes risk, it is mandatory to inform patients
about their elevated risk and to take time to deliver explanations,
in particular to low educated individuals, as recently stressed in a
study carried out in the US that included a large number of mi-
nority populations [215]. This needs to be done appropriately in
order to raise the awareness and understanding of T2DM and its
risk factors, while avoiding or minimizing negative effects, such
as emotional distress and denial [216].
Strategies for detection of people at high risk for
diabetes
Community based strategies
Various approaches exist: (i) measuring PG in specified popula-
tion groups (e.g. age over 40) to determine prevalent prediabetes
(a strategy that will detect undiagnosed diabetes as well); (ii) us-
ing computer database searches/risk-scoring algorithms or col-
lecting questionnaires to provide an estimate of the risk for inci-
dent diabetes (a strategy that leaves the current glycemic state
undetermined); (iii) using risk scores or questionnaires as pri-
mary screening tools to identify sub-groups of the population in
whom glycemic testing may be targeted efficiently.
Alternative (iii) has been tested in the IGLOO study [122]. In that
study, the use of the FINDRISC score as initial instrument, fol-
lowed by the measurement of FPG in individuals with a score ≥ 9
and by the OGTT in individuals with FPG between 5.6 and
6.9mmol/l, would have led to the identification of 83% of T2DM
cases and 57% of IGT cases, at a cost of an OGTT in 38% of the sam-0; 42 (Suppl. 1): S3–S36
Fig. 1 Community based strategies for detection
of people at high risk for type 2 diabetes.
S13Guidelinesple and a FPG in 64% [122]. Therefore, a multiple step approach
may be proposed, consisting of using first a risk score, then mea-
suring fasting BG, and if FPG is increased, lastly performing an
OGTT. An alternative may be performing an OGTT in all individu-
als with a high test score.
A similar approach was tested in the Anglo-Danish-Dutch study
of intensive treatment in people with screen-detected diabetes
in primary care (ADDITION [183]). Stepwise screening strategies
were performed using risk questionnaires and routine clinical
practice data plus random blood glucose, HbA1c and fasting
blood glucose measurement. Diabetes was diagnosed using the
1999WHO criteria and estimated 10-year coronary heart disease
risk was calculated using the UK Prospective Diabetes Study risk
engine. Out of 76308 people aged 40–69 years, a total of 3057 in-
dividuals with screen-detected diabetes were identified.
A community-based strategy (l" Fig. 1) should consist of a screen-
ing test as a first step in order to estimate the risk for current dia-
betes or prediabetes and the risk for future diabetes (A). In agree-
ment with the IDF, we recommend the use of opportunistic
screening by health-care personnel including those working in
general practice, nurses and pharmacists [172] (A). Self-adminis-Criteria for screening for diabetes and prediabetes within targeted populat
a)White people agedover 40 years or people fromBlack, Asian andminority ethnic g
the following risk factors:
" a first degree family history of diabetes and/or
" BMI over 25 kg/m2 and/or
" waistmeasurementofover ≥ 94 cm forWhite andBlackmen and≥ 80 cm forWhit
Asianmen and/or
" systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg or tr
" HDL-cholesterol ≤ 0.35 g/l (0.9mM) or triglycerides ≥ 2 g/l (2.2mM) or treated dy
b)Women with a history of gestational diabetes or with a child weighing > 4 kg at bi
c) People with history of temporarily induced diabetes, e.g. steroids,
d) People who have ischaemic heart disease, cerebrovascular disease, peripheral vas
e)Women with polycystic ovary syndrome who have a BMI ≥ 30 kg/m²,
f) People who have severemental health problems and/or receiving long term anti-p
g) People with a history of IGTor IFG.
Paulweber B et al. IMAGE-Gtered questionnaires may also be used to identify people at risk
(e.g. by anyone on the Internet, or in pharmacies, or as part of na-
tional health surveys) and used to prompt further diagnostic test-
ing by a health care provider. If a person is considered to be at in-
creased risk for diabetes, they will proceed to PG measurements
(either fasting or preferably using an OGTT). At the very least,
measurement of random capillary blood glucose can be used
with an improved performance if measurement is done in the
postprandial period [217]. A high HbA1c level may also identify
a subset of asymptomatic people with diabetes. Indeed, the sen-
sitivity of HbA1c measurement for the screening of undiagnosed
diabetes was found to be fairly good as compared to FPG [218].
HbA1c was less sensitive for detecting prediabetes or diabetes
when compared to OGTT results [219]. The available resources
may define the testing regime used in each country/locality.
Clinical practice-based strategies
A diagnostic test may be used in routine clinical practice but as it
is time-consuming, one may propose to select the patients with
at least one obvious risk factor for diabetes, such as age > 40 years,
overweight or obesity, components of the MetSy, family historyTable 5 IMAGE criteria for
screening for diabetes and predia-
betes within target populations
ions
roups agedover 25 yearswith 1 ormore of
e, Black andAsianwomen, and ≥ 90 cm for
eated hypertension and/or
slipidemia
rth,
cular disease,
sychotic drugs,
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Table 6 Suggested priorities for diabetes prevention
Highest priority
" persons with IGT (IGT ± IFG) (Evidence A)
High priority
" persons with isolated IFG (Evidence C)
" persons withMetSy (age (45 years) as defined by the ATPIII criteria or other
criteria which are associated with increased T2D risk (e.g. IDF criteria for
MetSy) (Evidence C).
Medium priority
" persons with overweight, obesity, or physical inactivity (Evidence C)
Low priority
" general population (Evidence C)
S14 Guidelinesof GDM, polycystic ovary syndrome or ethnicity (migrants). Such
factors are identified in the sections above, and have been consid-
ered in other recent guidelines, including IDF [172], Diabetes UK
[220], France [221], American Diabetes Association [222], that all
recommend targeted or opportunistic screening of high risk indi-
viduals. Some of these recommendations have already been vali-
dated [223]. l" Table 5 summarizes the populations we recom-
mend for targeted screening (Evidence I, B). Systematically tar-
geted screening programmes may be possible here. For example,
GPs or health insurance companies with computerised databases
can pro-actively identify all people with various combinations of
risk factors and post the questionnaires to these targeted groups.
A screening strategy may consist of PGmeasurement at fasting or
even better of OGTT due to its higher sensitivity. One alternative
may be a stepped approach including an initial screening ques-
tionnaire in the process (l" Fig. 1). Two risk factors, obesity and
CVD, provide some examples for the operation of a targeted
screening process.
Cosson et al. [224] performed OGTT in 933 overweight or obese
patients with mean age of 39 years and free of known glycemic
abnormalities. Their FINDRISC score was retrospectively calcu-
lated using the clinical files. Prediabetes or diabetes was diag-
nosed in 26% of the subjects of whom 75% would not have been
diagnosedwith FPG alone. Selecting the subjects with a FINDRISC
≥ 11 to be screened directly with an OGTT had a sensitivity of
78%, a specificity of 44% and limited the number of OGTTs to
575 (60% of the study sample) [224] (B).
In patients with established CVD but without known diabetes:
the percentage of those who have IFG or unknown diabetes ac-
cording to FPG is higher than 17%, but the percentage of those
with prediabetes or diabetes according to OGTT is far higher
(> 50%). In other words among patients with CVD and glucose ab-
normalities, in most cases it is the 2-hour PG which is elevated,
whereas FPG is often normal [225]. Therefore, in patients with
CVD a scoring diabetes risk test can be applied but an OGTT
should be carried out in all patients [226] (B).
In practice, the screening strategy depends on local possibilities.
However, due to the very high number of obese subjects, OGTT is
perhaps best reserved for those with higher scores, whereas the
very high prevalence of diabetes or prediabetes in CVD patients
suggests that performing OGTT routinely in these patients is the
best strategy (l" Table 6).
Recommendations
A As OGTT has a higher sensitivity than FPG for detecting diabe-
tes and is the only test to detect IGT, a definite categorization of
glycemic state needs an OGTT.
A Several risk scores are available and valuable for detecting cur-
rent undiagnosed diabetes and/or to rate the risk for developing
T2DM. The FINDRISC meets the requirements of being a simple,
non-invasive and inexpensive tool and has been shown to be a
reliable tool both for detecting undiagnosed diabetes and for pre-
dicting future diabetes risk in several European cohorts.
B Performance of diabetes risk scoresmust be assessed in the tar-
get population where they will be ultimately applied.
A After scoring for diabetes risk, it is mandatory to inform partic-
ipants about their risk and to take time to deliver explanations, in
particular to low educated individuals. This needs to be done ap-
propriately in order to raise the awareness and understanding of
T2DM and its risk factors, while avoiding or minimizing negative
effects, such as emotional distress and denial [216].Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201A A community-based strategy should consist of using a screen-
ing test as a first step in order to estimate the risk for current dia-
betes or prediabetes and the risk for future diabetes. It is recom-
mended the use of opportunistic screening by health-care per-
sonnel including those working in general practice, nurses and
pharmacists. If after this first step a person is considered to be at
increased risk for diabetes, they will proceed to PG measure-
ments (either fasting or preferably using an OGTT) in order to de-
termine more precisely their glycemic status.
B In routine clinical practice, a screening strategy should be tar-
geted to patients with at least one obvious risk factor for diabetes.
It may consist of PG measurement at fasting or even better of
OGTT due to its higher sensitivity. One alternative may be a
stepped approach including an initial screening questionnaire
(score of risk for diabetes) in the process. As examples, due to
the very high number of obese subjects, OGTT is best reserved
for those with higher scores, whereas the very high prevalence
of diabetes or prediabetes in CVD patients suggests that perform-
ing OGTT routinely in these patients is the best strategy.Prevention of T2DM and its Comorbidities
!
Methodology
This section was compiled following a systematic search for pri-
mary studies, systematic reviews and meta-analyses [69,178] of
research on preventing the onset of T2DM. The initial search was
undertaken using MEDLINE with follow-up of cited references.
The final selection was limited to randomized controlled trials
(RCTs) published in English between1979 and 2008, which fea-
tured development of T2DM as a study endpoint and used stan-
dard criteria for the diagnosis of diabetes mellitus. Key data from
the major studies are summarized in (l" Tables 7, 8, 9).
Findings for prevention by lifestyle modification
Major T2DM prevention studies
Da-Qing Study (CDQDPS) [184,227]. Cluster randomisation was
used to allocate 577 people with IGT attending 33 participating
clinics to diet alone, exercise alone, diet-and-exercise combined
or no intervention. The participants in the dietary intervention
were encouraged to reduce weight aiming at < 24 kg/m2, other-
wise high-carbohydrate (55–65 E%) and moderate-fat (25–30 E
%) diet was recommended. Participants were encouraged to con-
sumemore vegetables, reduce simple sugar intake and control al-
cohol intake. The participants in the exercise intervention were
encouraged to increase their level of leisure-time physical activ-
ity by at least 1–2 “units” per day, one unit corresponding for in-0; 42 (Suppl. 1): S3–S36
Table 7 Characteristics of lifestyle intervention studies to prevent type 2 diabetes
Ref. Acronym Design Intervention (int, D = diet, PA = physical activity) Follow-up (years) DROP out
[184,227] CDQDPS Cluster
randomized
D: increase vegetables, decrease alcohol and sugar,
caloric and weight reduction if overweight
6 [104] (int) 44/577 (8%) at 6 years
PA: 1–2 units/day; 1 unit = 30min slow walking/house
cleaning, 20min fast walking/cycling, or 5min jumping
rope/swimming),
D + PA: individual counselling + compliance evaluation
by physician/nurse every 3m + small groups weekly for
1m, monthly for 3m and every 3m thereafter
20 [105]
(int + follow-up)
14/577 (2%) at 20
years
[231,232,
320,321]
DPS RCT D + PA: weight reduction 5% ormore; D: < 30 E% fat,
< 10 E% sat fat, 15 g fibres/1000 kcal; PA: ≥ 30min/day
3.2 [193] (int) 42/522 (8%) at 3.2
years
Individual, personalized dietary counselling; 7 sessions
during the first year and every 3m thereafter voluntary
gym 1–2 sessions/w
7 [195]
(int + follow-up)
47/522 (9%) at 7 years
[234,322] DPP RCT D + PA: weight reduction 7% 2.8 7.5%
D: 25 E% fat
PA (e.g. brisk walking) 150min/week (700 kcal/w)
Goal-based behavioural intervention; case-managers
(1/20–26 participants)
16-session core curriculum in groups during the first
24 w; individual session every 2m thereafter + “toolbox
funds” ($100/participant/year) for expenses (cook-
books, personal trainer, aerobic tapes, reinforcers for
fulfilling behavioural contracts etc.)
[186,235] IDPP RCT D + PA 2.5 1.5% (con)
D: decrease energy, refined carbohydrates and fats,
avoidance of sugar and inclusion of fibre-rich foods
9% (int)
Face-to-face counselling at baseline and every 6m; tele-
phone contacts at two weeks andmonthly thereafter
PA: Brisk walking 30min/day ormore (or comparable
physical labour or other activity)
[187] Japanese trial in
IGTmales
RCT (1 :4) Intensive vs. standard intervention: 4 5.6% (con), 4.7% (int)
at year 1
BMI goal < 22 kg/m2
D: reduce amount by 10% (smaller rice bowl etc.),
increase vegetables; total fat < 50 g/day, alcohol < 50 g/
day; eating out ≤ 1/day
PA: walking 30–40min/day
Face-to-face counselling in hospital every 2–3m
S15Guidelinesstance for 30 minutes of slow walking, 20 minutes of cycling,
10 minutes of slow running, or 5 minutes of swimming. The cu-
mulative 6-year incidence of T2DM was lower in all intervention
groups (41–46%) compared with the control group (68%). A 20-
year follow-up [184] found that the incidence of T2DM was per-
sistently lower in the combined intervention group compared
with the control group. There were no statistically significant dif-
ferences in CVD events, CVD mortality, or total mortality be-
tween the control group and the combined intervention groups,
on the other hand, the study was under-powered to detect such
effects. Although the non-significant 17% reduction in death
from CVD is suggestive of an effect, lifestyle intervention has not
yet been proven to prevent CVD morbidity and mortality in per-
sons at high risk for T2DM and further, well-powered studies are
needed to confirm this. Nevertheless, there is preliminary evi-
dence from CDQDPS [228] and other studies [229,230].
Finnish Diabetes Prevention Study (DPS) [185,231,232]. A total
of 522 middle-aged, overweight individuals with IGT were allo-
cated either to a the intensive lifestyle intervention or to the con-
trol group. The intervention included individualized advice and
behavioural support to achieve the intervention goals: bodyPaulweber B et al. IMAGE-Gweight reduction of ≥ 5%, total fat intake < 30% of energy, satu-
rated fat intake < 10% of energy, fibre intake of ≥ 15 g/1000 kcal,
and moderate exercise for ≥ 30min/day. Consumption of whole-
meal products, vegetables, berries and fruit, low-fat milk and
meat products, soft margarines, and vegetable oils rich in mono-
unsaturated fatty acids were recommended. The participants
were also individually guided to increase their level of physical ac-
tivity and individually tailored circuit-type resistance training
sessions were also offered to improve the functional capacity and
strength of the large muscle groups. The control group received
only general advice about healthy lifestyle at baseline. Body
weight reductions from baseline to years 1 and 3 were 4.5 kg and
3.5 kg respectively in the intervention group and 1.0 kg and 0.9 kg
in the control group. The cumulative incidence of T2DMwas 11%
[CI 6, 15%] in the intervention group and 23% [95% CI 17, 29%] in
the control group after 4 years, with 58% relative risk reduction.
None of those achieving all five lifestyle goals developed T2DM.
Post hoc analyses showed that adopting a diet with moderate fat
andhigh fibre content [233], aswell as increasing physical activity
[97] were independently associated with a reduced risk of T2DM.
After a median of seven years follow-up, the marked reduction in
the cumulative incidence of T2DMwas sustained.uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
Table 8 Population characteristics (means) of lifestyle intervention studies to prevent type 2 diabetes
Ref. Acronym Age
(years)
BMI
(kg/m2)
Waist (cm)
(male/female)
Blood pressure
(mmHg)
Lipids TC
(mmol/l)
MetSy
(%)
FPG
(mmol/l)
[184,227] CDQDPS 45 26 – 134/89 (con) 5.3 – 5.5
132/87 (int) 5.2 5.6
[231,232,
320,321]
DPS 55 31 101 138/86 5.6 74% 6.1
[234,322] DPP 50 34 105 – – 53% 5.9
[186,235] IDPP 45 (con) 26 91/86 124/76 5.1 46%
46 (int) 26 89/88 122/74 5.2
[187] Japanese trial in
IGTmales
30–60 24 – 124/79 (con) TC – 6.2
123/78 (int) 5.5 6.3
Table 9 Main results and outcome of lifestyle intervention studies to prevent type 2 diabetes
Ref. Intervention Number of T2DM cases
(per 100 person years)
Risk reduction Numbers-
needed-to-treat
[184–227] CDQDPS At 6 years: At 6 years: 4.2 (D)
90/133 (con) = 15.7 DRR (adjusted): 3.8 (PA)
57/130 (D) = 10.0 0.69 (D), p < 0.3 4.6 (D + PA)
58/141 (PA) = 8.3 0.54 (PA), p < 0.0005 for 6 years
58/126 (D + PA) = 9.6 0.58 (diet + PA), p < 0.005; no diff. between ints
At 20 years: At 20 years:
11.3 (con) Adjusted HRR:
6.9 (combined int) 0.57 (combined int)
[231,232,320,321] DPS At 3.2 years: At 3.2 years: 22 for 1 year
59/257 (con) = 7.8 HRR 0.42, p < 0.001
27/265 (int) = 3.2
At 7 years: At 7 years:
110/257 (cont) = 7.4 HRR 0.57, p < 0.001
75/257 (int) = 4.3
[234,322] DPP 11.0 (con) HRR 0.42 6.9 for 3 years
4.8 (int)
[186,235] IDPP 3-years cumulative incidence:
55.0% (con), 39.3% (int)
RRR 28.5%, p = 0.018 6.4 for 3 years
[187] Japanese trial in
IGTmales
4-years cumulative incidence:
9.3% (con), 3.0% (int)
RRR 67.4%, p < 0.001
S16 GuidelinesUnited States Diabetes Prevention Program (DPP) [229,234].
The DPP compared the efficacy of intensive lifestyle intervention
and standard lifestyle recommendations; the study also had a
metformin arm. A total of 3234 high-risk individuals with IGT
and slightly elevated FPG were recruited. Lifestyle intervention
in DPP was primarily undertaken by “case managers”. The goals
were to achieve and maintain 7% weight reduction by consuming
healthy, low-calorie, low-fat diet and to engage in physical activ-
ities of moderate intensity (such as brisk walking) 150 minutes
per week or more. Compared with placebo, lifestyle intervention
reduced T2DM risk by 58% at 2.8 years mean follow-up. Among
the lifestyle intervention group, 74% achieved the physical activ-
ity goal of > 150minutes/week at 24weeks. At one-year themean
weight loss was 7 kg (about 7%). Body weight at baseline and
weight reduction during intervention were most important pre-
dictors of T2DM risk [60]. For each kilogram lost, the risk of T2DM
was reduced by 16%.
Indian DPP (IDPP) [186,235]. A total of 531 subjects with IGT
were randomized into four groups (control, lifestyle modifica-
tion, metformin, and combined lifestylemodification andmetfor-
min). Lifestyle modification included advice on physical activityPaulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201(30 minutes of brisk walking per day) and reduction in total calo-
ries, refined carbohydrates and fats, avoidance of sugar, and in-
clusion of fibre-rich foods. After a median follow-up of 30
months, the relative risk reduction was 29% with lifestyle modi-
fication, 26% with metformin and 28%with lifestyle modification
and metformin, as compared with control.
Japanese Prevention Trial [187]. This trial randomized 458 men
with IGT to receive either an intensive lifestyle intervention or
standard management. Participants in the intensive intervention
group visited hospital every 2–3 months to receive detailed ad-
vise to reduce body weight if BMI was ≥ 22 kg/m2 (by consuming
large amount of vegetables and reducing the total amount of oth-
er food by 10%. Intake of fat (< 50 g per day) and alcohol (< 50 g
per day) were limited and physical activity recommended (30–
40min per day of walking). The intervention group achieved a
67.4% reduction in risk compared with controls. Body weight de-
creased by 2.2 kg and by 0.4 kg in the intervention and control
groups during 4 years.
Other studies relevant to prevention of T2DM by lifestyle mod-
ification. The following studies are not includedwith the “major”0; 42 (Suppl. 1): S3–S36
S17Guidelinesprevention studies because of a variety of limitations including
low power, inadequate randomization or insufficient description
of the methodology or content of the lifestyle intervention. Some
studies, although not primarily focusing on prevention of T2DM,
have also published findings related to T2DM incidence and are
summarised below.
An early randomised intervention study, the Malmöhus study
[236] included 267 men with IGT and found lower rates of devel-
opment of T2D (13% vs. 29%) in those receiving dietary interven-
tion, although the published report neither defined clearly what
type of diet was advocated nor the degree of adherence.
The “Whitehall Borderline Diabetes Study” [237] assessed the ef-
fectiveness of carbohydrate restriction in the prevention of
T2DM. A total of 204 men with IGT were randomized to one of
four treatment groups: (i) carbohydrate 120 g/day + placebo, (ii)
“control diet“ with sucrose limitation + placebo, (iii) 120 g/day
carbohydrate + 50mg phenformin and (iv) sucrose limitation
+ 50mg phenformin. After 5 years, the incidence of T2DM cases
in each group was as follows: 18%, 13%, 18%, and 9%, with none
of the differences significant.
The feasibility of a diet and exercise intervention was assessed in
217 men with IGT in the Malmö feasibility study [238]. Effects of
exercise training (twice weekly 60-min with various dynamic ac-
tivities) and diet (reduction in refined sugar, simple carbohy-
drates, fat, saturated fat, energy, alcohol and increase in complex
carbohydrates and vegetables) were compared with a non-ran-
domized group receiving no intervention. After 5 years, 11% of
the intervention and 29% of the reference groups had developed
T2DM. The 12-year follow-up [154] revealed that mortality in the
former IGT intervention group was lower than in those who re-
ceived “routine care” only (6.5 and 14.0/1000 person years,
p = 0.009).
In 200 womenwith IGT and previous GDM, intensive versus rou-
tine dietary advice and emphasizing the importance of regular
exercise was tested at the University of Melbourne [240]. Advice
was delivered using a diet sheet and reinforced during frequent
telephone contacts. Annual incidence rates for T2DM were 6.1%
in the intervention group versus 7.3% in controls, with no differ-
ence between groups.
In Auckland [241], 176 subjects with IGT or newly diagnosed
T2DM were randomized to dietary intervention designed solely
to reduce total dietary fat and “usual diet“ controls. Despite lower
2-hour glucose, insulin and incidence of T2DM or IGT at one year
in the intervention group, there was no difference after 5 years.
The SLIM Study [177,178] assessed the effect of a diet and exer-
cise intervention based on general public health recommenda-
tions on glucose tolerance, insulin resistance, and CVD risk fac-
tors in individuals with IGT. Altogether 147 participants with
IGT were randomised to receive either intensive lifestyle inter-
vention or standard care. After three years, meanweight changes
were greater in the intervention than in the control group (1.1 kg
and + 0.2 kg; p = 0.011). Desired changes in insulin resistance and
2-h glucose were observed only in the intervention group.
Among the 106 who completed the intervention, the cumulative
incidence of T2DMwas 18% in the intervention group and 38% in
the control group, a relative risk 0.42 (p = 0.025), representing a
58% risk reduction. However an intention-to-treat analysis,
which included 121participants, attenuated the effect with a
non-significant relative risk (RR) of 0.58 (p = 0.07).
The primary aim of The Multiple Risk Factor Intervention Trial
(MRFIT) [242] was prevention of coronary heart disease (CHD)
among 12866 men at high CHD risk, followed up over 6–7 years.Paulweber B et al. IMAGE-GThe intervention included dietary counselling aimed at reducing
saturated fat and cholesterol and increasing polyunsaturated fat,
and body weight reduction if needed. In the intervention group,
11.5% developed T2DM, compared with 10.8% of the control
group with a HR of 1.08 [95% CI: 0.96, 1.20]. However, among
smokers HRwas 1.26 [95% CI 1.10, 1.45] and among non-smokers
0.82 [95% CI 0.68, 0.98] (p = 0.0003). Thus, the intervention re-
duced the risk of T2DM only among non-smokers.
A one-year trial in Italy [243] compared the effectiveness of a
structured lifestyle intervention program in reducing the onset
of the MetSy or T2DM in 375 persons with metabolic disorders
recruited from a population-based cohort. Intervention consisted
of general information from family physician (control group), fol-
lowed by 5 training sessions with structured core but flexible
contents (intervention group only) in line with general dietary
recommendations (50–60% of energy as carbohydrates, < 30%
energy as fat, < 10% energy as saturated fat, 15–20% energy as
protein, and 20 to 30 g fibre/day) and with individualized exer-
cise andweight loss goals. After one year, 1.8% of the intervention
group and 7.2 of the control group had developed T2DM, with an
odds ratio (OR) of 0.23 [95% CI 0.06, 0.85] (p = 0.03).
Prevention of T2DM in children and adolescents
Applying the predefined search criteria failed to identify any
RCTs designed to prevent the onset of T2DM in children or ado-
lescents and there is a need for “long-term studies of multi-eth-
nic cohorts followed into adulthood to determine the natural his-
tory and effectiveness of intervention strategies, particularly life-
style“ [10]. Expert opinion, drawingmainly on evidence in adults,
identifies weight loss and/or prevention of weight gain as the
best way to prevent T2DM. The American Academy of Pediatrics
has made the following recommendations: supporting breast
feeding, promoting healthy eating habits and physical activity, i.
e. discouraging sedentary activities such as watching TV or play-
ing video games, screening for family readiness for change, edu-
cation about complications of obesity, maintaining normal,
healthy body weight, and avoidance of smoking [244,245]. At
present, the evidence for the long-term effectiveness of obesity
prevention programs in children and adolescents is insufficient.
The best results have been obtained when schools and family
are involved [246]. Nevertheless, on the basis of evidence on the
determinants of obesity, lifestyle changes are strongly recom-
mended for all children and adolescents at risk for overweight,
IGT and T2DM.
Recommendations
A Intensive lifestyle interventions that encourage people to
change their diet and to increase their level of physical activity
should be used to prevent or delay the onset of T2DM in adults
with IGT. The NNT for prevention of one case of T2DM of 6.4
[95% CI 5.0, 8.4] at mean follow up ranging from 1.83 to 4.62
years [247].
A Weight reduction is an essential element of prevention of
T2DM prevention. Sustained weight reduction by 5–7% is suffi-
cient to substantially lower the risk of T2DM.
B An increase in physical activity even at a level of 30 minutes
per day of moderate exercise reduces the risk of T2DM and is
therefore recommended.
B A diet with high fibre (≥ 15 g per 1000 kcal), moderate fat
(≤ 35% of total energy) reduced saturated and trans fat (< 10% of
total energy) can lower body weight and reduce the risk of T2DM
and is therefore recommended.uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
Table 10 Characteristics of pharmacological intervention studies to prevent type 2 diabetes
Ref. Acronym Design Intervention (D = diet, PA = physical
activity, P = placebo)
Follow up
(years)
Drop
out
Adverse effects
[249] SMOMS RCT, DB, PC 8-w very-low-calorie D, then D + PA 3 gastrointestinal
+ Orlistat, O, 3 × 120mg/d, (n = 153) 33% 88%
+ P (n = 156) 37% 63%
[250] XENDOS RCT, DB, PC Low caloric D + PA 4 gastrointestinal
+ Orlistat, O, 3 × 120mg/d, (n = 1640) 48% 36%
+ P (n = 1637) 66% 23%
[258] BOTNIA RCT, DB, PC, + 12m
wash out
1.5 hypoglycemia
Glipizide, G, 2.5 mg7d, (n = 17) 1 41%
P (n = 17) 32%
[255] STOP-
NIDDM
RCT, DB, 3-m wash-
out: data not avail-
able
D + PA prescription gastrointestinal
+ Acarbose, A, 3 × 100mg/d, (n = 682) 3.3 30% 13%
+P (n = 686) 3.5 18% 3%
[65,260] DPP RCT, DB, intention-
to-treat
Standard lifestyle recommendation 2.8 7.5% gastrointestinal
(events/100 person-yr)
+ Metformin, M, 2 × 850mg/d, (n = 1037) M: 78, D + PA: 24, p: 31
+ Intensified D + PA (n = 1079)
+ P (n = 1082)
+ Troglitazone, T, discontinued due to safety 31
[186] IDPP RT Individual Dmodification 2.5 26 gastrointestinal
+ Standard lifestyle advice (con, n = 136) M, D + PA +M: 5
+ D + PA (n = 133) hypoglycemic
symptoms:
+ Metformin, M, 2 × 500/250mg/d, (n = 133) M, D + PA +M: 22
+ Combined D + PA +M (n = 129)
[262] TRIPOD RCT, DB,PC, open-
label follow-up
Lifestyle (standard D + PA) –
+ Troglitazone, T, 400mg/d, (n = 133) 2.6 19
+ D + PA (n = 133) 2.3 11
[188] DREAM RCT, DB, PC, 2 × 2
factorial design
+ 2–3mwash out
17-d SB P run-in, compliant patients enrolled,
D + PA
3 CVevents/HF
RO + Rosiglitazone, RO, 8mg/d, (n = 2635) 75/14
+ P + lifestyle (n = 2634) 772 55/2
658 ns/p = 0.01
[264] DREAM RCT, DB, PC, 2 × 2
factorial design
+2–3mwash out
+ Ramipril, RA, ‑15mg/d, (n = 2623) 3 27% cough/angioedema:
9.7%/0.1%
RA + P + lifestyle (n = 2646) 22% 1.8%/0.2%
S18 GuidelinesC Comorbidities, particularly MetSy, should be monitored and
taken into account while planning the diet [119,248].
C Currently there is no evidence from long-term prevention
studies that reducing total dietary carbohydrate prevents T2DM.
Carbohydrate sources should mainly be whole-grain cereal, fruit,
vegetables, and legumes.
D There is no evidence from clinical trials of the effectiveness of
interventions to prevent the onset of T2DM among children and
adolescents. However, on the basis of physiological evidence and
research in adults it can reasonably be assumed that maintaining
a healthy weight through physical activity and balanced/healthy
nutrition is the key factor will be important to prevent or post-
pone the onset of T2DM among youth.
Findings for prevention by pharmaceutical treatment
Studies of the effectiveness of drug treatment in preventing or
delaying the onset of T2DM have been performed mostly in per-
sons at high-risk of T2DM, such as those who are obese and/orPaulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201exhibit IGT, or women with a history of GDM. Key data of these
studies are summarized in l" Tables 10, 11, 12.
Antiobesity treatment
Orlistat. The Scandinavian Multicenter Orlistat in Metabolic Syn-
drome (SMOMS) study was performed in obese subjects with the
MetSy (n = 309). After 8-weeks on a very-low caloric diet, partic-
ipants were given the intestinal lipase inhibitor, orlistat or place-
bo in addition to lifestyle modification. Over 36 months the inci-
dence of diabetes was 58% lower in the orlistat group compared
with placebo, with no differences in insulin secretion and activity
[249].
The XEnical in the prevention of Diabetes in Obese Subjects
(XENDOS) study was conducted in 3277 obese subjects, of whom
694 had IGT. They received orlistat or placebo in addition to life-
stylemodification. After amedian follow up of 48months, the HR
for all patients was 0.59 (p = 0.028), for those with IGT it was 0.550; 42 (Suppl. 1): S3–S36
Table 11 Population characteristics (means) of pharmacological intervention studies to prevent type 2 diabetes
Ref. Acronym Age
(years)
BMI
(kg/m²)
Waist (cm)
(male/
female)
Blood
pressure
(mmHg)
Lipids
HDL‑C
(mmol/l)
Lipids TG
(mmol/l)
MetSy or
diabetes risk
FPG
(mmol/l)
[249] SMOMS 47 (O) 37 119 144/91 1.1 2.4 309 Obese + MetSy 6.4
47 (P) 38 119 144/91 1.2 2.5 6.3
[250] XENDOS 43 (O) 37 115 131/82 1.2 1.9 3277 Obese, 694 IGT 4.6
44 (P) 37 115 130/82 1.2 1.9 4.6
[258] BOTNIA 58 (G) 28 88 143/88 1.0 1.8 First-degree relatives +
IGT
5.3
53 (P) 29 90 134/83 1.1 1.6 5.3
[255] STOP-
NIDDM
54 (A) 31 102 131 1.2 2.1 1429 IGT + IFGa 6·2
55 (P) 31 102 131 1.2 2.1 6.2
[65] DPP 51 34 105 125/79 1.0 – 3234 IGT + IFG 6.0
[186] IDPP 35–55 26 124 (con) 1, 1.9 531 IGT
122 (D + PA) 2, 2.0
121 (M) 3, 1.7
123
(D + PA +M)
4, 1.8
[262] TRIPOD 35 (T) 31 – – – – 266 pGDM, 63% IGT 5.3
34 (P) 30 5.2
[188] DREAM-
Rosi
55 (Ro) 31 101/96 136/83 – – 739 IFG, 4530 IGT 5.8
55 (P) 31 102/96 136/84 5.8
[264] DREAM-
Rami
55 (Ra) 31 136/83 IGT: 1513 (Ra), 1515
(P)
5.9
55 (P) 31 – 136/83 – – IFG: 366 (Ra), 373 (P) 5.9
a 90% family history of diabetes, 78% BMI > 27 kg/m2, 53% > 1 risk factor for T2DM, 51% high blood pressure, 48% dyslipidemia, 23% women with a history of gestational diabetes
S19Guidelines(p = 0.0024), but there was no difference in the rate of progres-
sion from NGT to IGT [250].
Rimonabant. One sub-group analysis of the Rimonabant-In-Obe-
sity (RIO)-Europe study compared effects of the endocannabi-
noid receptor antagonist rimonabant (n = 399) with placebo
(n = 123) as part of a lifestyle intervention in healthy obese sub-
jects with a mean BMI of 36 kg/m2 [251]. Within 24 months, ri-
monabant treatment achieved weight reduction and improve-
ment of HDL‑C and triglycerides. Although only 0.5% of the rimo-
nabant group, compared with 4.1% of the control group, devel-
oped diabetes, the high drop-out rates (58% and 55%) and low in-
cidence of T2DM limit the relevance of the study. In October
2008, rimonabant was withdrawn from the market because of
concerns about risk-benefit ratios so that it cannot be used for
diabetes prevention [251].
Bariatric surgery. The Swedish Obesity Surgery (SOS) trial
studied 2010 severely obese subjects (BMI > 35 kg/m2) who
underwent surgery for obesity (gastric banding, gastroplasty,
gastric bypass) and 2037 patients who chose conventional treat-
ment in a matched pairs-design non-randomized study. Subjects
undergoing surgery achieved a reduction in body weight of 20–
30 kg, accompanied by a reduction in cardiovascular risk factors.
After 8 years, the surgical group had a greatly reduced risk of de-
veloping diabetes (OR: 0.16) [252]. Two recent reviews analyzed
the available evidence for the use of bariatric surgery in overt di-
abetic and in obese patients. While surgery improved T2DM in
87% and resolved it in 79% of cases [253] and was more efficient
than conventional treatment to induce weight loss in obese pa-
tients [254], the evidence on safety is less clear due to limited
number and quality of studies [254].Paulweber B et al. IMAGE-GOral glucose lowering drugs
Alpha glucosidase inhibitors. In the Study-To-Prevent-NIDDM
(STOP-NIDDM), persons with IGT (n = 1.429) were randomized
in a double-blind trial to either the alpha glucosidase inhibitor,
Acarbose, or placebo. After a mean follow-up of 3.3 years, the
acarbose-treated group achieved 25% and 36% RR reduction
based on one or two OGTTs in progression to diabetes compared
with placebo. The effect of acarbose was observed across all ages,
at all BMIs, and in both sexes, while there was some evidence of
an accompanying improvement in CVD risks [255–257].
Sulfonylurea.Within the BOTNIA study, 34 first-degree relatives
of patients with T2DM and IGTwere assigned randomly to either
glipizide or placebo. At 6 months of treatment, measures of insu-
lin secretion/action such as fasting plasma insulin and measures
of insulin resistance and HDL‑C had improved in the glipizide
group. Thereafter, the treatment was withdrawn and the partici-
pants observed for another 12 months of washout. At 18 months,
both FPG and 2-h PG were lower in the glipizide than in the pla-
cebo group. The prevalence of T2DM was 29.4% in the placebo
group and 5.9% in the glipizide group, corresponding to an 80%
relative risk reduction at 18 months. However, although not
reaching statistical significance in this study, there was some evi-
dence suggesting a need for caution in the use of glipizide be-
cause of an increased frequency of symptoms suggesting hypo-
glycemia [258].
Biguanides. As described above, the Whitehall Borderline Diabe-
tes Study examined the ability of carbohydrate restriction to pre-
vent the onset of diabetes inmenwith IGT (n = 204) with or with-
out treatment with phenformin, but detected no difference in theuideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
Table 12 Main results and outcome of pharmacological intervention studies to prevent type 2 diabetes
Ref. Acronym Number of T2DM cases per group Risk reduction Number needed to treat
[249] SMOMS O: 8 (5.2%) HR: 0.63 –
P: 17 (10.9%)
[250] XENDOS O: 102 (6.2%) HR for all: 0.59, p = 0.028) 10 IGTs/4years
P: 147 (9.0%) HR for IGT: 0.55, p = 0.0024c
[258] BOTNIA V: 5.9% ARR: 23.5% –
P: 29.4% HR = 0.30
[255] STOP-NIDDM V: 105 (15%) ARR: 8.7% –
P: 165 (24%) HR: 0.64, p = 0·0003
[65] DPP Incidence/100 person-years: RRR:
D + PA: 4.8 D + PA vs. P: 58% 6.9/3 years (D + PA)
M: 7.8 M vs. P: 31% 13.9/3 years (M)
P: 11.0 D + PA vs. M: 39%
[186] IDPP D + PA: 0.623, p = 0.018 HR: D + PA: 0.62, p = 0.018 6.4/3 years
M: 0.651, p = 0.029 M: 0.65, p = 0.029 6.9/3 years
D + PA +M: 0.629, p = 0.022 D + PA +M: 0.63, p = 0.022 6.5/3 years
[262] TRIPOD T: 30% (12.1%/y) HR: 0.45 (non-adjusted), 0.44 (adjusted) –
P: 14% (5.4%/y)
[188] DREAM-RO RO: 280 (10.6%) HR: 0.38, p < 0.0001b 6.9/3 years
P: 658 (25.0%) a
[264] DREAM-RA RA: 17.1% (449) HR: 0.91 –
P: 18.5% (489)
a CV events: RO: 306 (11.6%), P: 686 (26.0%); b Composite primary endpoint: HR: 0·40, p < 0·0001; c Progression NGT to IGT: no difference
S20 Guidelinesincidence of diabetes between the different groups after 45 years
[259].
As decribed above, the US DPP, a multicenter RCT, tests an inten-
sive lifestyle intervention with metformin (850mg twice daily),
or troglitazone (400mg daily) or placebo [260] in high-risk per-
sons with IGT (n = 3.234) and slightly elevated fasting plasma glu-
cose (> 5.5mmol/l), with about 45% of the study population from
Non-Caucasian groups such as African-American and Hispanic.
After a mean follow-up of 2.8 years, the relative reductions in
the progression to diabetes were 58% in the lifestyle group and
31% in the metformin vs. placebo-treatment. As these data were
based on an OGGT performed during ongoing treatment, another
OGTT was performed after a 1–2-weeks washout period. After
the washout, diabetes was slightly but not significantly more
common in the metformin group with a OR of 1.49 ([0.93, 2.38]
p = 0.098). Comparison of the probabilities of developing diabetes
during the DPP and during thewash out period revealed that 26%
of the metformin effect did not persist upon drug withdrawal.
Nevertheless, metformin still reduced the incidence of diabetes
by 25% [65].
The IDPP studied persons with IGT (n = 531) who were slightly
younger and less overweight than in DPP and DPS. They received
the following interventions: control, lifestyle modification, met-
formin or combined lifestyle modification + metformin. After
median follow-up of 30 months, the relative risk reductions ver-
sus control were between 26–29% for all study arms. The lifestyle
intervention was less intensive and the diabetes incidence was
higher (55.0% in 3 years) than in the DPP and DPS. Of note, as in
the Indian Diabetes Prevention Study, metformin, when added to
lifestyle intervention exerted no benefit beyond that of the life-
style intervention [186].
Thiazolidendiones. “Insulin sensitizer” such as thiazolidine-
diones which are agonists at the peroxisome proliferator activa-
tor receptor-gamma have been also tested in prevention. The tro-
glitazone arm of the DPP was discontinued because of concerns
about liver toxicity. Before discontinuation (at a mean of 0.9Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201years), the incidence of diabetes was 3.0/100 person-years was
not different versus intensive lifestyle intervention, but lower
than in the placebo and metformin arms. During the 3 years after
troglitazone withdrawal, the incidence of diabetes was compara-
ble to that in the placebo group indicating that its effect did not
persist upon withdrawal [261].
In the Troglitazone In Prevention of Diabetes (TRIPOD) study, His-
panic women with previous gestational diabetes (n = 235) were
randomized to receive the troglitazone, since withdrawn from
sale, or placebo. After a median follow-up of 30 months, the inci-
dence of T2DM was 5.4% and 12.1% with troglitazone and place-
bo. Thus, troglitazone treatment was associated with a 56% rela-
tive reduction in progression to diabetes which remained even
after an 8-mwashout period [262].
The Pioglitazone In Prevention of Diabetes (PIPOD) study was
performed as an open-label observational trial using pioglita-
zone (45mg daily) in 89 women participating in TRIPOD, of
whom 30 had received verum during the previous study. After a
median follow-up of 36 months, 65 women had completed all
study visits: The rates of annual and cumulative incidence of dia-
betes were 5.2% and 17%. It is noteworthy that parameters of in-
sulin resistance were not affected, whereas body weight in-
creased [263].
In the Diabetes REduction Assessment with ramipril and rosigli-
tazone Medication (DREAM) Study, 5.269 adults with IFG or IGT,
or both, and no previous cardiovascular disease were randomly
assigned to receive rosiglitazone (8mg daily) vs. placebo or rami-
pril (up to 15mg) vs. placebo. After a median follow up of 3 years,
rosiglitazone treatment reduced the incidence of T2DM as as-
sessed from a HR of 0.38 [95% CI 0.33, 0.44] (p < 0.0001) and of
the composite primary end point (death or onset of diabetes:
hazard ratio (HR: 0.40 [0.35; 0.46]) (p < 0.0001). In addition, rosi-
glitazone for 3 years increased the likelihood of regression to nor-
moglycemia in adults with IFG or IGT, or both [188,264].
Antihypertensive and lipid-lowering drugs. Several meta-analy-
ses and reviews of studies on angiotensin receptor (AT1) blockers0; 42 (Suppl. 1): S3–S36
S21Guidelinesor angiotensin converting enzyme inhibitors (ACEI) report an as-
sociation with reduced risk of T2DM [265,266]. However, occur-
rence of diabeteswas not a primary endpoint in these studies and
the methods used to diagnose and detect diabetes were hetero-
geneous. No prospective RCT had examined the ability of antihy-
pertensive drugs to prevent diabetes prior to the DREAM study.
After a median follow up of 3 years, ramipril treatment was not
associated with lower incidence of diabetes at a HR of 0.91 [0.80,
1.03] or death, but with increased probability (“HR” 1.16, p =
0.001) of regression to normoglycemia compared with placebo.
At the end of the study, the median 2-h PG but not FPG was
slightly lower in the ramipril than in the placebo group (p =
0.01) [264].
Post hoc analyses of placebo-controlled statin trials show con-
flicting results on associations between statin therapy and diabe-
tes incidence [267–270]. However, currently, there is no prospec-
tive RCT investigating the effect of lipid lowering drugs on diabe-
tes onset.
Recommendations
A In persons with IGT, metformin and acarbose can be used as
second line strategies for prevention of T2DM, provided that the
drugs are tolerated (gastrointestinal side-effects), and contrain-
dications to metformin therapy (kidney, liver diseases, hypoxic
conditions) are considered [65,179,186,255].
A In obese people with or without IGT, carefully monitored anti-
obesity treatment with orlistat, in addition to intensive lifestyle
modification, can be used as a second line strategy for obese pa-
tients to prevent T2DM.
C In severely obese patients at high risk of T2DM and CVD, bar-
iatric surgery in addition to careful monitoring and lifestyle
change can induce sustained weight loss for [252,271], but long-
term safety is less clear so that it cannot be recommended for dia-
betes prevention at present.
C Glucose lowering drugs such as glipizide or thiazolidendiones
may reduce the risk of T2DM in certain high risk groups, but ei-
ther long-term efficacy or safety are unclear so that these drugs
cannot be recommended for diabetes prevention at present
[179].
C Antihypertensive and lipid-lowering drugs cannot be recom-
mended for the prevention of T2DM at present.
Considerations of societal and public health aspects
International organizations (IDF, EASD, WHO) have issued con-
sensus statements on prevention programs [172,272] and a
number of national or regional programs are already imple-
mented at the societal level [273,274]. The pan-European DE-
plan project further described public health approaches for im-
plementing prevention of T2DM at the primary care level [239].
The majority of the prevention programs designed at community
and national levels are based on implementation of lifestyle in-
terventions in public health and primary healthcare settings
[185]. Data on the efficiency of the population approach are
scarce, but public health surveys demonstrate its utility if based
on the promotion of healthier lifestyle [185,275]. This suggests
that the combination and coordination of individualized and
population approaches at the societal level would be useful
[172]. The health sector cannot implement the population ap-
proach on its own, so other stakeholders (e.g. schools, commun-
ities, politicians, industry/employers) need to be involved [172],
particularly for coordinated prevention in adolescents [276]. Pre-
vention programs also need to address cultural differences in di-Paulweber B et al. IMAGE-Getary habits and physical activity patterns, particularly in minor-
ities [277,278]. Governments should develop and implement na-
tional diabetes prevention plans including a wide range of initia-
tives in different segments of societies such as advocacy (provid-
ing support for relevant associations and organizations and a fa-
vorable economic environment), community support (to produce
a favorable environment for adequate nutrition by education and
for physical activity by sport facilities and urban design), fiscal
and legislative changes (food pricing labeling and advertising as
well as environmental and infrastructure regulation), engaging
of the private sector (promotion of health at workplace and en-
suring healthy policies in food industry) and media support
[172].
Recommendations
A Interventions to prevent T2DM should be implemented at the
societal level though a structured public health plan which
should take into account both high-risk/targeted approach and
population approaches.
C The structured plan should also include specific approaches to
meet the needs of subpopulations, e.g. adolescents, minorities
and disadvantaged groups.
B The establishment and implementation of an effective plan for
the prevention of T2DM at national levels requires government
initiatives comprising advocacy, community support, fiscal and
legislative changes involving infrastructure, engagement of pri-
vate sector and continuous media communication.
A This plan should be part of a network with other relevant pre-
vention programs and public educational activities.Supporting Change in Lifestyle Behaviour for Adults
at Risk of T2DM
!
Changing an existing habit requires people to establish a motiva-
tion or intention to change, make decisions and action plans, rec-
ognise and overcome barriers (both practical and psychological),
initiate the new routine, and then to maintain the new routine,
resisting temptations to relapse back to former habits. Ap-
proaches for supporting changes in diet and physical activity vary
from simple information-giving to more intensive programmes,
which may or may not be based on theoretical models of behav-
iour change [279–283].
Methodology
The recommendations on this topic are based on a systematic re-
view, which summarised the available scientific evidence on the
relationship between increased intervention effectiveness and:
(i) theoretical basis, (ii) behaviour change techniques used, (iii)
mode of delivery, (iv) intervention provider, (v) intervention in-
tensity, (vi) characteristics of the target population (e.g. gender,
ethnicity), (vii) setting. Our systematic “review of reviews” of
the scientific evidence base on dietary and/or physical activity in-
terventions is published separately andwill be available to down-
load from the IMAGE website (http://www.image-project.eu).
Only the key recommendations and a summary of the evidence
are presented here. The review examined systematic reviews,
published between 1998 and 2008, which focused primarily on
populations of adults at risk of developing T2DM and/or CVD. Ar-
ticles were identified by searching multiple electronic databases
of published evidence and other sources. The methodological
quality of studies was systematically assessed using an estab-uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
Table 13 Evidence underlying the recommendations on supporting behaviour change
Evidence Evidence gradea
Overall intervention effectiveness
Dietary or diet plus physical activity interventions can have effects onweight loss.Meannet weight loss in successful interventions varies from
3–5 kg at 12months and from 2–3 kg at 36months
1++
Weight loss from dietary or diet plus physical activity interventions can be sustained for 48months and 7 years (2–3 kg). 1+
Physical activity interventions can have effects at up to 18months of follow up. The increase for successful interventions is 30–60minutes of
moderate activity per week.
1+
Physical activity interventions can also have small effects on weight at up to 12months of follow up (decrease 1–2 kg). 1+
Dietary and/or physical activity interventions can strongly reduceprogression toT2DM(49% relative reduction in risk) at 3.4 years of followup. 1++
Interventions need to paymore attention to behaviour maintenance, once the active phase of intervention is completed. During the active
phase of interventions the net weight loss at 3–12months was on 0.08 bodymass index units per months. During themaintenance phase
(from 6–60months), patients regained weight at a rate of 0.03 bodymass index units per month.
1++
Theoretical basis
Interventions for weight loss (diet or physical activity) which stated a theoretical model as their foundation delivered no greater weight loss
than interventions that did not state their theoretical underpinnings.
2+
Behaviour change techniques
The planned use of established behaviour change techniques in dietary and/or physical activity interventions increases the amount of weight
loss and physical activity produced at 6months of follow up.
1+
Interventionswith diet plus physical activity produce greater weight loss than thosewith dietary change only at up to 24months of follow up. 1+
Interventions based onmotivational interviewing aremore effective than traditional advice at least in the short-term (3 to 6months of follow
up).
1++
Using social support (usually from a family member) increases effectiveness of weight loss interventions at 12months of follow up. 1+
Interventions which include the use of pedometers to self-monitor walking activity producemoderate weight loss andmoderate increases in
moderate levels of physical activity at up to 4months of follow up.
1+
Dietary and/or physical activity interventions which include prompting of self-monitoring alongside other “self-regulatory techniques”
(Specific goal setting; Providing feedback on performance; Review of behavioural goals) produce an average weighted effect sizemore than
twice that of other interventions.
2+
Prompting self-monitoring of behaviour and/or outcomes and prompting self-talk, alongside other intervention techniques (i.e. not in isola-
tion), are associated with increased intervention effectiveness for both dietary and physical activity interventions.
2+
Providing instruction and the use of relapse prevention techniques (for dietary change), prompting practice, individual tailoring, setting goals
and timemanagement (for physical activity) may also enhance intervention effectiveness.
2+
Mode of delivery
Successful physical activity and/or dietary interventions have been delivered using group, individual or combined (individual and group)
modes of delivery.
1++
There is no strong evidence of any difference in the effectiveness of physical activity and/or dietary interventions between individual, group
andmixedmodes of delivery at up to 12months of follow up.
2+
Intervention provider
Successful physical activity and/or dietary interventions have been delivered by doctors, nurses, dieticians/nutritionists, exercise specialists
and lay people. It should be noted however that these providers were often working within a multi-disciplinary team.
1++
There is no strong evidence of any difference in the effectiveness of physical activity and/or dietary interventions delivered bymedically
trained health professionals (doctors, nurses), other professionals (psychologists, counsellors, dieticians, health educators), public health
students, or lay people at up to 12months of follow up.
2+
Intensity
When intensity is considered in terms of intervention duration or total contact time, there is insufficient evidence to draw any clear conclu-
sions about its impact on the effectiveness of dietary and/or physical activity interventions.
–
A greater frequency of meetings, particularly in the active phase of the intervention is associated with greater effectiveness in dietary and/or
physical activity interventions at up to 15months of follow up.
2++
A greater total number of personal contacts/intervention sessions is associated with greater intervention effectiveness at up to 36months of
follow up.
2+
Different populations
Gender: 2+
There seems to be no substantial difference betweenmen and women in responsiveness to dietary and/or physical activity interventions
(once recruited) at up to 16months of follow up. [However, strong gender imbalances in recruiting are reported, so theremay be some types
of intervention which suit womenmore thanmen.]
Older people: 1+
Dietary and/or physical activity interventions can produce weight loss in older populations at up to 34months of follow up.
There is evidence suggesting that older people (over age 45) are more responsive to dietary and/or physical activity interventions at up to
34months of follow up.
2+
Black and minority ethnic groups: 1+
Combined dietary and physical activity intervention can be effective for a wide range of ethnicities, including Caucasian, Afro-Caribbean,
Hispanic, American Indian and Asian (mainly East Asian) populations at up to 34months of follow up.
Disability groups: –
The basic effectiveness of interventions is not yet established in adults with physical limitations. High quality evidence focusing on the effec-
tiveness or relative effectiveness of dietary and/or physical activity interventions in adults with physical limitations or other disabilities is
urgently needed.
(continued)
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Table 14 Definitions of established behaviour change techniques
Source Basis for categorisation of whether studies used established behaviour change techniques or not
Avenell et al. [323] Definitions of behaviour therapy varied by study but include self-monitoring, stimulus control, problem solving, relapse
preventionmanagement, cognitive restructuring, self-assertion, social support, goal setting, self-reinforcement.
McTigue et al. [324] Behavioural interventions are strategies to help patients acquire the skills, motivations, and support to change diet and exer-
cise patterns. These include barrier identification, problem solving, self-monitoring, social support, goal-setting, developing
action plans, relapse prevention, stimulus control, cognitive restructuring.
Shaw et al. [325] Behavioural therapy aims to provide the individual with coping skills to handle various cues to overeat and tomanage lapses in
diet and physical activity when they occur and to providemotivation essential tomaintain adherence to a healthier lifestyle
once the initial enthusiasm for the program has waned. Therapeutic techniques in studies relating to the benefit of using
“established behaviour change techniques” include stimulus control, self-control and therapist-controlled contingencies, self-
monitoring, problem solving, goal setting, behaviour modification, reinforcement.
NICE Obesity Guidance [308] This guidance document comprises a summary of/expansion of reviews by Shawet al. [325], McTigue et al. [324], andAvenell
et al. [323]. Definitions vary by analysis but typically include cue avoidance, self-monitoring, stimulus control, social support,
planning problem solving, cognitive restructuring,modifying thoughts, relapse prevention, reinforcement of change, coping
strategies, coping imagery, goal setting, social assertion, reinforcement techniques for enhancingmotivation.
Table 13 Continued
Evidence Evidence gradea
Settings
Successful interventions have been delivered in a wide range of settings, including health care settings, the workplace, the home, and in the
community. However, evidence on the differential impact of different settings on effectiveness is lacking.
1++
There is tentative evidence that remotely deliveredwalking support interventions (using internet or phone-baseddelivery) can produce short-
term effects on physical activity (at 3 months of follow up).
2+
a Based on SIGN evidence grading system; * Evidence grading is explained in the methods section and in Appendix 2
S23Guidelineslished rating system [284] and data were only extracted from re-
views meeting a pre-set quality standard. Selection and data ex-
traction were undertaken independently by two reviewers and
any disagreements resolved by discussion. We identified 3856
potentially relevant articles, of which 30 met the quality and se-
lection criteria. We systematically extracted data relevant to the
specific aims above, rated each piece of evidence, using the SIGN
evidence rating system and produced detailed evidence tables.
Further discussion of the evidence inworkshops of experts in pri-
mary care, behavioural science and diabetes prevention (the IM-
AGE study group) helped to derive the recommendations below.
Findings
The evidence showed that interventions to promote lifestyle
changes are more likely to be effective if they target both diet
and physical activity, mobilise social support, involve the
planned use of established behaviour change techniques (as de-
fined in l" Table 14) and provide a higher frequency of contacts.
Specific techniques to support behaviour change and mainte-
nance were also associated with increased effectiveness. l" Table
13 provides a concise summary of the evidence we examined.
Recommendations
Individual level interventions for people at risk of T2DM should:
A Aim to promote changes in both diet and physical activity
A Use established, well defined behaviour change techniques
(e.g., specific goal-setting, relapse prevention, self-monitoring,
motivational interviewing, prompting self-talk, prompting prac-
tice, individual tailoring, time management), as defined in l" Ta-
ble 14.Paulweber B et al. IMAGE-GD A clear plan of intervention should be developed based on a
systematic analysis of factors preceding, enabling and supporting
behaviour change in the social/organisational context in which
the intervention is to be delivered. The plan should also identify
the processes of change and the specific techniques and method
of delivery designed to achieve these processes. Such planning
should ensure that the behaviour change techniques and strat-
egies used are mutually compatible and well-adapted to the local
delivery context. Following the procedures of the PRECEDE-PRO-
CEED model [285], Intervention Mapping [286], or a similar in-
tervention-design procedure is recommended.
A Work with participants to engage social support for the
planned behaviour change (i.e. engage important others such as
family, friends, and colleagues).
B Maximize the frequency or number of contacts with partici-
pants (within the resources available).
A Include a strong focus on maintenance. It is not clear how best
to achieve this, but behaviour change techniques designed to ad-
dress maintenance include establishing self-monitoring of prog-
ress, providing feedback (e.g. on changes achieved in blood glu-
cose and other risk factors), reviewing of goals, engaging social
support, use of relapse prevention/relapse management tech-
niques and providing follow-up prompts.
C Building on a coherent set of ʼself-regulatoryʼ intervention
techniques (Specific goal setting; Prompting self-monitoring;
Providing feedback on performance; Reviewof behavioural goals)
may provide a good starting point for intervention design. How-
ever, this is by no means the only approach available and It is
worth noting that self-regulation techniques are not normally
used in isolation (e.g. techniques designed to explore and en-uideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
S24 Guidelineshance initial motivationwould normally be applied prior to goal-
setting).
A Interventions to prevent T2DM may be delivered by a wide
range of people/professions, subject to appropriate training (in-
cluding the use of established behaviour change techniques).
There are examples of successful physical activity and/or dietary
interventions delivered by doctors, nurses, dieticians/nutrition-
ists, exercise specialists and lay people, often working within a
multi-disciplinary team.
A Interventions to prevent T2DM may be delivered in a wide
range of settings. There are examples of successful physical activ-
ity and/or dietary interventions delivered, in health care settings,
the workplace, the home, and in the community.
A Interventions to prevent T2DM may be delivered using group,
individual or mixed modes (individual and group). There are nu-
merous examples of successful physical activity and/or dietary
interventions using each of these delivery modes.
C No specific intervention adaptations are recommended for
men or women, although steps may be needed to increase en-
gagement/recruitment of men.
D People planning interventions should consider what adapta-
tions may be needed for different ethnic groups (particularly
with regard to culturally-specific dietary advice), people with
physical limitations and people with mental health problems.Models of Care and Economic Aspects of
T2DM Prevention
!
Methodology
This section updates and extends a recent systematic review that
focused on environmental determinants of cardiovascular dis-
ease, which shares many risk factors with diabetes [287]. The ini-
tial review employed an iterative process, in which PubMed and
Google were searched, initially using the following search terms:
(environment or community) and (measures or index or risk fac-
tors or determinants), (built environment or nutrition environ-
ment or obesogenic environment or social environment) and car-
diovascular (risk factors or disease), subsequently complemented
by diabetes.
For the review of the economic aspects of diabetes prevention
strategies, PubMed was searched using the terms: (economics of
preventing diabetes), (economics diabetes prevention) and (eco-
nomic evaluation diabetes prevention), with follow up of refer-
ences cited.
To guide the review of health systems issues, a questionnaire was
sent to all IMAGE partners seeking their input as to how they
might implement a model of diabetes prevention in their own
country. It was supplemented by a review of tabled results from
the IMAGE questionnaire “Analyses of Type 2 Diabetes Prevention
Programmes at national level” sent to all IMAGE partners. The re-
sults were then interpreted in the light of a series of studies
undertaken by the European Observatory on Health Systems
and Policies on the health system response to chronic diseases
[288,289], human resources in the health sector [290,291], social
insurance systems [292], and primary care in Europe [293]. This
used, as a conceptual framework, the Chronic Care Model [294],
which was developed in the USA but is now forming the basis of
innovative models of care in several other countries. The compo-
nents of the Chronic Care Model are support for self-manage-
ment, appropriate delivery system design, decision support
methods, and clinical information systems.Paulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201Findings
Health in all policies
A comprehensive policy response to the growing challenge of
T2DM will require action at two levels. The first is action at the
societal or community level, to create environments that are less
obesogenic. The second is action at the individual level, to identi-
fy and intervene in those at risk.
The marked increase in prevalence of T2DM has mirrored the
epidemic of its major modifiable risk factor – obesity. Large scale
societal changes, and in particular the industrialisation of food
production and the growth in motorised transport, both coupled
with rising incomes, have contributed to a situation in which
people are consuming more calories than they expend, and sub-
sequently gaining weight at an alarming rate. This phenomenon
is seen in its most extreme form in populations that have evolved
over generations in settings at risk of periodic famine, who now
have access to secure and plentiful food supplies and where mo-
torised transport has brought about greatly reduced physical ac-
tivity [225]. This has led researchers to coin the term “obesogenic
environment” [295]. This is defined as “the sum of influences that
the surrounding opportunities or conditions of life have on pro-
moting obesity in individuals or populations” [296]. Thus the in-
creasing prevalence of T2DM has its origins in policies that lie far
outside the health sector. These have recently been reviewed
elsewhere [287], but in brief, obesity is correlated with both ob-
jective measures of the environment, such as “walkability” [297]
and urban sprawl [298] or the structure of the retail food market
[299] as well as how individuals perceive the environment in
which they live (for example, fear of violence as a deterrent to
physical activity) [300]. Many of these factors are modifiable, for
example by incorporating health considerations into urban plan-
ning [262] or fiscal or legislative changes affecting food market-
ing (such as advertising bans or taxes on “junk” foods [233]).
Consequently, no matter how intensive they are, individualised
interventions within the health sector can only begin to over-
come the pervasive forces arising from the environments within
which people work, as recognised by the IDF [172] and the Amer-
ican Heart Association (AHA) [301]. Similarly, a key element of
the European Unionʼs public health strategy is Health in All Poli-
cies [302]. However, while there is a large volume of evidence
correlating characteristics of the environment with levels of obe-
sity, and thus T2DM, there are no population-based intervention
studies (for example to change the built environment or retail
food sector) that have been shown to reduce obesity. This is un-
surprising given the complexity and scale of such potential inter-
ventions. However, on the basis of the clearly demonstrated asso-
ciation between the environment and obesity, we recommend
that any individualised model of care for diabetes prevention is
accompanied by other policy responses to address obesity preva-
lence in the population. A
The economic aspects of diabetes prevention strategies
Using data from 2001 and 2002, the average annual cost of health
care in Italy for T2DM were estimated to be 1910 €/patient, with
52% of costs accounted for by medication, 28% by hospitalisation,
and 11% by diagnostic procedures [303] (2).
An earlier Swedish study calculated the annual direct and indi-
rect costs of diabetes per person to be approximately 6338 €/year.
28% of the costs were for healthcare, 41% for lost productivity
and 31% fell on the municipality and relatives [304]. The recent
IDF Diabetes Atlas [305] estimates that, in 2010, USD 105.5 billion
will be spent on healthcare for diabetes in Europe, equating to a0; 42 (Suppl. 1): S3–S36
S25Guidelinesmean expenditure of USD 2046 per person with diabetes in the
region [306]. Evidently, the cost is high, emphasising the impor-
tance of identifying cost-effective strategies for prevention.
The DPP group evaluated the progression of disease, costs and
quality of life of their own program using a Markov simulation
model. They estimated that, compared with placebo, the lifestyle
intervention delayed the onset of T2DM by 11 years and de-
creased the absolute incidence by 20%. This translated into a cost
per QALY of approximately 1100 US$; or $ 8800 from a societal
perspective; and the intervention was cost-effective across all
age groups. Further, in a sensitivity analysis, cost-effectiveness
improved.
However, the DPP groupʼs analysis was later challenged by inde-
pendent researchers who found the cost-effectiveness to bemore
modest: concluding that “lifestyle modification… should be rec-
ommended to all high-risk people.” but that the DPPmay be, “too
expensive for health plans or a national program to implement”
and suggested that lower cost methods would be needed for “real
world” delivery [307] (2).
One study examined cost-effectiveness in a European context,
modelling the application of the intervention used in the DPS to
a hypothetical Swedish population of 60 year olds [308]. It as-
sumed that those at risk, on the basis of IGT, had already been
identified (so a more comprehensive evaluation would need to
incorporate these costs). It took a societal perspective and re-
ported a cost per QALY of 2363 €.
In a separate study, a group in the UK conducted a cost-effective-
ness analysis of: screening for T2DM and IGT and then imple-
menting lifestyle interventions in those found to have IGT [309]
(2). They used a hybrid decision tree/Markov model to simulate
the long term (50 year time horizon) effects of the strategy, both
in terms of clinical and cost-effectiveness outcomes. For each
QALY gained, the estimated cost of the strategy was 6242 £
(7802 €). They found that, given a willingness-to-pay threshold
of 20000 £ (25000 €), the probability of the intervention being
cost-effective was 93% and so concluded that, in a population
aged 45 at above-average risk, the strategy seemed to be cost ef-
fective.
However, a quite different conclusion emerged from a recent
meta-analysis [310] (2+). This noted that most of the available
evidence came from research settings, among high-risk popula-
tions and that, despite encouraging evidence of effectiveness, so
far the economic case for a widespread lifestyle or drug interven-
tion to prevent development of T2DM has not been made.
Adapting a model of care to the circumstances of
each country
In considering which model of care to adopt, it is necessary to
take account of the tremendous diversity of health care systems
across Europe. There is a need for flexibility, with the model
adopted being tailored to the circumstances of individual coun-
tries.
Ten responses to the survey among IMAGE partners conducted
for this work package were obtained, from Bulgaria, Finland,
Greece, Latvia, The Netherlands, Poland, Spain, Switzerland,
Ukraine and the United Kingdom. The responses, along with
those to the IMAGE “Analyses of T2DM Prevention Programmes
at national level” questionnaire, identify very fewexamples of ex-
isting national diabetes (or obesity) prevention programs.
The Finnish DPS model, which has attracted moderate overall
support, is viewed as facing several obstacles, mainly in gaining
financial support, although there are a variety of possible sourcesPaulweber B et al. IMAGE-Gof funding, including pharmaceutical companies, health insur-
ance agencies and local and regional authorities, as well as na-
tional governments. In terms of settings, there was most support
for primary health care, with university hospitals and endocri-
nologists also mentioned. There were few precedents for the de-
livery of such a program in the patientʼs home.
Two examples of potentially national level programmes were
identified. The Krakow (Poland) “City” project for the prevention
of CVD and T2DM, which commenced in 2002, is described as
being very similar to the DPS model, with screening based on
the FINDRISK and simple biochemical indices, while those at risk
are offered lifestyle intervention in the form of individual consul-
tations. Since 2005 Poland has also participated in the DE-PLAN
project and there is local enthusiasm for scaling this up to nation-
al level.
In Finland, FIN‑D2D, an implementation project (in the primary
health care setting) of the Finnish national program for the pre-
vention of T2DM, ran from 2003 to 2007 [274]. It was conducted
in 5 hospital districts – covering a total population of 1.5 million.
Subjects at high risk (identified using the FINDRISC) were offered
lifestyle modification, which although drawn directly from the
DPS seemed to be somewhat more flexible in terms of its ap-
proach. There were individual, self-acting and group interven-
tions. At enrolment, subjects underwent a global risk assessment
including a questionnaire; and then, together with their health
professional, agreed on the level of intervention required. Fur-
ther, there was flexibility as to the setting: interventions could
also be implemented outside the health care system by private
or third sector organisations. At the time of writing the evalua-
tion of FIN‑D2D is not yet published but will be extremely impor-
tant as it is one of the first projects to actually implement lifestyle
interventions to prevent diabetes in the primary care setting.
Similarly, the results of the “Diabetes in Europe-Prevention using
Lifestyle, Physical Activity and Nutritional Intervention Plan”
(DE-Plan), which involved 25 institutions from 17 European
countries, will be invaluable. The DE-Plan project is testing mod-
els of lifestyle modification intervention in individuals at high
risk of T2DM. Since the programmes are being implemented in
existing health care systems, they will provide important evalua-
tions of the cost-effectiveness and feasibility of the models used
[239].
Recommendations
A Any model of care for diabetes prevention should be accompa-
nied by other policy responses to address the determinants of
obesity in a population.
D Anymodel of caremust be able to be adapted to the specifics of
each health care system. From the evidence available to date,
FIN‑D2D appears to provide themost flexible approach. The eval-
uations of FIN‑D2D, DE-PLAN and other programs such as the
Dutch “Roadmap”will be invaluable in providing evidence for fu-
ture recommendations on model of cares. The cost-effectiveness
of “real world” T2DM prevention programs has not yet been
clearly established.Recommendations for Economic Evaluation of
T2DM Prevention Strategies
!
Effective interventions to prevent T2DM diabetes, to treat its
symptoms and delay its complications will reduce the burden of
disease to society and to patients, but require new resources souideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
S26 Guidelinesthere is a need to analyze the cost-effectiveness of these inter-
ventions.
A The recommended perspective of economic evaluation is a
large societal perspective including: payerʼs (state and local gov-
ernments, health insurance companies), providerʼs and partici-
pantʼs perspectives of analysis [311,312] (1++), [307,313] (2++).
A The economic costs of the intervention, not financial costs
have to be assessed. All resources used, not only paid for, should
be considered.
A The ingredient approach for costs analysis is recommended
which consists of the following steps: (i) measurement of all re-
sources used by resource category (e.g. personnel, materials &
supplies, laboratory tests, equipment etc.), (ii) eliciting unit costs
(prices) of resources used (for the year of evaluation) and (iii)
multiplying quantity of resources used by their prices. The ingre-
dients approach allows comparability between different inter-
vention settings. The evaluation for another year can be easily
undertaken using revised prices of the resources used.
A It should be ensured that the time of personnel allocated to the
intervention is netted out from the remaining activities.
D Where exact measurement of costs such as office materials,
utilities, office space, computer etc. is difficult, the estimated
standard values of these costs per person-month of personnel
time involved can be applied.
B To support future planning of the necessary resources for inter-
vention, the costs should be assessed for two periods: (i) start-up
(pre-implementation phase of the programme, costs spent once),
(ii) post start-up (actual program running) [239,311,314], and for
two levels: (i) management level (costs by health care provider
and authorities involved in planning, organizing, continuous
training of the intervention managers, monitoring and supervi-
sion of the intervention) and (ii) participant level (all costs at the
individual level of delivery of the intervention).
A Two type of costs are to be analysed: (i) direct and (ii) produc-
tivity (indirect) costs. Direct medical costs comprise costs of
identifying high-risk groups, laboratory testing, implementing
and maintaining the intervention, costs of care incurred by the
intervention that are captured by costs of medical care outside
the analysed intervention. Direct non-medical costs include out-
of-pocket payments (e.g. traveling) and purchases, costs of
change of food due to the intervention, as well as value of leisure
time physical activities. It is recommended to estimate the value
of time spent on intervention by the participant using the aver-
age hourly wage in this country in the year of evaluation. Indirect
costs represent the value of production lost due to absence from
work or usual activity resulting from the intervention as well as
present value of future productivity lost due to premature death
either caused or averted by intervention. The human capital ap-
proach is recommended, applying the average annual wage and
unemployment rate of the country in the year of evaluation.
A Three groups of effects of the intervention are to be analysed:
(i) benefits achieved, measured in monetary units; (ii) effects
measured in specific units such as number of cases of T2DM
avoided; (iii) outcomes measured in time gained, adjusted for
quality of life – Quality Adjusted Life Years (QALYs) [315]. The
weights are then aggregated across time periods. The costs asso-
ciated with the added years of life can be excluded from analyses
[316] (2++).
B We recommend excluding from the analysis the costs associ-
ated with longer life achieved with intervention.
A Present the cost-effectiveness ratios for strategies applied. Pro-
vide an incremental cost-effectiveness analysis, comparing costsPaulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201and effects with lack of intervention or with current standard of
practice.
A In order to estimate the full economic impact of the interven-
tion, the lifetime health and economic consequences of prevent-
ing T2DM (progression of disease, costs and quality of life) should
be quantified. The modeling approach is recommended when di-
rect primary or secondary empirical evaluation is not possible
[198,307,315,317,318].
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The oral glucose tolerance test (OGTT) is recommended by the
WHO for diagnosis of T2DM.
Preparation and cautions
The OGTT should be performed in the morning, after at least
three days of unrestricted carbohydrate intake (more than 150 g
of carbohydrate daily). The test should not be done during an
acute illness, as the results may not reflect the patientʼs glucose
metabolism when healthy. A full test dose of glucose for adults
should not be given to a person weighing less than 43 kg, due to
the fact excessive amount of glucose may produce a false positive
result.
The OGTT procedure
The test should be implemented after an overnight fast of 10 to
16 hours (water is allowed). Smoking or physical activity is not
permitted during the test. Usually the OGTT is scheduled to begin
in the morning (7–9 am) as glucose tolerance exhibits a diurnal
rhythm with a significant decrease in the afternoon. At baseline,
the blood sample for glucose determination is taken. The patient
is then given a glucose solution to drink. The standard dose is 75 g
of glucose in 250–300ml of water. It should be ingested within 5
minutes. For children, the test load should be 1.75 g per kg of
body weight, up to a maximum of 75 g of glucose, The next blood
sample is collected at 120min after the glucose load.
Plasma glucose measurement in blood samples
The processing of the samples after collection is important to en-
sure accurate measurement of plasma glucose. This requires rap-
id separation of the plasma after collection. Laboratory measure-
ments rely upon the use of separated plasma and only immediate
separation can prevent the lowering of the glucose in the sample.
Only if the plasma separation is completely impossible to be done
immediately upon collection, glycolysis inhibitors, e.g. sodium
fluoride (6mg per ml of the whole blood) can be used. Rapid
cooling of the sample may also be helpful in reducing the loss of
glucose if the plasma cannot be immediately separated. In this
case, the sample should be placed immediately after collection
into ice-water but the plasma separation should occur within 30
minutes. The plasma should be frozen until the glucose concen-
tration can be measured.
International Federation of Clinical Chemistry (IFCC) recom-
mended that all glucose measuring devices report the results in
plasma values. The reason for this recommendation is the fact
that plasma glucose values are approximately 11% higher than
the values of whole blood glucose measured in the same sample.
Moreover, WHO recommendation is that venous plasma glucose
should be the standard method for measuring and reporting.
However, it should be noted if one converts from venous to capil-
lary plasma glucose the conversion is different in the case of fast-
ing or post-load glucose values. Fasting values for venous and
capillary plasma glucose are identical, while the conversion is
necessary only for post-load glucose.Paulweber B et al. IMAGE-GMethods and Procedures
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Methods
The IMAGE project is described in detail on its website (http://
www.image-project.eu/). Briefly, the development of this guide-
line followed a pre-defined step-wise procedure addressing:
(i) Stakeholder involvement: the IMAGE guideline development
group included diabetes specialists, public health and primary
care health professionals, behavioural and social scientists, epi-
demiologists, patientsʼ organisations, health professional organi-
sations, multidisciplinary, health economists, and health promo-
tion, health policy and health services researchers (for details see
Acknowledgements and website). All stakeholders were con-
sulted at numerous stages including the design of the project,
definition of the scope and purpose, identification of relevant
evidence and developing and refining drafts and final versions
of the guideline.
(ii) Scope and purpose: the overall objectives of the guideline
were developed through consultation with all stakeholders by
email, teleconference and a 2-day symposium. By this process,
the clinical questions and target population covered by the
guideline were defined and separate working groups established
to synthesise the evidence under the following headings: defini-
tions of risk and target population; screening tools, diagnosis and
detection; prevention of T2DM and its comorbidities; supporting
change in lifestyle behavior for adults at risk of T2DM; models of
care and economic aspects of T2DM prevention; and recommen-
dations for economic evaluation of T2DM prevention strategies.
(iii) Evidence identification and review: systematic methods
were used to identify relevant evidence using defined search
strategies appropriate to the specific topic (see Methodology sec-
tions), use of multiple databases, follow up of cited references,
and consultation with experts in the field. Criteria for selecting
and evaluating the quality of the evidence were based only on
publications in peer-reviewed scientific journals and are de-
scribed in detail (see Methodology sections). Throughout the
guideline, SIGN guidance was used to define the criteria for levels
(quality) of evidence and grades of the resulting recommenda-
tion, which are provided at the end of each chapter. Health bene-
fits, side effects, and risks were considered in formulating these
recommendations whichwere linked to the supporting evidence.
Prior to publication, experts externally reviewed the guideline. A
procedure for updating the guideline is to be defined.
(iv) Clarity and presentation: the recommendations were re-
viewed to ensure they are specific and unambiguous. Contextu-
ally specific issues arising in each participating European country
were discussed to minimise any misunderstanding or misinter-
pretation. Different options for management are clearly present-
ed and the key recommendations are easily identifiable. The
guideline is supported by tools and materials for its application
(see website).
(iv) Implementation and dissemination: Potential organization-
al barriers to applying the recommendations were discussed and
addressed where possible. The potential cost implications of ap-
plying the recommendations were considered (recognising thatuideline for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S3–S36
S36 Guidelinesprecise values will depend on national circumstances such as mix
of inputs and unit costs) and the guideline presents key review
criteria for monitoring and/or audit purposes. A plan for dissem-
inating the guideline to relevant professional groups and persons
with increased diabetes risk is in development.
(v) Editorial independence: The guideline is editorially indepen-
dent from the funding body. Conflicts of interest of guideline de-
velopment members have been recorded in the Acknowledge-
ments.
Procedures
At the initial meeting of the guideline development group (Mu-
nich, November 2007), the partners discussed the overall project
strategies and, based on their specific expertise, assigned them-
selves to the different working groups. Working group leaders
were decided by consensus within each group. Communication
occurredwithin and across theworking groups by email, intranet
and face-to-face meetings. During a 2-day meeting (Vienna,
March 2008), the available information was pre-screened, exclu-
sion and inclusion criteria defined, methodology for evidence
identification, grading and recommendation development was
further discussed and additional partners allocated to the work-
ing groups. Drafts on specific topics were circulated by email and
discussed at a further 1-day meeting (Helsinki, June 2008) andPaulweber B et al. IMAGE-Guideline for Diabetes Prevention… Horm Metab Res 201across the WPs at a further 2-day meeting (Mallorca, November
2008). In January 2009, the completed drafts were disseminated
as a first version of the completed guideline to all stakeholders
via email and intranet. After consensus was reached on the con-
tents, the guideline was shortened and edited. Consensus on the
final version of the guideline, authors list and publication strat-
egies was achieved during the final 2-day IMAGE meeting (Lis-
bon, October 2009).
Strengths and limitations
The evidence-based guideline focuses primarily on the European
environment. It does not address specific requirements for ethnic
minority groups and people with different social and cultural
backgrounds. Although the working groups took note of the spe-
cific need for prevention of obesity and diabetes in children with
metabolic risk factors, it was determined that this laid outside
the scope of this guideline. Although many of the interventions
identified can be expected to have similar effects in children, the
metabolic, psychosocial, behavioural and medical requirements
may be different. Despite these limitations, the IMAGE guideline
applies to more than 80% of people with increased metabolic risk
in Europe. Further work is necessary to extend the scope of the
guideline and to address the needs of children and specific ethnic
groups.0; 42 (Suppl. 1): S3–S36
Executive Summary
!
When we ask people what they value most,
health is usually top of the list. While effective
care is available for many chronic diseases, the
fact remains that for the patient, the tax payer
and the whole of society: Prevention is Better
Than Cure.
Diabetes and its complications are a serious threat
to the survival and well-being of an increasing
number of people. It is predicted that one in ten
Europeans aged 20–79 will have developed dia-
betes by 2030. Once a disease of old age, diabetes
is now common among adults of all ages and is
beginning to affect adolescents and even children.
Diabetes accounts for up to 18% of total health-
care expenditure in Europe.
The Good News is That Diabetes is Preventable.
Compelling evidence shows that the onset of dia-
betes can be prevented or delayed greatly in indi-
viduals at high risk (people with impaired glucose
regulation). Clinical research has shown a reduc-
tion in risk of developing diabetes of over 50% fol-
lowing relatively modest changes in lifestyle that
include adopting a healthy diet, increasing physi-
cal activity, and maintaining a healthy body
weight. These results have since been reproduced
in real-world prevention programmes. Even a de-
lay of a few years in the progression to diabetes is
expected to reduce diabetes-related complica-
tions, such as heart, kidney and eye disease and,
consequently, to reduce the cost to society.
A comprehensive approach to diabetes preven-
tion should combine population based primary
prevention with programmes targeted at those
who are at high risk. This approach should take
account of the local circumstances and diversity
within modern society (e.g. social inequalities).
The challenge goes beyond the healthcare system.
We need to encourage collaboration across many
different sectors: education providers, non-gov-
ernmental organisations, the food industry, the
media, urban planners and politicians all have a
very important role to play.
Small Changes in Lifestyle Will Bring Big
Changes in Health.
Through Joint Efforts, More People Will
be Reached.
The Time to Act is Now.
Take Action to Prevent Diabetes – The IMAGE Toolkit
for the Prevention of Type 2 Diabetes in Europe
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DPS: Finnish Diabetes Prevention Study
FINDRISC: Finnish Diabetes Risk Score
IFG: Impaired fasting glucose
IGT: Impaired glucose tolerance
OGTT: Oral glucose tolerance test
T2DM: Type 2 diabetes mellitusLindström J et al. IMAGE Toolkit for DiabetesWhy is it Time to Act?
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The alarming epidemic
" In Europe, around 55million adults have diabe-
tes.
" By 2030, this figure is estimated to rise to 66
million adults.Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S37–S55
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Number of goals* achieved
Programme goals were: No more than 30% of daily energy from fat;
no more than 10% of energy from saturated fat; at least 15 g/1000 kcal of
fibre; at least 30 min/day of moderate physical activity; at least 5% weight
reduction.
*
Fig. 1 Achieving all five of the lifestyle goals* prevented diabetes for at
least 7 years in the Finnish Diabetes Prevention Study (DPS). Modified from:
Lindström et al. [11].
S38 Guidelines" The highest increase in incidence is in the 30–40 year old age
group. This has, and will continue to have, a strong impact on
national economies due to loss of productivity.
Risk factors: Obesity, unhealthy diet, and sedentary
lifestyle
Diabetes develops as a result of an interaction between genes and
lifestyle. Obesity is an important risk factor for diabetes. More
than half of European adults can be classified as overweight or
obese. Genetically, most of us are inadequately adapted to the
modern lifestyle with its constant supply of energy-dense food
and beverages and a minimal requirement for physical activity.
What causes diabetes?
Diabetes is caused by the inability of the bodyʼs cells to respond to
insulin, which results in lower uptake of glucose from the blood
by body tissues (“insulin resistance”). To compensate, the pan-
creas produces and secretes more insulin to clear blood glucose
from the circulation. Over time, the pancreas becomes exhausted
and is unable to produce sufficient insulin to keep up with the
demands of the body. This leads to elevated blood glucose (hyper-
glycaemia) and finally to the development of diabetes.
Large number of unknown cases
The progression to diabetes generally takes many years and is
mostly asymptomatic. This means that the number of people
not knowing that they have diabetes is very high. Studies esti-
mate that for every one or two diagnosed cases of diabetes there
is one undetected case.
Complications through late diagnosis
Diabetes is a severe disease. If it is not diagnosed and treated
properly it can lead to serious and costly complications such as
cardiovascular disease, diabetic neuropathy, diabetic foot syn-
drome with amputations, renal failure and blindness. Hypergly-
caemia (even prior to diabetes) also increases cardiovascular risk
and exacerbates periodontal infection (gum disease).
Costs for the healthcare system and society
The longer the duration of the disease, the more likely it is that
there will be costly complications. In European countries, diabe-
tes accounts for up to 18% of total healthcare spending. With an
ageing population, these costs are likely to increase if the epi-
demic cannot be reversed. Furthermore, the costs to society
through lost productivity may be as much as five times the direct
healthcare costs. Additionally, diabetes has a major impact on the
quality of life of the patients and his/her family.
Prevention is possible: Evidence from international
studies
Evidence from large trials from Finland, Sweden, the USA, China,
India, and Japan has proven that lifestyle interventions can halt,
or at least delay, the onset of diabetes in people who are identi-
fied as having high risk. The key to prevention is lifestyle changes
such as weight reduction (if participants were overweight), in-
creased physical activity, dietary modifications to increase die-
tary fibre and reduce total and saturated fat intake. The more of
these goals the participants achieved, the lower was their risk of
developing diabetes (l" Fig. 1).
These findings from clinical studies have been successfully repli-
cated in “real-world” prevention programmes in health-care set-
tings in many European countries.Lindström J et al. IMAGE Toolkit for Diabetes Prevention… Horm Metab Res 2010; 4Economic and social benefits of diabetes prevention
The cost effectiveness of lifestyle interventions has been docu-
mented in a number of clinical trials.
The costs of preventive interventions must be compared with the
substantial annual cost per year of treating diabetes and its com-
plications.How Can I Make a Difference?
!
Prevention as a collaborative effort –
key partners to engage
Diabetes is not only an individual health problem, but also a pub-
lic health problem. The increasing prevalence of diabetes has its
origins in cultural changes and policies that lie far outside the
health sector. Thus, the responsibility for preventive efforts does
not depend only on the healthcare system. An effective and sus-
tainable prevention strategy requires action at both the individu-
al and the societal level. Therefore a wide range of partners have
to be involved in both approaches (l" Fig. 2).
Why and how to involve societal partners
Effective diabetes prevention for individuals needs to be em-
bedded into a supportive social environment. Therefore all soci-
etal partners should aim to create a less obesogenic/diabetogenic
environment to facilitate lifestyle changes and sustainability of
changes. The promotion of healthy food and physical activity
should ideally become part of an “media campaign” including
schools, universities, communities, work environment, etc. with
the aim of attracting people to choose them because of their
health enhancing effects.
Practical tips for societal support
" Contact work place communities to support health promotion
" Contact the restaurants and cafeterias in your area and suggest
menu labelling (fat, fibre and energy content), healthy options
and campaigns2 (Suppl. 1): S37–S55
Local and national media
Providing continuous, comprehensive and reliable information
on healthy lifestyle issues
Local and national authorities
Responsible for long-term strategy planning, sustainability and quality management of the preventive efforts
Individual level
Political level: health in ALL policies, following a national action plan for prevention with focus on
Other relevant prevention
programmes
Societal level
a)
b)
c)
d)
Advocacy
Community support
Fiscal and legislative changes involving infrastructure
Engagement of privte sector (e.g. health at workplace and ensuring healthy policies in food industry)
As the measure for preventing or
delaying type 2 diabetes are
effective in management of obesity
(and its comorbidities) as well as
the effects of premature
atherosclerosis leading to
cardiovascular diseases, there
should be a procedure to network
with other relevant prevention
programmes and public
educational activities
Target group:
Goal:
Involved players:
persons at risk
for T2DM
Promote lifestyle changes to
reduce diabetes risk and improve
health
Multidisciplinary team of
–
–
–
–
doctors, dentists, nurses
public health experts
registered dieticians
exercise specialists
Target group: whole population
Goal: Integration of less obesogenic/
diabetogenic/sedentary environment
Involved players:
–
–
–
–
–
–
local decision makers/
city planners
kindergartens and schools
communities industries
sports clubs facilities
patient associations
health insurance companies
Fig. 2 Diabetes prevention as a collaborative effort.
S39Guidelines" Cooperate with kindergartens, schools, universities and adult
education centres offering programmes for healthy eating and
physical activity
" Contact local sports clubs and suggest promotions for special
groups and discounts for high-risk clients
" Collaborate with non-governmental organisations (e.g. patient
associations)
" Ask local and national authorities or decision makers (e.g. pol-
iticians) for support in health promotion
" Involve insurance/health insurance companies
" Get the local and national media interested, for example by en-
gaging prominent people as “ambassadors” for promoting
healthy lifestyle or by initiating a contest (e.g. “The healthiest
company”, “The healthiest class”, “The healthiest city district”)
" Make use of communication channels (e.g. audio, video, mobile
services, social media)
" Establish a website resource promoting healthy lifestyle
How to build a multidisciplinary prevention team
Diabetes prevention requires the involvement of several profes-
sional disciplines, including medicine, behaviour change, nutri-
tion, and physical activity. To build a strong prevention team
and network of professionals, aim to engage experts from these
various backgrounds who have an interest in and enthusiasmLindström J et al. IMAGE Tfor diabetes prevention. Remember that any prevention pro-
gramme needs to be mindful of, and sensitive to, cultural and
ethnic differences.
Practical tips for networking
" Assess your capabilities (what are your skills, are they up-to-
date?)
" Find out about relevant existing projects; identify potential for
collaboration (e.g. projects focusing on prevention of obesity,
cardiovascular diseases, respiratory diseases, degenerative
joint problems, depression)
" Involve the people who are in charge of allocating healthcare
resources in your district/centre
" Establish networks or “quality circles” of people who are active
in prevention, so that you can exchange experiences and learn
from each other
" Increase your advocacy and marketing skillsHow to Budget and Finance a Prevention Programme
!
The cost per person for diabetes prevention interventions varies
substantially between countries and depending on the setting,
the mode, and intensity of intervention offered.oolkit for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S37–S55
S40 GuidelinesMake a realistic budget (see the Appendix)
Take into consideration:
" Administrative costs
" Salary costs
" Travel costs
" Laboratory costs
" Costs for the intervention
" Premises
" Materials
Possible sources of income:
" Alternative public funding, e.g. charity funding or stipends
" Contributions from collaborating partners
" Private funding, legacies, health insurance companies
" Participation fees
" Contributions from participants in seminars
" Charitable and research bodies
The number of clients who can be treated by a full-time preven-
tion team depends on various factors (budget, setting, number of
contacts, etc.).How to Identify People at Risk
!
Diabetes risk factors
Modifiable risk factors are linked to higher diabetes risk. These
are the factors where you should aim to support change to pre-
vent diabetes. Most important are:
" Overweight and obesity
" Increased risk: body mass index (BMI) 25–30 or waist cir-
cumference 80–88 cm (women) or 94–102 cm (men)
" High risk: BMI > 30 or waist circumference > 88 cm (women)
or > 102 cm (men)
" For other ethnic groups than Europids cut-off points are low-
er, (see Alberti et al. [1] for these)
" Low physical activity (see chapter “Physical activity to prevent
diabetes”)
" Unhealthy diet (see chapter “Nutrition and dietary guidance to
prevent diabetes”)
" Hyperglycaemia: Over 30% of people with hyperglycaemia will
develop diabeteswithin the next 5 years; over 10 times the risk
of an average person
" Impaired fasting glucose IFG: fasting plasma glucose 6.1–
6.9mmol/l (110–125mg/dl)
" Impaired glucose tolerance IGT: plasma glucose 2 hours after
75 g glucose load 7.8–11.0mmol/l (140–199mg/dl) in an
oral glucose tolerance test (OGTT)
" Hypertension and lipid disorders: these indicators of the met-
abolic syndrome often correspond with hyperglycaemia
" Depression: may be associated with physical inactivity and an
unbalanced diet
Non-modifiable risk factors are useful in the identification of in-
dividuals whowould benefit frommaking lifestyle changes. Most
important are:
" Age: risk increases with increasing age; recommended age lim-
it for risk assessment is > 40 years
" Family history of diabetes: a marker of genetic predisposition
" Ethnicity: people originating from South East Asia, Japan, Chi-
na have higher risk
" Women with gestational diabetes or babies weighing > 4 kg at
birth – an indication that a woman is susceptible to glycaemic
disordersLindström J et al. IMAGE Toolkit for Diabetes Prevention… Horm Metab Res 2010; 4" History of cardiovascular disease: a marker of disturbed me-
tabolism
" Low birth weight: being born small for gestational age predis-
poses to diabetes
Environmental risk factors contribute to lifestyle. Ideally, envi-
ronmental conditions should make a health-promoting lifestyle
an easy, attractive and affordable choice for everyone (population
approach). Environmental risk factors include:
" Environment promoting inactivity: e.g. lack of bike lanes, play
grounds, sport facilities
" Environment promoting unhealthy diet: e.g. lack of supermar-
kets or work place cafeterias with healthy and affordable food
and drink options
" Low socioeconomic status
" Cultural and religious constraints
" Stress & distress: e.g. unemployment, partnership problems,
multi-morbidity, social isolation of the elderly
Risk assessment
A lifestyle programme aiming at increased physical activity and
dietary modification could be beneficial for a wide range of peo-
ple. However, as resources are normally limited, intensive pro-
grammes should be targeted at individuals at increased risk of
developing diabetes (high-risk approach) (l" Fig. 3). To identify
adults at high risk several approaches can be used. Please note
that there are no absolute threshold values for risk and therefore
inclusion criteria should be based on the combination of risk fac-
tors and the resources available.
Several risk scoring algorithms have been developed for estimat-
ing diabetes risk (see Appendix). The Finnish Diabetes Risk Score
FINDRISC (see Appendix) is one example. It is a low-level, fast,
simple and non-invasive questionnaire that gives an estimate of
individualʼs risk of getting diabetes in the next 10 years. It can be
filled in by the person himself/herself and also serves as a “mini-
intervention” as it gives information about diabetes risk factors in
a simple and easy-to-understand way. If the score value is high
(> 14) a blood test is recommended to detect possible diabetes
(OGTT being the “gold standard” test).
Computer searches of existing databases, for example General
Practitionerʼs patient records can be used to identify high-risk in-
dividuals. The search algorithm can include available parameters
like age, BMI, fasting blood glucose, blood pressure, and family
history of diabetes (see Appendix).
Hyperglycaemia can be diagnosed by measuring blood glucose
either in the fasting state (→ IFG) or after an oral glucose load
(→ IGT). Some high-risk individuals may have previously undiag-
nosed diabetes (i.e. fasting glucose ≥ 7.0mmol/l (126mg/dl) or 2-
h glucose ≥ 11.1mmol/l (200mg/dl) or HbA1c ≥ 6.5) and should
be referred on for appropriate treatment.
Many of the people you try to reach will see no need to take ac-
tion since subjectively they feel healthy and do not understand
the implications of being at high-risk for diabetes. Often ethnic
minorities/immigrants and people with low socio-economic sta-
tus have a high-risk profile. Theremay be additional challenges in
engaging and delivering services to these populations (see Ap-
pendix).2 (Suppl. 1): S37–S55
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Fig. 3 Care pathway for healthcare provider.
For further details, please see “IMAGE-Guideline for
diabetes prevention” [15].
S41GuidelinesStrategies and practical tips for encouraging participation
in intervention activities
" Personalise risks and benefits: “How would diabetes affect
your life?”
" Emphasise short-term positive benefits, rather than long-term
threats: “If you do this, you will lose weight and increase your
energy levels/feel good about yourself (as well as reducing your
risk of getting diabetes)”
" Watch your language: Donʼt talk about “patients” but about
“clients” – the people you are working with are not ill yet! Fo-
cus on health not on illness
" Use your prevention network for communication and motiva-
tion: e.g. physicians and pharmacists have a high credibility
and thus could act as “recruiters” and motivators
" Ensure that the health professionals making the referrals are
aware of the benefits of the prevention programme and if ap-
propriate, take steps to strengthen their belief that interven-
tion programmes are valuable
" Initiate a “snow-ball system”: Ask clients you treat to dissemi-
nate the FINDRISC questionnaire to their relatives and friends
" Offer incentives
" Offer choices in the mode of intervention delivery (group, indi-
vidual, information for self-help)
" If the person is not willing or able to participate now, ask again
later; it is never too late to get benefits from lifestyle change!Lindström J et al. IMAGE THow to Change Behaviour
!
Elements of an effective lifestyle intervention
programme
Changing behaviour is a complex process. Helping a person to
change an existing behaviour requires:
" Individually tailored intervention and advice
" Support for developing motivation to make changes, goal-set-
ting & action planning
" Ongoing support and encouragement tomaintain change & ad-
vice on how to manage setbacks
l" Fig. 4 is a model which shows the processes involved in behav-
iour change. Examples of the possible content for three behaviour
change sessions (Initiating motivation; Taking action; Maintain-
ing motivation) can be found in the appendix.
Important considerations when supporting behaviour change:
1. Responsibility for changing behaviour: Behaviour change is the
responsibility of the individual but with support from health-
care providers. Try to create a relationship of “equal expertise”;
the individuals are experts on their circumstances and what
works for them; the healthcare providers have expert informa-
tion, which may be useful to the individual
2. Empowerment: Focus on empowering the individual. Behav-
iour change is not a passive process and only the individual
concerned can make the necessary changes. Give encourage-
ment and help develop the clientʼs confidence that he/she will
be able to do this
3. Choice: It should always be the individualʼs choice to change a
behaviour. Present clients with all relevant information and
support them through the decision making process. If an indi-oolkit for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S37–S55
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Emphasise empowerment/ownership of goals, risk and actions
Develop tools, strategies and motivation to manage lifestyle in the long term
Fig. 4 A process model for supporting lifestyle behaviour change. Source: Sheppard & Greaves, 2009.
S42 Guidelinesvidual is confident, feels it is important, and is ready to change
a behaviour, then an action plan can be made. If he/she does
not feel ready to change this decision must be respected.
Clearly state that the door is always open for future discussions
and decisions.
4. Support: The amount of support individuals need will vary.
Everyone is different and tailoring the intervention to suit the
individual is essential
An intervention programme for behaviour change
should include: (see Appendix for more details)
" Support for changes in diet and physical activity
" Support for self-monitoring & self-regulation – encourage indi-
viduals to monitor physical activity levels and what they eat
(activity and food diaries may be helpful if the patient is will-
ing) & encourage personal management of their behaviour
change (i.e. regular reflection on progress with a focus on iden-
tifying what works and problem solving, as below).
" Goal-setting – plan when, where, and how to perform the new
behaviour. Ensure goals are SMART: specific, measurable,
achievable, relevant, and time-framed. Consider setting both
short-term goals and long-term goals
" Action planning– An action plan should include three sections:
a) Clear goals
b)Clear information on who is providing social support, where
and when the support will happen and
c) Coping strategies on how to deal with problems that may oc-
cur
" Coping strategies & problem solving – explain how to identify
and cope with barriers that stop individuals achieving their
goals, and how to solve/deal with problems when they occur
(i.e. how their plans can be revised to work better).
" Social support – engage others who are important such as fam-
ily, friends and peers, to help support/encourage behaviour
change. Support may be emotional, practical or informational
(e.g. help with planning activities). Encourage clients to invite
a supporter along to sessions if they wish.Lindström J et al. IMAGE Toolkit for Diabetes Prevention… Horm Metab Res 2010; 4" A strong focus on strategies which help maintain changes in
behaviour – for example, using relapse management strategies
(e.g. explaining that setbacks are normal and provide useful
learning experiences, identify what has caused any setbacks
and make new coping plans to deal with these barriers to
change).
Supporting people to undertake behaviour change is not simple
and ideally it requires appropriate training. An effective interven-
tion can be delivered either individually (face-to-face) or in a
group setting (see the Appendix for example “behaviour change
session plans”). The selection of intervention mode should be
based on local facilities, resources, and client preferences. Addi-
tional education content on physical activity and healthy diet
should be integrated into the programme (see subsequent sec-
tions).
Time frame for implementing a lifestyle intervention
programme: An example
A lifestyle intervention programme could run over a 5-week peri-
od with additional maintenance sessions in the following 6. Core
active intervention sessions are once aweek for the first 3 weeks;
Week 1 develop motivation, Weeks 2 & 3 make decisions, learn
coping strategies, develop an action plan. Week 5 is after a two
week gap to allow individuals to go away and try out their action
plan and find out what works and what does not. Week 5 is the
first maintenance session, involving progress review and relapse
management. Education on diet and physical activity (ideally in-
cluding active learning techniques) should be interspersed with
or integratedwithin the behaviour change sessions; although it is
recommended to establish motivation prior to any detailed edu-
cational input. Furthermaintenance sessions can thenbe accessed
at gradually longer periods as the need for support reduces, e.g.
after onemonth, twomonths and then threemonths.
A suggested timeline for the intervention is in the Appendix
(l" Fig. 7).2 (Suppl. 1): S37–S55
Table 1 The F.I.T.T. principle for combining cardiorespiratory endurance training and resistance training
F. I. T.T. principle Aerobic endurance training Resistance training
F requency How often 3×/week (minimum), max. 2 days gap between training sessions 2–3×/week
I ntensity How hard (a) light tomoderate (40–60% VO2max/50–70% HRmax) (e.g. brisk
walking – 5–6 km/h) (slightly increased breathing rate) (b) vigorous
(e.g. jogging – 8–10 km/h) (increased breathing rate and sweating)
light tomoderate (slight muscular fatigue)
T ime How long (a) light tomoderate 45–60min (in total > 150min/week) (b) vigorous
30–40min (in total > 90min/week)
1–3 sets of 8–15 repetitions for each exercise
Type What kind walking, jogging, cycling, swimming, hiking, skiing about 8 different strength exercises (using the
major muscles of the body) (e.g. with fitness
machines, resistance-bands or just with your own
body weight)
S43GuidelinesIntervention intensity
Aim tomaximise the frequency of contact or number of contacts,
particularly in the active intervention phase (the stage where
motivation is established, plans made and new behaviour(s) ini-
tiated and practised). Clearly the ability to do this will depend on
the resources available.
Effective communication
When discussing lifestyle change with clients it is important to
avoid a solely advice-giving approach. To improve on how you
communicate with individuals focus on three areas:
Speaking: focus attention on speaking with clarity and purpose
" Use understandable words.
" Be non-judgemental and respectful.
" Moderate rate of speech.
Active listening: concentrate attention on the person speaking
and closely follow what is being said
" Reflect on what the client says and clarify their position.
" Show interest in the patientʼs ideas and encourage/praise any
positive “change talk”.
" Summarise what has been said.
" Extend or interpret their ideas – ask if your interpretation is
correct.
Non-verbal communication: A large proportion of communica-
tion is non-verbal and it may be consistent or contrasting towhat
is said
" Maintain good eye contact
" Use a tone of voice similar to the person seeking help
" Occasional heading nodding, smiling, hand gestures where ap-
propriate
One approach which can be used to discuss lifestyle change is
motivational interviewing (MI). MI is a directive, person-centred
counselling style which aims to enhance individualsʼ intrinsic
motivation to change behaviour by exploring and resolving am-
bivalence. In this counselling style the relationship between the
individual and the professional is more like a partnership than
an expert/recipient relationship. The professional respects the in-
dividualʼs autonomy and freedom of choice (and consequences)
regarding her or his own behaviour.Physical Activity to Prevent Diabetes
!
The term physical activity includes the full range of human
movement, from activities of daily living and active hobbies, to
exercise and competitive sport.Lindström J et al. IMAGE TWHY increase physical activity?
Physical activity is one of the main pillars in the prevention of
diabetes. Being physically active leads to various health enhanc-
ing adaptations (reduced blood pressure, reduced resting heart
rate, improved body composition (e.g. through reduced abdomi-
nal adiposity), improved lipid profiles and improved glucose ho-
meostasis, improved insulin sensitivity, reduced systemic in-
flammation, improved psychological well-being).
HOW to encourage your client to increase physical
activity?
Changing habits is difficult for everybody. Therefore, it is impor-
tant to motivate your clients to start, and then to keep being
physically active. The following advice/key messages will help
you to give adequate support:
" Increase awareness of the need to be active
" Discuss clientʼs history of physical activity
" Discuss pros and cons of increasing physical activity
" Help to set realistic and individual goals
" Increase daily physical activity, because every single bout of
physical activity is useful (e.g. walking, gardening, etc.)
" Advise your client to be physically active for at least 30min on
a minimum of 5 days a week
" Preferably a combination of cardiorespiratory endurance
training and resistance training*
" Encourage the adoption of enjoyable physical activities as hav-
ing fun is an important factor in keeping active
" If your client has co-morbidities recommend that they have a
physician consultation before starting vigorous exercise
* To educate about how to gain training benefits from a combina-
tion of cardiorespiratory endurance training and resistance
training, we can apply the F. I. T.T. principle (see l" Table 1).
Please keep in mind that these are general guidelines for individ-
uals of moderate fitness levels. The F. I. T.T. recommendations are
based on “optimal figures” and sometimes they may not be
reached by someone in the target group. Hence, it may be neces-
sary to break down the recommendations into gradual steps in
order to avoid physical and mental overload. Remember that
ANY increase in physical activity from the clientʼs baseline level
is likely to be beneficial.Nutrition and Dietary Guidance to Prevent Diabetes
!
A balanced, nutritious, enjoyable diet is essential for health. It al-
so gives pleasure and psychological and social well-being. Sus-
tained weight loss of 5% or more in overweight people lowersoolkit for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S37–S55
Table 2 Dietary recommenda-
tions for diabetes prevention
Goals for food intake Goals for long-term nutrient intake
" Consuming fruit, vegetables, and legumes in abundance
(≥ 500 g or five portions per day)
" Energy intake balanced with physical activity levels to
achieve or maintain healthy body weight
" Choosing whole grain in all cereal products " Total fat 25–35 E%* (60–80 g/daywith 2000 kcal daily
intake level), of which saturated or trans fat ≤ 10 E%
" Limit sugar to ≤ 50 g/day, including sugar in food and
beverages
" Dietary fibre 25–35 g/day
" Consuming vegetable oil and/or soft margarines and/or
nuts as the primary source of fat
" Salt (NaCl) ≤ 6 g/day
" Limiting butter, other saturated fat and partially hydro-
genated fats
" Alcohol ≤ 5 E%
" Choosing low-fat milk andmeat products
" Consuming fish regularly (≥ 2 per week)
" Consuming alcoholic beverages in moderation (≤ 2 drink/day
formen and ≤ 1 drink/day for women) if at all
" Other goals according to individual needs (e.g. body weight,
diseases, medications, age)
* E% = proportion of total energy
Table 3 The Eat Clever principle* provides brief practical advice for counsellors
Eat Clever
Estimation of the dietary pattern
compared to the recommendations
Use the food diary, or interview to help your client to become aware of his/her dietary pattern and food consumption.
Compare dietary intake to the recommendations. Consider special needs, resources and readiness to change food habits.
Aims in the long and short term Discuss both short and long term goals: what is your client willing and able to do at themoment? Help to set practical,
achievable targets and proceed with small steps. Make a plan with your client.
Tools, guidance and support Which kind of tools, guidance, support or skills are needed and available? Involving the family and friends and group
counselling are all worth considering.
Composition of the diet A diet with high sugar and other refined carbohydrates and low fibre content, or high saturated and trans fat contentmay
increase the risk for diabetes and other related disorders. Whole grains andmoderate amounts of coffee and alcohol may
decrease the risk. Encourage the use of herbs and spices to reduce salt. Refer to your national nutrition recommendations
but consider the special requirements of peoplewith high diabetes risk, such as the improvement of the components of the
metabolic syndrome. Take into account any additional disease your client may have.
Lifestyle for the whole life Diet is influenced by culture, religion, ethical, physiological, psychological, social and economical aspects, availability, and
individual likes and dislikes. Help your client to find his/her own healthywayof life. Lifestyle change is a process and relapses
are part of it. Help your client to learn from these experiences to develop successful strategies over time.
Energy Excessive energy intake causes weight gain. If the client is overweight, make a plan with her/him to support gradual weight
loss (step by step). Focus on substituting foods with high saturated fat and/or refined carbohydrate content with lower-
energy items. Howmanymeals and snacks, beverages and alcohol included, does he/she have during a day and night?
Some regularity in the daily meal plan helps to control over-eating.
Variety Emphasise variety instead of restriction. A health-promoting diet provides satiety and pleasure as well as protective
nutrients. Encourage clients to try new foods. Give advice on how to read food labels. This can help your client to feel
more confident and expand their healthy food choices.
Evaluation Evaluation and self-monitoring help in achieving andmaintaining new foodhabits. Bodyweight and/or waist circumference
should bemeasured regularly. Encourage your client to use a food diary (see Appendix) or some othermethods tomonitor
eating habits: the number ofmeals and snacks, the amounts of certain food stuffs, such as vegetables, whole grains, sugar,
alcoholic beverages, vegetable oil and/or fat etc.
Risks management Dietary guidancemust be based on evidence from nutrition and behavioural sciences. Focus on the big picture: changing
one aspect in the diet affects many others. Strict restrictions and “crash dieting”may lead to an unhealthy diet, and can
cause damage in the long term as well as psychological and social harm. Amulti-disciplinary team, including a registered
dietician and a psychologist, can give essential support to avoid these risks.
* Please apply these principles in the framework of your national recommendations
S44 Guidelinesdiabetes risk substantially. Modification of the diet towards a
healthier composition further reduces the risk and also improves
risk factors for cardiovascular diseases (l" Tables 2 and 3).Other Behaviours to Consider
!
Smoking
Smoking is a well-established risk factor for many chronic dis-
eases, including diabetes and its complications. As well as other
harmful effects, smoking increases visceral fat accumulation andLindström J et al. IMAGE Toolkit for Diabetes Prevention… Horm Metab Res 2010; 4insulin resistance. All smokers should be encouraged to quit
smoking. However, weight gain is common with smoking cessa-
tion and therefore dietary advice on avoiding weight gain should
be given alongside smoking cessation advice (e.g. managing crav-
ings and withdrawal symptoms by using short bouts of physical
activity as a stress-relief activity, rather than eating snacks).
Referral to local smoking cessation groups and direction to infor-
mation on the Internet may be advisable. Pharmacotherapy or
nicotine replacement therapy may be helpful in selected cases.2 (Suppl. 1): S37–S55
S45GuidelinesStress and depression
There is increasing evidence of a link between depression and
both diabetes and cardiovascular disease. This suggests that it
may be of value to pay attention to the presentation of depressive
symptoms in obese people. Should you suspect someone has
symptoms of depression or stress, consider referring to a physi-
cian/counsellor/psychologist.
Sleeping patterns
Both short (< 6 h) and long (> 9 h) sleep durations may have asso-
ciations with increased risk of developing diabetes. Sleep depri-
vation may impair the balance of hormones regulating food in-
take and energy balance.
Discuss with your clients their sleeping habits and patterns. Long
sleep durationsmay be amarker of sleep-disordered breathing or
depression and should be treated appropriately. There is also a
close association between obesity and obstructive sleep apnoea
syndrome.Evaluation and Quality Assurance
!
Evaluation and continuous quality assurance are essential ele-
ments of a successful primary prevention programme. It is im-
portant to use them in a structured way to evaluate whether
you are doing the right things and to allocate resources in the
most effective way.
To obtain valid and reliable indicators, measurements and meth-
ods should be standardised and valid. In addition to needs of in-
ternal quality assurance, unified quality standards are necessary
for systematic evaluation and reporting at the national and at the
EU level. The IMAGE evaluation and quality assurance data collec-
tion template (see Appendix) suggests recommended content for
evaluation data which can be further adapted to local needs and
circumstances.
For further details, please see the “IMAGE quality indicator” re-
port [14]. It provides a more comprehensive approach, detailed
background information, and references for the recommended
measurement protocols. It includes different types of quality as-
surance tools and presents quality indicators for different pre-
vention strategies, as well as scientific evaluation indicators and
measurement standards to be used if scientific analysis and re-
porting are planned.Risks and Adverse Effects
!
Compared to drug-based therapies, side-effects of lifestyle inter-
ventions are typically mild and transient. Furthermore, the bene-
fits of a sustained lifestyle change can be assumed to be much
larger, as changing lifestyle can have a number of additional ef-
fects on the human body and mind (improved quality of life,
energy, mobility and self-esteem, reduction in depression and
cardiovascular risk factors), which can be seen as “positive side
effects”. Time-limited interventions which lead to sustained life-
style changes can have long lasting effects. Using a drug treat-
ment for diabetes prevention treats one targeted risk factor (i.e.
lowering glucose) and the effect normally disappears after the in-
dividual stops taking the drug. For patients who do not respond
to lifestyle change, pharmaceutical options may be beneficial.
However, a sustained lifestyle change is the safest form of a ther-
apy for people with increased diabetes risk.Lindström J et al. IMAGE TJoin Forces to Make a Difference!
!
If we work together using this strong evidence base we can halt,
or at the very least delay the progression of diabetes and posi-
tively impact the quality of life of the millions of people who are
at high risk of diabetes.
Take Action to Prevent Diabetes.
You Can Make a Difference. Do it Now!
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Preparatory phase
1. When you plan a diabetes prevention programme, think big
and holistically, beyond your initial target group, think about
ages, ethnic groups, and family groups. Which members of
your community have the highest risk and/or are most in need
of preventive activities?
2. Find out about the target groups in advance
" Their network and relations
" Where they live/work etc
" What do you know about the group
" What has been done in this group before
" What worked and what did not, what were the successful
factors?
3. Agree on strategic alliances. This is an aspect of great signifi-
cance if you plan to carry out a prevention project.
4. The director/top management must approve the project and
future involvement. Create a positive cooperative atmosphere
with all employees, show respect, listen, include and involve.
5. Select suitable premises for the intervention programme, near
towhere participants live or work. Cooperate with local organ-
isations, insurance companies, healthcare centres, hospitals,
sports teams, schools and other.
" The premises must have rooms both for big gatherings/
meetings/lectures and rooms for individual consultations
and testing.
" Sufficient rooms/space for taking care of children, with ac-
tivities that can keep them occupied if necessary.
" What is your main objective – what do you plan to achieve?
The overall objective must be clear and concrete, and the re-
sults should be checked against the programme aims.
" Finances: Consider your funding needs and your funding
sources. Create a funding plan.
" Ethics: Apply for necessary permissions and approvals for data
collection (local ethics committee, data protection authorities).
Be sure that you have the necessary insurances.
Project description and planning
1. Make a detailed plan including;
" Timeframe – realistic estimates regarding the time schedule
of different phases (l" Fig. 5)
" Who – who is the target population? What is the target
group familiar with, what are they lacking?
" Estimated number of participants to include2 (Suppl. 1): S37–S55
Month
Preparatory phase
Planning
Recruiting team
Recruiting participants
Intervention
Evaluation
0 2 4 6 8 10 12 14 16 18
Fig. 5 Example timeframe.
S47Guidelines" How – where will the participants be recruited from, and
how?
" Intervention structure – group/individual sessions, content,
and frequency of sessions
" Intervention content – Practical activities such as; physical
activities, exercises indoor or outdoor, cooking sessions, cog-
nitive therapy, phone interviews, Internet platforms, use of
mass media etc.
" Special needs – e.g. translation, limited mobility/access is-
sues
" Follow-up
Recruiting project team members
1. Selecting the optimal multi-disciplinary team is essential. It is
absolutely crucial to pick teammembers that make the project
an optimal experience for participants; this will help you with
attendance rates and reduce the chance of drop-outs.
2. Decide the target group (gender, age, ethnicity – or families)
before you invite collaborators.
3. Assess your capabilities and ensure that the skills of your team
members are complementary and cover the wide range of
skills and knowledge required (including expertise in dietary
and physical activity advice and behaviour change). Team
members need the following qualities:
" Talent for teamwork
" Fighting spirit
" Enjoy challenges
" Respect for the participants independent of ethnicity, sex,
religion, occupation, socio-economic status and attitude
4. When involving cooperating partners make sure everybody is
aware of time constraints and that they understand and accept
what it means to be involved in the programme.
5. The team must have and the experience and ability to work
within an interdisciplinary team.
6. Everyone must talk to participants as an equal, and ensure that
all participants are acknowledged, even if they are in a group.
Recruiting participants
Recruitment is a crucial part of a project.
1. Make a realistic time schedule
2. Use various identification and recruitment strategies, sources
may include:
" Physicians
" The local health centre/occupational health services/phar-
macists
" Schools, workplaces
" The participantsʼ own contacts/networkLindström J et al. IMAGE T" Internet
" Mass media
" Mailing
Practical project work
A well prepared and planned project will help to simplify the
running of an intervention programme, including handling un-
foreseen events. Include in the project budget items that need to
be ordered in advance.
1. Recruitment
" Inclusion criteria, how and where to meet the participants
" Weight scale and height measurements – where is the
equipment placed?
" Plastic measuring tape band for waist circumference – follow
international guidelines
" Questionnaires as necessary/desired
" Structured documentation sheet
2. Testing
" Blood sample supplies and equipment, blood testing, pro-
cessing, storing and analyses.
" Treadmill for testing of physical fitness, pedometer, activity
measurements
" Nutrition and physical activity diaries
" Glucometers
3. Group sessions/teaching
" Computer and LCD projector
" Board/clip board
" Audiovisual equipment
" Whiteboard
" Clear and descriptive illustrations
4. Diaries for participants to make a note of physical activity and
dietary behaviours
5. Physical and practical activities
" Group/individuals
" Indoor/outdoor
" Weather conditions, vacations, religious feasts etc.
" New activities
" Cooking courses
" Time of day, and the time of year
6. Support materials
" Toys & drawing equipment for children
" CD-player if music is wanted
" Up-to-date information on teams/organisations in the area
that the participants can joinoolkit for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S37–S55
S48 GuidelinesSpreadsheet/Budget Calculation for Programme Costs
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Administrative costs
" Rental fee for use of office, meeting rooms etc.
" Project management (clerical, accountant)
" Recruitment of participants
" Information, advertising, written presentations and Internet
access
" Overhead costs
Salary costs
" Project coordinator
" Personnel at test stations
" Prevention managers – multi-disciplinary team (full/part-
time)
" Interpreters
" Overhead costs
Travel and subsistence
" Meetings (programme management, networking, education)
" Travel and transport for project workersTable 4 Risk screening tools for prevalent and incident diabetes
Score and source Predictive variables
Screening scores for prevalent T2D
The Dutch score.
Diabetes Care 1999; 22: 213
Age, sex, BMI, presence
physical activity
The Cambridge risk score.
Diabetic medicine 2006; 23: 996
Age, sex, BMI, family hi
The Danish risk score. Diabetes Care 2004; 27: 727–733 Age, sex, BMI, family hi
The Finnish diabetes risk score FINDRISC.
www.diabetes.fi/english/risktest
Age, BMI, waist circumf
activity, consumption o
FindRISKGermany HormMetab Res 2009; 41: 98 Age, BMI, waist circumf
Australian risk score AUSDRISK .
www.ausdrisk.com
Age, sex, ethnicity, fam
medication, current sm
circumference
The German diabetes risk score.
www.dife.de
Age, waist circumferen
redmeat, whole-grain b
The ADA risk score.
Diabetes Care 1995; 18: 382
Age, sex, delivery of ma
diabetes
Screening scores for incident T2D
The San Antonio Heart Study.
Annals of Internal Medicine 2002; 136: 575
Age, sex, BMI, ethnicity
diabetes + 2-hour gluco
The Rancho Bernardo Study.
Diabetes Care 2005; 28: 404
Age, sex, triglyceride, fa
The ARIC Study.
Diabetes Care 2005; 28: 2013
Age, ethnicity, waist cir
diabetes + HDL cholest
The Finnish diabetes risk score FINDRISC .
www.diabetes.fi/english/risktest
Age, BMI, waist circumf
activity, consumption o
DESIR. Diabetes Care 2008; 31: 2056 Waist circumference, h
glucose
The FraminghamOffspring Study.
Archives of Internal Medicine 2007; 167: 1068
Fasting glucose, bodym
of T2D
Diabetes risk score for urban Asian Indians.
Diabetes Research and Clinical Practice 2005; 70: 63
Age, BMI, waist circumf
University of Nottingham. QDScore®
http://www.qdscore.org/
Age, sex, ethnicity, bod
treated high blood pres
For further details, please see “IMAGE-Guideline for diabetes prevention” [15].
Lindström J et al. IMAGE Toolkit for Diabetes Prevention… Horm Metab Res 2010; 4Costs for risk assessment
" Premises and equipment for testing (i.e. blood test, analyses,
questionnaires)
Costs for the intervention programme
" Premises and equipment for testing (i.e. blood tests, analyses)
" Premises and equipment for the different interventions
" Office equipment (from computers to pencils)
" Telephones and communication
" Quality management
Possible sources of incomes
" Alternative public funding
" Health insurances
" Contributions from collaborating partners
" Private funding, legacies
" Contributions from participants in seminars
" Other incomesRisk Screening Tools
!
See l" Tables 4 and 5.of obesity, use of antihypertensive medication + family history of diabetes,
story of diabetes, use of antihypertensive or steroidmedication, smoking
story of diabetes, known hypertension, physical activity
erence, use of antihypertensive therapy, history of high blood glucose, physical
f fruit, vegetables and berries, family history of diabetes
erence, use of blood pressure medication, history of high blood glucose
ily history of diabetes, history of high blood glucose, use of anti-hypertensive
oking status, consumption of vegetables or fruit, physical activity and waist
ce, height, history of hypertension, physical activity, smoking, consumption of
read, coffee, and alcohol
crosomic infant, race, education, obesity, sedentary lifestyle, family history of
, fasting glucose, systolic blood pressure, HDL cholesterol, family history of
se, diastolic blood pressure, total and LDL cholesterol, triglyceride
sting glucose
cumference, height, fasting glucose, systolic blood pressure, family history of
erol and triglyceride
erence, use of antihypertensive therapy, history of high blood glucose, physical
f fruit, vegetables and berries, family history of diabetes
ypertension and smoking (M) or familial history of diabetes (W) + fasting blood
ass index, HDL-cholesterol, triglyceride level, blood pressure, parental history
erence, family history of diabetes, physical activity
y mass index, smoking status, family history of diabetes, social deprivation,
sure, heart disease and use of corticosteroids.
2 (Suppl. 1): S37–S55
Table 5 Finnish diabetes risk score FINDRISC
Score
Age (years)
" < 45 0
" 45–54 2
" 55–64 3
" > 64 4
Bodymass index
" ≤ 25 0
" > 25–30 1
" > 30 3
Waist circumference (cm)
" men < 94, women < 80 0
" men 94 – < 102, women 80 – < 88 3
" men ≥ 102, women ≥ 88 4
Do you usually have at least 30minutes of physical activity at work and/or
during leisure time (including normal daily activity)?
" yes 0
" no 2
How often do you eat vegetables, fruit or berries?
" every day 0
" not every day 1
Have you ever takenmedication for high blood pressure on regular basis?
" no 0
" yes 2
Have you ever been found to have high blood glucose (e.g. in a health
examination, during an illness, during pregnancy)
" no 0
" yes 5
Have any of themembers of your immediate family or other relatives been
diagnosed with diabetes (type 1 or type 2)?
" no 0
" yes: grandparent, aunt, uncle or first cousin 3
" yes: parent, brother, sister, or own child 5
Total score:
S49GuidelinesChallenges of Working with Special Consideration
Groups
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Ethnic minorities/immigrants
" Avoid stigmatisation of any kind. Consider and talk to all indi-
viduals as equals.
" The challenges will be different for 1st, 2nd and 3rd generation
because of language, education level, and the problems related
to living in two different cultures.
" Non-western immigrants are often classified as a “low socio-
economic status group”, due to low income and education.
Somemay have no formal education. However, this is often be-
cause they never had the opportunity to go to school, so it does
not necessarily mean that they are socially deprived.
" Experiences from immigration projects indicate that the use of
interpreters is essential, especially in the introduction phase.
Experience from the project InnvaDiab in Norway further indi-
cates that using local lay people as interpreters works better
than using professional interpreters. In Germany the initiative
MiMi (migrants for migrants) is a successful prevention initia-
tive. The local interpreters aim to talk to the immigrants in a
way that gives comfort, “especially at their own religious and
cultural level”. Be aware that even if immigrant participants
can cope with everyday language, they may not understand
medical questions or abstract questions, and it is usually notLindström J et al. IMAGE Tsufficient to take the right medical actions and only briefly dis-
cuss lifestyle changes.
" As healthcare workers we must be open to and able to accept
the various differences between cultures. It is also important
to bewilling to learn about the clientʼs culture, values and daily
life. We must convey this to immigrants so that they feel that
we understand and accept their distinctive characteristics. This
means that we must have a clear understanding of their situa-
tion and their cultural background, both from their native
country and in their new country. The need for mutual respect
cannot be emphasised enough. Avoidance of misunderstand-
ings is essential for mutual respect.
" Create a climate that allows for the clientsʼ culture.
" Consultation at the planning stages with representatives of
specific ethnic groups who are to be offered diabetes preven-
tion programmes is essential to inform appropriate planning
and adaptation.
People on low incomes
" Avoid stigmatisation of any kind. Consider and talk to all indi-
viduals as equals.
" It is vital to talk with them – not to them!
" This group is often difficult to reach, even though they have a
high need to undertake lifestyle intervention programmes.
They often avoid health information if, for example, they have
experienced behaviour changes as overwhelming and restric-
tive before. The experience with those of low social status is
very similar to immigrants, and we can use the same advice
and follow similar procedures.Example Behaviour Change Session Plans
!
Please find below 3 example session plans, which contain ideas
on how to implement a behaviour change session. The session
content specified below should be integrated with education on
physical activity and healthy diet. It is strongly recommended
that specialised training is undertaken to gain the necessary skills
and knowledge to undertake such complex work (l" Fig. 6).
Structure of initiating motivation session
(approx. 90min)
Introduction to behaviour change programme session
(15min)
Welcome everyone & introduce yourself. Explain overall aim of
the intervention sessions, format of this session, lead an “ice
breaker” activity & agree rules for working in a group. Highlight
the client-centred approach of the work: Remind participants
that they are the experts in their own behaviour change; the
trainerʼs role is to support change, not to prescribe it.
Knowledge & understanding the process of change
(15min)
1. Introduce individuals to the process of behaviour change (use
diagrams & models). Explain the importance of understanding
that behaviour change is a process towork through and explain
the rationale for the session.
2. Explore with the clients their prior knowledge/past experi-
ences of behaviour change. “Has anyone tried to change a be-
haviour before?” “What happened?” “What helped/hindered
your efforts?oolkit for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S37–S55
Session 1 Session 2
Intervention process for supporting behaviour change in adults at risk of developing type 2 diabetes
Session 3
Understand pro-
cess of behaviour
change
Explore motivation
for change: e.g.
risk awareness,
confidence,
expectations
Initiate action
plan. Self-
monitor
progress
Decision
to act
Plan action:
SMART goals,
social support
and coping
strategies
Engage
social
support
Review
progress and
motivation
Habit
Manage
setbacks
Over-arching philosophy of intervention:
1.
2.
Emphasise empowerment/ownership of behavioural goals, risk, planning activities and actions
Participants should end up having the tools, strategies and motivation to be able to manage their lifestyle in the long term,
even when faced with a range of new challenges
Fig. 6 Intervention process for supporting behaviour change in adults at risk of developing type 2 diabetes. Session plan.
S50 GuidelinesEstablish motivation for behaviour change (45min)
1. Explore clientsʼ perceptions of risk for developing type 2 diabe-
tes. Ask people to suggest what the consequences of having
type 2 diabetes would be. Provide information sheet on conse-
quences and complications of type 2 diabetes. Ask clients to
work out their risk scores using the risk charts/tools. Ask cli-
ents to discuss in groups what might be some of their un-
healthy behaviours.
2. Explore expectations of behaviour change –what do the clients
think that making changes in behaviour will lead to? Ask cli-
ents to work in groups and identify the benefits of physical ac-
tivity and a healthy diet and how they prevent the develop-
ment of type 2 diabetes. Emphasise strongly that it is possible
to prevent the development of diabetes by changing unhealthy
behaviours – so it is worth them making the effort!
3. Discuss perceived importance for change. Ask clients to think
about the reasons why they are involved in the programme
and why they might want to make the effort to change behav-
iours. Ask clients to assess how important they think it is to
change their diet and getting more physically active (impor-
tance review). Ask clients to identify expected benefits and
costs of changing a behaviour, write it down on a decisional
balance sheet.
4. Explore confidence for change – assess clientsʼ perceived con-
fidence about changing their diet and/or physical activity (con-
fidence review). How do clients feel about their ability to suc-
cessfullymake a change? Explore issues of confidence for phys-
ical activity/dietary change – discuss what people perceive to
be barriers to change. Ask the group to think of ways round
them. Ask the group to make a list of positive attributes that
can help people make changes (e.g. organised, committed)
and get participants to identify for themselves some that relate
to them.Lindström J et al. IMAGE Toolkit for Diabetes Prevention… Horm Metab Res 2010; 4Social support (12min)
Small group/pair work. Ask participants to identify positive and
negative sources of social support. Ask groups/pairs to come up
with ideas of how to seek more positive support and avoid nega-
tive support. Ask clients to identify their own need to develop so-
cial skills. Ask clients to identify social barriers to change. Feed-
back ideas to the main group (write up on flip chart). Provide in-
formation on “the best ways to provide social support” and the
important role of good social support in behaviour change. En-
courage participants to invite someone to the sessions who will
support their attempts to change.
Homework (3min)
Explain homework: Ask participants to use their decisional bal-
ance sheet and think about their review of their confidence and
importance. Are they ready to make a change (even a small
one)? Ask them to try as an experiment to change (at least for
the next week) one simple habit (e.g. eating a piece of fruit once
a day; going for a 10-minute walk once in the week etc.
Structure of action planning session (approx. 90min)
Introduction to action planning session
Welcome everyone. Explain format of the session (2min)
Review homework set in the previous session (5min)
Discuss with participants how easy/hard it was to complete the
goal they had set themselves. What difficulties (if any) did they
face? Did anything/anyone facilitate/prevent them achieving the
goal? Praise all successes2 (Suppl. 1): S37–S55
Table 6 Action plan worksheet
Themost important reasonswhy I want tomake this change are:
" I want to lose weight so that I will havemore energy and feel good about
myself.
" I donʼt want to get diabetes.
" …
" …
My SMART goals are:
" Go for a 20-minute walk
" …
" …
" …
Specify:What, how, where, when
" 20-minutewalk, around the nearby local park, everyWednesday after work
at 6 pm
" …
" …
" …
Social Support:Other people who could helpme to achievemy goal:
Person Possible ways to help
" My friend Sarah " Comewithme on the walk and
keepme company
" … " …
" … " …
" … " …
Coping Plan:
Possible obstacle/barrier to change Howwill I respond?
If… Then…
" … it is raining " … I will take an umbrella and/or
wear waterproof clothing
" … " …
" … " …
" … " …
S51GuidelinesMake decisions (10min)
Revisit perceived importance to change and confidence to change
(use decisional balance sheets). Emphasise that it is very impor-
tant for participants to clarify their motivations for change. Ask
participants to make decisions about if they are ready to make
changes and if so, what changes they want to make. Remember:
it must be their decision.
Key messages on physical activity and healthy diets
(20min)
Discuss basic information on physical activity: What types?
Where do you fit it in with your day-to-day life? How much to
do?
Discuss basic information on healthy diets:What to eat?When to
eat? How much to eat?
Self-monitoring behaviour (5min)
Explain the importance of self-monitoring as key motivation
strategy. Discuss different types of self-monitoring (diaries, pe-
dometers etc).
Create an action plan (20min)
1. Introduce the principles of SMART goals and practice setting
SMART short- and long-term goals.
2. Action plan – Ask clients towrite out as clearly as possible their
action plan for behaviour change. Focus on setting SMART
goals and creating a goal ladder to focus on developing a pro-
gressive series of goals that will lead to the final outcome goal.
Make sure that in addition to SMART goals the action plan con-
tains details on 1) what kind of social support they will need &
who will provide it and 2) what coping strategies (see below)
they will use if needed (l" Table 6).
Relapse prevention (25min)
1. Knowledge of behaviour change: Refresh clients on the process
of behaviour change and emphasise the normality of setbacks.
Explain that setbacks should be seen as an opportunity for
learning.
2. Problem solving: Give clients tools to deal with setbacks. Ex-
plain about “high-risk” situations and “if-then” plans. Work
through examples
3. Problem solving (mood/emotion): how to identify and deal
with negative thoughts, moods, and stress.
4. Identify barriers to change: Address barriers and facilitators to
becoming more physically active and improving diet. Look at
cost, environment, emotional/cognitive and social support.
Identify places & things, people, thoughts and feelings that are
or are not helpful.
Homework (3min)
Put action plan into practice and self-monitor progress. Practice
identifying negative thoughts, writing them down and counter-
ing then with positive thoughts.
Structure of maintenance session (approx. 90min)
Introduction to maintenance session (5min)
Welcome everyone. Explain format of the session Refresh indi-
viduals on the process of behaviour change. Place emphasise on
the importance of sustainable/lifelong of behaviour change and
explain the rationale for, and format of, the session.Lindström J et al. IMAGE TReview last session & homework (10min)
Ask the group to reflect on how easy/hard it has been to achieve
their action plans. Did they successfully use their coping strat-
egies? Did participants notice any negative thoughts? Were they
able to stop these thoughts and reframe with positive thoughts?
Discuss motivation for behaviour change (5min)
Discuss motivation for change; ask the clients “why are you mak-
ing the effort to make changes?”
Review progress: (20min)
Ask group to reflect on how easy/hard it has been to achieve their
action plans. Review achievements in behaviour change in rela-
tion to 1) risk outcomes (e.g. weight, pedometer counts) 2) be-
havioural goals. Review goals sheet and action plan and identify
achievements, surpassed goals, or goals not yet achieved. Focus
on achievements. Highlight the importance of self-monitoring –
ask clients to evaluate their progress using their diaries, goals
sheets, action plans. Review successes and setbacks. Do goals
need to be re-set?
Relapse management (25min)
Celebrate success and “re-frame” failure or setbacks as learning
opportunities. Reflect on the use of coping strategies – have any
been used? If so, what has worked and what has not? Identify
barriers which participants have experienced. Separate into
groups to discuss the barrier most relevant to them: cost, envi-
ronmental, emotional, knowledge. In the group, discuss strat-
egies to overcome the barrier and solve the problem. Feedbackoolkit for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S37–S55
1 week
2 weeks
3 weeks
5 weeks
2 months
4 months
7 months
12 months
Session 1
Initiating motivation
Session 2
Action planning
Session 3
Action planning
Session 4
Revisiting motivation
Session 5
Repeat
Session 6
Repeat
Session 7
Repeat
Optional session 8
Fig. 7 Suggested
timeline for implement-
ing a lifestyle interven-
tion programme.
S52 Guidelinesproblem-solving ideas to the main group. Reinforce need for self-
monitoring of behaviour change (using pedometers, diaries etc).
Explore satisfaction/dissatisfaction with behaviour change. Ask
clients to talk reflect on what has worked well & reinforce areas
of satisfaction. Reframe dissatisfaction where possible or encour-
age goals to be re-set where unattainable. Ensure focus is on
graded levels of goals so as to build success and confidence. Ask
clients to think about their levels of expectation for behaviour
change – are they realistic?
Role of rewards (5min)
Highlight the importance of regularly reviewing goals and prog-
ress and rewarding achievements. What achievements are clients
most proud of? Have there been any unexpected benefits to
change? Ask clients to identify ways in which they can reward
themselves for successes.
Social support (10min)
Ask clients to identify positive & negative sources of social sup-
port that they have experienced. Did the social support they put
in their action plan work? If not, why not? Ask group to come up
with ideas of how to seek more positive support and avoid nega-
tive support (e.g. peer pressure at mealtimes).
Rewrite action plans (10min)
Re-write action plans (where necessary). Focus on adjusting/re-
setting goals (consider extending goals if desired), identifying rel-
evant sources of social support, identifying rewards and adapting
coping strategies. Concludewith a re-cap of the process of behav-
iour change, the normality of relapses and encourage clients to
self-manage new challenges and ongoing diet and PA changes.
Suggested programme timeline
The group-based intervention programme consists of 7 sessions
(with an optional 8th) for 8 to 15 people. The first 3 sessions can
be completed weekly, with a 2 week break before the 4th session
to allow individuals to go away and attempt their behaviourLindström J et al. IMAGE Toolkit for Diabetes Prevention… Horm Metab Res 2010; 4change. The repeated maintenance sessions are completed at 2
(+ 1 week), 4, 7 and (optional) 12 months. NB: Education on the
specifics of diet/cooking/shopping for health and physical activ-
ity should be interspersed with or integrated with the content
on behaviour change (l" Fig. 7).
SMART goals (Source: NHS health trainer handbook)
Once the participant has decided upon a health behaviour they
want to change, they need to set a goal to change their behaviour.
Your role is to help the participant to set a goal that is detailed
and likely to be achieved. Goals should be SMART, that is:
Specific– Measurable – Achievable – Relevant – Timely
Specific – some goals can be vague and difficult to measure. It is
important to set goals that are clear and precise. For example, a
vague goal would be ‘being fit and healthy’ whereas a clear, spe-
cific goal would be “I will work out at the local gym for at least 30
minutes three times a week at 7 pm on Monday and Thursday
and 10 am on Saturday.” To help the participant make their goal
more specific, ask them questions such as:
" What are you going to do?
" How are you going to do it?
" Where are you going to do it?
" When are you going to do it?
" With whom are you going to do it?
Measurable – making the goal specific means that it should be
easy to measure whether or not the participant has achieved
their goal. The example above, “I will work out at the local gym
for at least 30 minutes three times a week at 7 pm on Monday
and Thursday and 10am on Saturday,” is measurable. The partic-
ipant can record the number of times they went to the gym in
one week, and also how long they worked out for each time. It
would be hard to measure a vague goal like “being fit and
healthy”.
Achievable – set goals that arewithin the participantʼs reach. Fail-
ing to achieve a goal can have a negative effect on their motiva-
tion to work towards their goal. For example, an unrealistic goal
could be ʼeat no chocolate or sweets for the next seven daysʼ. A
more realistic goal could be “eat no more than three portions of
chocolate or sweets in the next seven days”. It is important to
make the first goal quite easy to achieve to boost the participantʼs
self-confidence and encourage them to carry on. Participants
should remember that the best way of changing behaviour and
maintaining change is to build on small successes.
Relevant – does the participant think that the goal is relevant to
them? You need to check with the participant that they see a
clear link between their goal and their health or how they feel,
and that it is a behaviour that they want to change.
Timely – is this goal the right thing for them to try to achieve right
now? If so, set a time frame in which the goal can be achieved. If
you donʼt set a target date for the completion of the goal, it could
go on and onwithout the participant ever achieving it. For exam-
ple, if your next session with the participant is a week away, aim
for the goal to have been completed by that time. If the goal re-
quires a longer time frame, decide together whether there are
any mini-goals that the participant could achieve in time for the
next session (l" Table 6).2 (Suppl. 1): S37–S55
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See l" Table 7.Food Diary
!
See l" Table 8.Table 8 Food diary
Name: Date:
What you ate and drank Notes
→ 9 am mug of coffee with cream & sugar,
croissant, glass of orange juice
ate in a hurry
9 am – 12 – –
12 – 3 pm large pepperoni pizza,
can of soft drink
busy at work,
so ate at my desk,
was really hungry!
3 pm – 6 pm 2mugs of coffee with milk and
sugar
felt full & tired
6 pm – 9 pm steak with french fries, small salad
(lettuce & tomato, no dressing),
pint of beer
in a restaurant
with friends
9 pm→ a bag of sweets (100 g) at home by TVWhy use a food diary?
Keeping a food diary can help your client to become more aware
of his/her eating pattern: the health promoting habits and the
possible problem areas. It can be an excellent tool for facilitating
discussions.
Use the food diary as a basis for goal setting and planning. Later
on, repeating the food diary shows what has changed over time
and helps tomaintain the new habits. Making a note of social sur-
roundings and feelings during meals can also be helpful, espe-
cially if your client has particular problems, such as excessive or
uncontrolled eating.
A simple template food diary is printed above, but a small note-
book can be used as well. Keeping a food diary for a week would
be optimal, but even a couple of days can give useful information.
Explain to your client that the purpose of the food diary is to help
him/her in his/her journey to better diet andwell being. Ask him/
her to write down everything he/she eats and drinks, and to
maintain their usual eating and drinking habits. Short notes are
enough, such as “a cup of coffee with sugar and a doughnut” or
“a large bowl of vegetable salad with olive oil vinaigrette and
two slices of whole grain wheat bread with butter”. Only if you
are using the food diary to collect detailed data on nutrient in-
takes (e.g. for research purposes), would you need to use a more
detailed and structured format.
Compare the food diary with your clientʼs personal goals. This can
be done either individually or in a small-group session. Pay atten-
tion to the number of meals and snacks during a typical day, the
amount of certain types of food, such as vegetables, whole grains,
deserts, alcoholic beverages, and sources of soft and hard fat. Let
the client express his/her own opinions, experiences and ideas;
use open-ended questions. Encourage the client to make his/her
own suggestions for new solutions and further progression. Re-
member to give positive feedback!oolkit for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S37–S55
Table 9 Image evaluation and quality assurance data collection
Core items Additional items
Personal data
Personal identification Marital status
Education
Employment status
Screening
Method used in screening
Risk screening result and interpretation
Health and health behaviour
Chronic diseases and regular medications Family history of diabetes and CVD
Smoking:
" never/previously/irregularly/daily " products used, amount, frequency
Physical activity:
" method used in measuring (for example: interview, diary, recall, pedometers, accelerometers)
" type, frequency, intensity " work-related, commuting, leisure
Nutrition:
" method used in measuring (for example: interview, diary, recall, pedometers, accelerometers)
" Dietary pattern: Number of meals and snacks including beverages,
consumption of vegetables, fruits, bread and cereal (whole/refined
grain), fats and oil, sweets, beverages, alcohol e.g.
" Energy proportion (E%) of fat, saturated and trans fat, dietary fibre
(g/day, g/1000 kcal), total energy, alcohol (g, E%), added sugar (g, E%)
Clinical data – baseline and follow-up
Body weight Fasting insulin
Body height 2 hour OGTT glucose + insulin
Waist circumference HbA1c
Systolic and diastolic blood pressure Lipids (total, LDL, HDL Cholesterol and triglycerides)
Plasma glucose (fasting, random or postprandial) Additional measures, e.g. liver function tests
Health related quality of life
Content of the intervention
Intervention facilitator(s)
Type of intervention (group, individual etc.)
Frequency, duration and other details
Focus of the intervention (weight, diet, smoking, physical activity, e.g.)
Reinforcement plan
Success of the intervention
Adherence (proportion of planned intervention visits completed)
Changes in lifestyle (line 3) and clinical (line 4) indicators
Maintenance
Plans how to sustain possible lifestyle changes after intervention
S54 GuidelinesImage Evaluation and Quality Assurance Data
Collection
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See l" Table 9.The Development of the IMAGE Toolkit for Diabetes
Prevention
!
Aim
The Grant Agreement between the Public Health Executive
Agency (PHEA; now European Agency for Health and Consumers,
EAHC) and the IMAGE Group 2006309-IMAGE stated that the
primary objective was “The development of practice-oriented
European guidelines for the prevention of type 2 diabetes
(T2DM)”. To implement this specific objective, a working group
4(a) was established. The group collected the latest evidence
and summarised their findings in “A European Evidence-Based
Guideline for the Prevention of Type 2 Diabetes – IMAGE-Guide-
line for diabetes prevention”. A second working group, 4(b), was
also set up with the aim to create a credible, simplistic, concise,
clear, pragmatic, accessible document with a positive messageLindström J et al. IMAGE Toolkit for Diabetes Prevention… Horm Metab Res 2010; 4about health promotion (“a toolkit”) with step-by-step tips on
how to initiate and manage a lifestyle intervention to prevent
type 2 diabetes.
Members of the working group
The members of the working group were selected based on their
practical and/or scientific experience in the field of diabetes pre-
vention andwere suggested and invited by IMAGE steering group
members. Further, the members represent different professional
backgrounds which are relevant to diabetes prevention, includ-
ing health psychology, physical activity, nutrition, health promo-
tion, diabetology, health services provision, health policy devel-
opment and service user representation.
Group meetings
The IMAGE Toolkit group had two meetings: the first in Frank-
furt, Germany 25–26 May 2009, and the second in Helsinki, Fin-
land 24–25 August 2009. Work was assigned to group members
during the meetings and the majority of work was completed be-
tween and after meetings. Communications were via e-mails and
telephone calls.2 (Suppl. 1): S37–S55
S55GuidelinesTarget group
The target group for the Toolkit was anyone with an interest in
establishing a programme to prevent type 2 diabetes. This in-
cludes service providers in the field of health care and health pro-
motion but also politicians and policy-makers. The Toolkit aimed
to provide a good balance between clear, accurate information
and practical guidance. It is not intended to be a comprehensive
source of information, but preferably to be used alongside the
“IMAGE Guideline for diabetes prevention” and the associated
training curriculum (please see www.image-project.eu). Inter-
vention delivery staff is assumed to have basic knowledge about
e.g. diet and physical activity as well as their health effects and
supporting behaviour change. Finally, the Toolkit is not designed
to be used as intervention materials to be delivered directly to
those participating in prevention interventions, although it does
contain some examples of information sheets and materials
which might be used with participants (for further information,
please see www.image-project.eu).
Content of the toolkit
The Toolkit starts with an executive summary including the ra-
tionale for diabetes prevention. It is followed by chapters repre-
senting the background (type 2 diabetes prevalence, risk factors,
consequences, evidence of successful prevention), and giving in-
structions about the planning and development of prevention
programmes and the identification, and recruitment of partici-
pants at high risk for T2DM.
One of the core items of the toolkit is the description of what to
do and how to do it. Behaviour change is a processwhich requires
individual attention, and effective communication to achieve
motivation, self-monitoring, sustained support and other inter-
vention to prevent and manage relapses. This section includes a
model of intervention including empowerment and patient-cen-
tred messages. It is followed by key messages on behaviour (in-
cluding physical activity and diet) that are important in preven-
tion of diabetes, and practical advice for patient-centred counsel-
ling. The focus is on long-term, sustainable lifestyle changes. Of
note, detailed instructions about how to achieve weight reduc-
tion were left out because local and national guidelines as well
as other information are available elsewhere.Lindström J et al. IMAGE TFinally, a brief guide for evaluation and quality assurance in refer-
ence to the “IMAGE quality indicators” is included. This section is
followed by a consideration of possible risks and adverse effects.
The IMAGE toolkit main text ends with a positive mission state-
ment, emphasizing what can be achieved if we work together.
The appendix of the toolkit gives the reader a set of easy-to-use
tools including a checklist for prevention programme develop-
ment, templates for goal-setting and for food and physical ac-
tivity diaries, an example of a risk screening questionnaire (the
FINDRISC questionnaire) and a template for evaluation and qual-
ity assurance data collection.
Creation of the toolkit
The first draft of the toolkit was collated in July 2009. The draft
was sent to all members of the toolkit working group for com-
ments and suggestions. During the Helsinki meeting in August
2009, the content and structure of the document was addressed
page-by-page.
A revised versionwas prepared in September 2009 and sent to all
IMAGE work package leaders for comments and suggestions. In
mid-October, the toolkit was sent to the entire IMAGE study
group for comments. The IMAGE final convention took place in
Lisbon, 29–31 October 2009. During this meeting, the toolkit
was presented to the whole IMAGE study group followed by a
general discussion regarding, e.g. focus, content and wording. All
participants were invited to further comment in writing on the
version provided at the final convention. Based on the comments
and suggestions from the IMAGE group, a pre-final version was
prepared by JL, AN and PS in Dresden in December 2009.
The final revision phase was conducted via the global “Who is ac-
tive in diabetes prevention” network (www.activeindiabetespre-
vention.com) between December 2009 and January 2010, by in-
viting all 2900 members of the Network (who represent a wide
range of stakeholders in diabetes prevention from academics to
service providers in over 130 countries) to comment on the tool-
kit.
By the end of January 2010, 13 members of the Network and sev-
eral members of the IMAGE study group had submitted further
comments about the toolkit. These were collated and sent to the
chapter authors to give their response. Final revisions to the tool-
kit were made by JL, AN, PS and JT in February 2010.oolkit for Diabetes Prevention… Horm Metab Res 2010; 42 (Suppl. 1): S37–S55
Abstract
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Background: The marked increase of type 2 dia-
betes necessitates active development and imple-
mentation of efficient prevention programs. A
European level action has been taken by launch-
ing the IMAGE project to unify and improve the
various prevention management concepts, which
currently exist within the EU. This report de-
scribes the background and the methods used in
the development of the IMAGE project quality in-
dicators for diabetes primary prevention pro-
grams. It is targeted to the persons responsible
for diabetes prevention at different levels of the
health care systems. Methods: Development of
the quality indicators was conducted by a group
of specialists representing different professional
groups from several European countries. Indica-
tors and measurement recommendations were
produced by the expert group in consensus meet-
ings and further developed by combining evi-
dence and expert opinion. Results: The quality in-
dicators were developed for different prevention
strategies: population level prevention strategy,
screening for high risk, and high risk prevention
strategy. Totally, 22 quality indicators were gener-
ated. They constitute the minimum level of qual-
ity assurance recommended for diabetes preven-
tion programs. In addition, 20 scientific evalua-
tion indicators with measurement standards
were produced. These micro level indicators de-
scribe measurements, which should be used if
evaluation, reporting, and scientific analysis are
planned. Conclusions:We hope that these quality
tools together with the IMAGE guidelines will
provide a useful tool for improving the quality of
diabetes prevention in Europe and make different
prevention approaches comparable.
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The increase of type 2 diabetes is a major public
health problem, also within the European Union
(EU). Type 2 diabetes is increasing especially
among working-age populations starting already
in children and adolescents. Even if the preva-
lence of obesity remains stable until 2030, which
seems unlikely, it is anticipated that the number
of people with diabetes will more than double [1,
2]. Clinical studies have shown that even individ-
uals with high risk for diabetes can significantly
reduce their risk and delay the onset of type 2 dia-
betes by adopting a healthy diet, increasing phys-
ical activity, and maintaining or reducing bodytors… Horm Metab Res 2010; 42 (Suppl. 1): S56–S63weight [3–8]. Translating this evidence necessi-
tates active development of efficient prevention
strategies and programs [9]. To fulfil this need,
European level action has been taken by launch-
ing the IMAGE project to unify and improve the
various prevention management concepts, which
currently exist within the EU. IMAGE stands for
“Development and Implementation of a European
Guideline and Training Standards for Diabetes
Prevention” and it builds on the results of the EU
public health research project DE-PLAN “Diabetes
in Europe-Prevention using Lifestyle, Physical Ac-
tivity and Nutritional Intervention”, which relates
to the efficient identification of individuals at
high risk for type 2 diabetes in the community
S57Guidelines[10]. The objectives of the IMAGE project are: to develop an evi-
dence-based consented European guideline for prevention of
type 2 diabetes and a European curriculum and launch an e-
health training portal for the training of prevention managers
(PM). Furthermore, the project aims to produce European stand-
ards for quality management for these interventions. These ac-
tions will form a unique European-wide evidence-based guid-
ance system to systematically improve the prevention of type 2
diabetes in Europe [10].
Several projects aiming to enhance reporting related to diabetes
have been conducted at the European level. The European Core
Indicators for Diabetes Mellitus (EUCID) project (2006–2007) de-
veloped 27 indicators and demonstrated the feasibility of data
collection in different EU countries and future member states.
The aim of the project was to promote the planning for good dia-
betes health status and diabetes care organization in the different
countries [11]. Many consortia have developed quality indicators
specifically for clinical diabetes care. Despite recommendations,
quality issues or indicators are not often incorporated into the
clinical guidelines [12–16]. The OECD Quality Indicator Project
has published a list of nine health system level quality indicators
of diabetes care [17,18]. In the United States, the Diabetes Quality
Improvement Project (DQIP) has developed and implemented a
widely accepted and comprehensive set of national measures for
evaluation [19]. A working group including participants from 15
EU/EFTA countries has generated an indicator set composed of 31
indicators for monitoring diabetes and its complications within
EU/EFTA countries [20]. In several European countries efforts
have been made to implement quality indicators in diabetes care.
In Saxon, Germany, the Saxon Diabetes Management Programme
has developed an integrated quality management system [21]. A
Belgian study has produced a list of quality indicators for type 2
diabetes by evaluating 125 diabetes guidelines in five European
countries [12]. One group from the Netherlands provided a set
of quality indicators for pharmacological management of type 2
diabetes [22]. In the field of diabetes education, the International
Diabetes Federation has published standards including quality
indicators.
Continuous quality control and evaluation are the key elements
of a successful primary prevention program, and thus, unified
quality standards are necessary for systematical evaluation and
reporting of the prevention programs in the EU and on national
levels [10]. Currently, diabetes prevention programs often lack
methods for systematical follow-up and evaluation and there
are no standardized European level quality indicators for diabetes
prevention. This report describes the background and the meth-
ods used in the development of the quality tools in the IMAGE
project, and present the European quality indicators for diabetes
primary prevention programs. This report also focuses on pri-
mary prevention and is targeted to the persons responsible for
diabetes prevention at different levels of the health care system.Methodology
!
Process of developing indicators
Development of the IMAGE quality management system includ-
ing quality indicators was conducted by a group of specialists
representing different professional groups from several European
countries. Members of the group have been actively involved in
the pivotal studies on diabetes prevention such as the Diabetes
Prevention Study (DPS) [3] and have extensive experience in im-Pajunen P eplementation of the diabetes prevention programs within the
community.
The development of the quality management processes and qual-
ity indicators was based on combining evidence and expert opin-
ion. Indicators were produced by the expert group in consensus
meetings and further developed by a subgroup of experts. The
working group reviewed the existing scientific evidence in the
field. Based on that knowledge, measurement specifications were
designed and the standards of the indicator described. Initially,
109 quality indicators were developed. Further selection re-
vealed 22 quality indicators. In addition, 20 scientific outcome
evaluation indicators were developed. This process included de-
tailed group discussions and additional literature surveys. The fi-
nal approval and selection of the indicators were performedwith
a stepwise approval process in which the participants of the oth-
er IMAGEworking groups gave their comments on the quality in-
dicators before final selection.
Defining target population
The IMAGE quality indicators are presented separately for popu-
lation level and high risk prevention strategies as well as for
screening for high risk. The population level prevention strategy
aims to improve, develop, and implement primary prevention
programs and activities targeting the entire population. From a
societal perspective, this is not the sole responsibility of the
health care sector. Successful population level prevention of dia-
betes involves the participation of different community stake-
holders such as decision makers, educational system, food indus-
try, media, urban planning, and nongovernmental organizations.
Screening for individuals at high risk for type 2 diabetes is essen-
tial for successful interventions. Different methods to screen for
high risk individuals include the use of risk questionnaires, op-
portunistic screening, and computer database searching. Each
country and organization has to develop and introduce a method
suitable for its local needs and resources.
Clinical studies have consistently shown that diabetes can be pre-
vented or at least postponed by lifestyle changes related to
healthy nutrition, adequate amount of physical exercise, and
weight reduction [3–8]. In addition to lifestyle changes, drugs
such as metformin, acarbose, orlistat, and thiazolidinediones can
reduce the relative risk of diabetes in high risk individuals with
impaired glucose tolerance [5,7,25–29]. The aim of the high risk
prevention strategy is to identify high risk individuals and sup-
port them with life-style changes required to reduce their risk
for diabetes and other vascular risk factors.
The quality indicators were generated to be applicable to the
broadest possible population. The definition of high risk popula-
tion used here covers all subjects at risk for type 2 diabetes irre-
spective of the screening method used to identify these individu-
als. They are designed for adults, but not restricted to any specific
age groupwithin the adult population, and are applicable to both
genders, but may not be applicable to different ethnic groups.
Classification of indicators
Structure, process, outcome model
The quality assessment theory by Donabedian is called the struc-
ture/process/outcome (SPO) or the Donabedianʼs Triad Model
[30,31]. This theory comprises three quality elements: structure,
process, and outcome. Structure describes the material and hu-
man resources as well as the organizational structure. This in-
cludes facilities, financing, equipment, and personnel. Process
relates to activities undertaken to achieve objectives such as ac-t al. IMAGE Quality Indicators… Horm Metab Res 2010; 42 (Suppl. 1): S56–S63
S58 Guidelinestivities related to giving and receiving care or implementing in-
terventions. Outcome describes the effect of care or interventions
on the health status of a subject or population.
The IMAGE quality indicators are classified according to the struc-
ture/process/outcome (SPO) model [30,31] modified so that, for
practical reasons, combined structure/process indicators are pre-
sented. The structure/process indicators constitute the quality
criteria for diabetes prevention and the outcome indicators focus
on outcome evaluation and monitoring. Thus, indicators belong
either to structure/process or outcome categories. The latter in-
clude both intermediate and end-result indicators as appropriate
for the setting. Intermediate outcome indicators reflect changes
in biological status and may be regarded as short-term outcomes
[32].
Macro, meso and micro levels
Indicators are meant for users operating at different levels of the
health care system. At the macro level, indicators are developed
to be utilized by national level decision makers generating the
prerequisite for diabetes/obesity prevention. This means, for ex-
ample, representatives of the national level health institutes or
nongovernmental organizations.
The level of operative primary health care providers is called the
meso level. Depending on the country, indicators may be used by
individuals responsible for activities on diabetes prevention in
municipalities, health districts, health care centers, occupational
care, private sector, or local level nongovernmental organiza-
tions.
At the micro level, the indicators are meant for use by the person-
nel who execute the actual preventive work. This may be a physi-
cian, nurse, dietician, physiotherapist, or prevention manager.
The IMAGE quality indicators are categorized so that the popula-
tion level prevention strategy indicators include macro and meso
level indicators, screening for high risk indicators are applicable
to meso level, and the high risk prevention strategy indicators
for meso and micro levels.
Quality and scientific outcome evaluation indicators
The IMAGE indicators are divided into quality and scientific out-
come evaluation indicators. Quality indicators are the minimum
requirement to be taken into account when conducting preven-
tion activities depending on the level of operator. An additional
set of indicators, scientific outcome evaluation indicators, is pro-
vided for scientific evaluation purposes. Further, measurement
standards for scientific outcome evaluation are provided.Results
!
Quality indicators for diabetes prevention
Population level prevention strategy
At the macro level, a prerequisite for desired outcome in the pop-
ulation level prevention strategy is that policies and legislation
support an environment favoring diabetes prevention. In addi-
tion, each country should have a national diabetes prevention
plan in which specific prevention targets are defined. These tar-
gets should include consideration of the special needs of ethnic
minorities and underprivileged socio-economic groups. Further-
more, policies and legislation should take into account specific
measures needed for the prevention of obesity among children
and adolescent. To enable these tasks, the national health moni-Pajunen P et al. IMAGE Quality Indicators… Horm Metab Res 2010; 42 (Suppl. 1): Storing systems should provide sufficient information for con-
ducting efficient surveillance.
At the health care provider level, processes should support health
promotion including diabetes prevention. The health care pro-
vider should allocate sufficient resources to the preventive work.
Basic knowledge on population level prevention of diabetes/obe-
sity/cardiovascular diseases should be included in the curricula of
the medical professionals working for the health care provider.
Collaboration between different stakeholders active in the health
promotion field should be effective.
In addition to the above mentioned quality criteria on structure
and process, a list of outcome indicators were generated during
the course of the IMAGE work (l" Table 1, upper panel). With
these indicators at hand, decision makers can monitor and evalu-
ate the quality and effectiveness of the selected population level
strategies.
Screening for high risk
Screening is an essential part of the high risk prevention strategy.
In addition, screening protocols can be designed so that they sup-
port also population level prevention activities by increasing the
awareness of the disease. Different screening protocols should be
validated and evaluated at national level. The selected protocols
and strategies should be implemented by the health care pro-
vider. The employed screening protocol should contain a path-
way for diagnostic procedures, as well as defined intervention
strategies for the different subgroups (age, minorities etc.). The
health care provider should promote validated diabetes risk as-
sessment tools. Information technology systems should support
the implementation of screening.
Depending on the health care system, these indicators can be the
responsibility of either macro- or meso levels of operators. In ad-
dition, the indicators in l" Table 1, middle panel, were identified
as outcome indicators for screening for high risk.
High risk prevention strategy
At meso level, every screening strategy should incorporate clini-
cal pathways at the health care provider organization to deal
with individuals at risk for diabetes. The health care provider
should support a multidisciplinary approach for interventions.
High risk prevention strategies should be included in the educa-
tion of the healthcare professionals. The medical record system
should support interventions and chronic disease prevention in
general.
At micro level, the individualʼs risk factor profile should be as-
sessed in the beginning of the intervention process, and the mo-
tivation for behavioral changes explored. Structure and content
of the interventions should be defined and individualized targets
for interventions established. A plan for individual follow-up
should be defined and recorded. The indicators in l" Table 1, low-
er panel, were identified as outcome indicators at meso and mi-
cro levels.
In addition to the quality indicators related to the high risk inter-
vention strategy at micro level, target values which correspond to
the indicators were identified. In the DPS study [3], the following
targets were applied: weight reduction 5% or more, moderate in-
tensity physical activity 30 minutes daily or more, dietary fat less
than 30 E%, saturated fat less than 10 E%, intake of fiber 15 g/1000
kcal (15 g/4200 KJ) or more. These targets may be taken into con-
sideration when planning micro level diabetes prevention. How-
ever, intervention targets should be individualized based on the
baseline evaluation.56–S63
Table 1 Outcome quality indica-
tors for a population level preven-
tion strategy, screening for high
risk, and high risk prevention strat-
egies
Level
Population level prevention strategy
Proportion of population aware of diabetes and its risk factors Macro
Prevalence of diabetes in the population Macro
Percentage of the population physically inactive Macro
Prevalence of overweight, obesity, and abdominal obesity in population Macro
Percentage of population following national recommendations on nutrition Macro
Percentage of health care costs allocated to prevention programs Macro
Proportion of health care personnel per health care provider active in population level primary prevention Meso
Number of health promotion organizations active in population level primary prevention Meso
Screening for high risk
Proportion of the population screened by health care providers per year Meso
The percentage of identified high risk individuals directed to diagnostic procedures Meso
The percentage of identified high risk individuals directed to lifestyle interventions Meso
High risk prevention strategy
Number of healthcare professionals at health care provider level qualified for interventions per
100000 inhabitants
Meso
The percentage of remitted high risk individuals participating in lifestyle interventions Meso
Proportion of individuals dropping out of interventions Meso
Proportion of high risk individuals in interventions achieving clinically significant changes in risk factors at
1 year follow-up
Meso
Diabetes incidence rate among high risk individuals in interventions Meso
Proportion of planned intervention visits completed over 1 year Micro
Weight change over 1 year Micro
Change in waist circumference over 1 year Micro
Change in glucose over 1 year Micro
Change in the quality of nutrition over 1 year Micro
Change in physical activity over 1 year Micro
Table 2 Scientific outcome evalu-
ation indicators and measurement
recommendations
Indicator Unit Reference
Body weight kg FEHES [38], WHO STEPS [39]
BMI kg/m2 FEHES [38], WHO STEPS [39]
Waist circumference cm FEHES [38], WHO STEPS [39]
Fasting and 2-hour OGTT glucose mmol/l WHO [33,34,40]
HbA1c % IFCC [23,24]
Fasting insulin mU/l IFCC [41]
Total energy intake kcal/day IMAGE Toolkit [42,43]
Fat intake E% IMAGE Toolkit [42,43]
Saturated fat intake E% IMAGE Toolkit [42,43]
Fiber intake g/1000 kcal IMAGE Toolkit [42,43]
Physical activity METS [35,44–48]
Fasting total, HDL, and LDL cholesterol cholesterol mmol/l FEHES [38], CDC [49]
Fasting triglycerides mmol/l FEHES [38], CDC [49]
Systolic and diastolic blood pressure mmHg FEHES [38], WHO STEPS [39]
Smoking habits FEHES [38]
Drug treatments EHIS [50]
Costs € IMAGE Evidence-Based Guidelines
Quality of life Score WHO-5 [51], SF-36 [52], SF-12 [53] 15-D [54]
Treatment satisfaction Score DTSQ [55]
S59GuidelinesScientific outcome evaluation indicators for
diabetes prevention
l" Table 2 presents the recommended scientific evaluation indi-
cators to be used as outcome measures in scientific evaluation of
a diabetes prevention program.
To obtain reliable results, measurements and methods used in
the diabetes prevention programs should be standardized and
valid. l" Table 2 provides the references for the recommended
measurement protocols for the scientific outcome evaluation in-
dicators.Pajunen P eThe standards related to physical measurements (weight, height,
waist circumference, blood pressure) can be found from the Fea-
sibility of European Health Examination Survey (FEHES) recom-
mendations [38] and from the World Health Organization
(WHO), STEPSManual [39]. The FEHES recommendations include
also a questionnaire on smoking habits.
Recommendations on blood sampling and lipid measurements
are available in the FEHES recommendations and in the U.S. Cen-
ter for Disease Control and Prevention (CDC) which has a certifi-
cation program for lipid measurements [49].t al. IMAGE Quality Indicators… Horm Metab Res 2010; 42 (Suppl. 1): S56–S63
S60 GuidelinesThe WHO Laboratory Diagnosis and Monitoring of Diabetes Mel-
litus 2002 document provides standards for glucose measure-
ments including the oral glucose tolerance test (OGTT) [40]. Diag-
nosis of diabetes and risk assessment is based on fixed cutoff
points. For this reason all steps in the analytical process require
attention [33]. It is important to notice that preanalytical issues
may seriously affect the quality of the glucose assays. Glucose is
lost through glycolysis and NaF has been used for decades to in-
hibit glycolysis. In addition, ice slurry is often used to prevent
preanalytic loss of glucose. However, new Fluorid-Citrate-mix-
ture tubes allow prolonged storage and transport of the samples
and should be considered to assure a high quality measurement
process [33,34]. Even though this is expected to improve the pre-
cision of glucose measurements, it may increase the number of
individuals diagnosed with diabetes unless compensatory
changes in diagnostic cutoff points are made [33].
The International Federation of Clinical Chemistry and Labora-
tory Medicine (IFCC) has published standards for HbA1c mea-
surements [23,24]. Major differences exist in commercially avail-
able insulin assays. An IFCC working group on the Standardiza-
tion of Insulin Assays has been jointly establishedwith the Amer-
ican Diabetes Association and is currently developing a candidate
reference method for insulin analysis.
There is no consensus on what constitutes adequate measure-
ment and documentation of physical activity or nutrition. Die-
tary pattern and composition can be evaluated with several
methods: food diary, food frequency questionnaire, and check-
list. The selection of a method depends on availability, cultural
background, and resources and cooperativeness of a high risk
person. For accurate calculation of nutrient intakes, culturally
specific food composition databases are mandatory. The quality
of diet in relation to recommendations and dietary changes can
also be assessed based on frequency of consumption of recom-
mendable (e.g., vegetables, fruit, whole grain) and nonrecom-
mendable (e.g., soft drinks, pastries) food items.
Accurate methods to measure physical activity are pedometers
and accelerometers. Self-reported data can be collected via inter-
views, diaries, and recalls. Assessing physical activity should in-
clude: type of activity (e.g., walking, swimming), frequency
(number of sessions), duration, and intensity (level of physical ef-
fort). Using these four components, relative energy expenditure
can be estimated, often referred to metabolic equivalents, METS
[35].
The European Health Interview Survey (EHIS) includes standard-
ized questions on use of medications [50]. Issues related to health
economic evaluation and the costs are presented in the IMAGE
Scientific Guidelines. Quality of life should be measured with
standardized instruments and possible translations should be
certified. Treatment satisfaction can be measured for example
with the Diabetes Treatment Satisfaction Questionnaire: DTSQ
[55].
Micro level data collection form
The data items presented in l" Table 3 are an example of the con-
tent that is recommended to be included and adapted into the lo-
cal version of the data collection tools at the micro level diabetes
prevention. However, the local needs and circumstances are deci-
sive for the final form of the data collection form applied in differ-
ent prevention programs.Pajunen P et al. IMAGE Quality Indicators… Horm Metab Res 2010; 42 (Suppl. 1): SDiscussion
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As part of the IMAGE project, a set of quality and scientific out-
come evaluation indicators for diabetes prevention programs
were developed together with the development of the IMAGE
evidence-based guideline and the accompanying practical guide
for prevention. Therefore, the indicators are closely linked to the
guideline standards and aremeant to be used in conjunctionwith
the guidelines. The quality indicators are intended to provide
European decision makers, health care providers, and health care
personnel working with prevention activities the tools to moni-
tor, evaluate and improve the quality of diabetes prevention. In
addition, standards of measurements for scientific outcome indi-
cator were identified, aiming to report about the clinical trials
and effectiveness research across Europe, enabling comparisons
between different study groups.
Both individual and population level prevention strategies were
taken into account when developing the indicators. The quality
indicators were selected to represent different dimensions of
preventive work: population level prevention strategy, screening
for high risk, and high risk prevention strategy. To promote the
usability of the indicators, they were generated to be applicable
to the broadest possible population. The definition of high risk
population used covers all subjects at risk for type 2 diabetes ir-
respective of the screening method used in identifying the indi-
viduals.
Some of the macro level outcome indicators require data that can
only be obtained through population-based health surveys. The
Feasibility of a European Health Examination Survey (FEHES) col-
laboration [36], another EU-funded project provides recommen-
dations for organizing standardized health surveys. Further, pop-
ulation level standardized data may be available in the future
through the EUBIROD collaboration [37].
The quality indicators are intended to be used in prospective set-
tings, but may be applicable for retrospective analysis if the qual-
ity of data collection enables this. They comprise the minimum
level of quality standards. Individuals and organizations using
these measures are spurred to involve the scientific evaluation
perspective into the preventive work by using the scientific out-
come evaluation indicators and related instruments described in
themeasurement standards section. High qualitymethodology is
essential to attain reliable and comparable results.
As the responsibility of the implementation of the guidelines dif-
fers depending on the national and local legislation, the imple-
mentation of the guidelines may need adaptation to local regula-
tions and circumstances. At the micro level, individual targets
should be based on individualized baseline evaluation.
Even though data from the pivotal diabetes prevention studies
have proved the effect of preventive interventions, less data are
available on the effectiveness of implementing diabetes preven-
tion into everyday work in primary health care outside of pro-
spective RCTs. Thus, the development of the quality management
processes and quality indicators was based on combining evi-
dence and expert opinion. Some limitations related to the devel-
opment process should be noticed.
Even though the quality indicators are linked to the IMAGE scien-
tific guidelines data standards, target value assignment was diffi-
cult because of lack of data on the general population. It should
be noticed that target values related to weight reduction, nutri-
tion, and physical activity for micro level quality indicators are
drawn from the DPS Study, which was conducted in obese indi-
viduals with impaired glucose tolerance.56–S63
Table 3 Recommended contents
to be included and adapted in the
local versions of the data collection
forms to support, monitor, and
evaluate micro level diabetes pre-
vention
Core items Additional items
Personal data
Personal identification Marital status
Education
Ethnicity
Employment status
Screening
Method used in screening
Risk score type and result (if used)
Reason for intervention
Health and health behavior
Chronic diseases Family history of diabetes and CVD
Regular medications
Smoking:
" never/previously/currently " how often, products used
Physical activity:
" type, frequency, intensity " work-related, commuting, leisure
" method used inmeasuring (e.g., interview, diary,
recall, pedometers, accelerometers)
Nutrition:
" dietary pattern: for example, consumption of
vegetables, fruits, spreads and oil, bread and
cereal (whole/refined grain), sweets, beverages,
alcohol
" energy proportion (E%) of fat, saturated and
trans fat, dietary fiber (g/day, g/1000 kcal), total
energy, alcohol (g, E%), added sugar (g, E%)
" method used inmeasuring (e.g., food diary, food
frequency questionnaire or checklist)
Clinical data (measured)
Body weight 2-hour OGTT glucose
Body height HbA1c
Waist circumference Lipids (total, LDL, HDL cholesterol, and triglycerides)
Fasting glucose Additional measures (fasting insulin, etc)
Systolic and diastolic blood pressure
Content of the intervention
Type of intervention (group, individual, etc.)
Frequency, duration and other details
Targets for the intervention:
" weight, diet, smoking, physical activity
Reinforcement
Success of the intervention
Adherence (proportion of planned intervention
visits completed)
The Diabetes Treatment Satisfaction Questionnaire:
DTSQ
Changes in: health and health behavior
and clinical data
Health related quality of life
Maintenance
Plans how to sustain possible lifestyle changes
after intervention
S61GuidelinesIn conclusion, parallel with the development of the IMAGE guide-
lines for the prevention of type 2 diabetes, a quality management
system with quality and scientific outcome evaluation indicators
were developed. The indicators are presented by different levels
of the health care system. They can be used for internal quality
control, as well as for external comparison between operators.
These quality tools complement the IMAGE guidelines and the
prevention manager curriculum, and will provide a useful tool
for improving the quality of diabetes prevention in Europe.Pajunen P eAffiliations
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